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Abstract 
Malaria remains a devastating disease with respect to both mortality and the 
constraints it places on the economic development of the countries in which it is 
endemic.  Our laboratory is seeking new antimalarial targets, by characterising 
the protein kinases of the most lethal human malaria parasite, Plasmodium 
falciparum.  As central components of many diverse signalling pathways, protein 
kinases are crucial for the control of proliferation and differentiation in other 
eukaryotes; we hypothesise that they play similar roles in P. falciparum.  The 
life cycle of P. falciparum is complex, consisting of a series of tightly controlled 
stages of division and differentiation.  In the related apicomplexan parasite 
Toxoplasma gondii, stress stimuli have been implicated in an important 
differentiation step, from rapidly dividing tachyzoites, to quiescent bradyzoites 
(which enable immune evasion).  Evidence suggests that stress may also 
contribute to an essential differentiation stage, gametocytogenesis, in P. 
falciparum.  In yeast and metazoans, part of the stress response is mediated 
through phosphorylation of eukaryotic initiation factor 2α (eIF2α), which results 
in selective translation of mRNAs encoding stress response proteins.  Post-
transcriptional control of gene expression is suspected to play an important role 
in P. falciparum.  Importantly, the Goldberg laboratory recently demonstrated 
that similarly, in P. falciparum the eIF2α orthologue is phosphorylated in 
response to starvation. 
Here we identify the P. falciparum orthologue of the translation initiation factor 
eIF2α and provide bioinformatic evidence for the presence of three eIF2α 
kinases in P. falciparum; PfeIK1, PfeIK2 and PfPK4, only one of which (PfPK4) 
has been described previously (Mohrle et al., 1997).  We show that one of the 
novel eIF2α kinases, PfeIK1, is able to phosphorylate P. falciparum eIF2α in 
vitro.  In addition, initial experiments support previous observations that PfPK4 
is indeed an active protein kinase (Mohrle et al., 1997).  We present evidence 
that PfPK4 is essential for asexual growth, which precludes straightforward 
reverse genetics studies aiming to determine its possible role in 
gametocytogenesis.  In contrast, transgenic parasites allowed us to show that 
neither PfeIK1 nor PfeIK2 are required for asexual growth, or sexual 
development of the parasite in the mosquito vector.  However, preliminary 
evidence (requiring confirmation) may indicate that parasites lacking PfeIK1 3 
over-express PfPK4, which would suggest that PfeIK1 may play an important 
function in the parasite.  This study strongly suggests that a mechanism for 
versatile regulation of translation by several kinases with a similar catalytic 
domain, but distinct regulatory domains, is conserved in P. falciparum. 4 
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1  Introduction 
1.1 Malaria 
Malaria remains a devastating disease in most tropical and subtropical regions 
(Fig. 1-1) (Snow et al., 2005).  It is estimated that 40% of the world’s population 
is at risk from malaria, such that every year more than 500 million people 
become severely ill with the disease resulting in at least 1 million fatalities 
(WHO, 2007, Snow et al., 2005).  In humans, the disease is caused by infection 
with one of four species of the parasitic protozoan Plasmodium; P. falciparum, 
P. vivax, P. malariae, or P. ovale.  It has also recently been recognised that P. 
knowlesi, previously thought to infect only non-human primates, can infect and 
cause disease in humans (Cox-Singh et al., 2008, Luchavez et al., 2008).  
Infection with malaria parasites results in fever, headache, chills and vomiting, 
which if not treated promptly and effectively can progress to severe disease that 
may be fatal.  In addition to the threat to health, malaria also has a serious 
impact on socioeconomic development in endemic countries by impacting on 
long term demographics and the acquisition of human and physical capital (Sachs 
and Malaney, 2002).  To reduce this to a number, it has been calculated that in 
the long term, gross national product (GNP) per capita is reduced by more than 
half in malarious countries, compared to non malarious countries (Sachs and 
Malaney, 2002, http://www.rollbackmalaria.org/).  The emergence and spread 
of resistance to available antimalarial drugs in the parasite exacerbates the 
problem, adding urgency to the task of development of novel chemotherapeutic 
agents (Ridley, 2002b, Ridley, 2002a, Gelb, 2007). Clare Fennell, 2008     Chapter 1, 18 
 
Figure 1-1: Maps to illustrate the coincidence of the world malaria burden and poverty.   
A: Darker shades of blue indicate greater malaria burden.  B: Darker shades of red indicate greater 
poverty (adapted from Roll Back Malaria fact sheet 10 (http://www.rollbackmalaria.org/)). 
1.2 Plasmodium falciparum 
P. falciparum is responsible for the majority of lethal cases of malaria (Guerra 
et al., 2006), although there is increasing concern about the contribution of P. 
vivax to severe malaria (Joshi et al., 2008, Baird, 2007).  Fatalities from P. 
falciparum arise as the infection can progress to severe anaemia and central 
nervous system effects leading to coma and death.  P. falciparum is the major 
malaria parasite in sub-Saharan Africa, where greater than 90% of the world’s 
malaria is found (Snow et al., 2005).  As a consequence, P. falciparum is the 
most extensively studied of the human malaria parasites.  Completion of the P. Clare Fennell, 2008     Chapter 1, 19 
falciparum genome project in 2002 has transformed research into this parasite 
(Gardner et al., 2002, Waters, 2008).   
Plasmodium is a member of the apicomplexa, all of which are obligate 
intracellular parasites.  Other apicomplexan parasites of medical or agricultural 
importance include Toxoplasma gondii, an opportunistic parasite of 
immunocompromised individuals; Theileria spp, tick borne parasites of cattle in 
Africa; and Cryptosporidium, which is both an animal and opportunistic human 
parasite.  Genome sequences are available for species within each of these 
genera, which in conjunction with different in vitro culture and genetic 
manipulation possibilities is contributing to advances in our understanding of the 
apicomplexa as a whole (Abrahamsen et al., 2004, Gajria et al., 2008, Kim and 
Weiss, 2004).  Apicomplexan parasites are distinguished morphologically by the 
presence of an apical organelle complex for host cell invasion (Fig. 1-2).  
Apicomplexans have a complex life cycle with multiple developmental stages 
that occur in diverse tissues, often in more than one host; this probably reflects 
a series of evolutionary adaptations to optimise the exploitation of hosts 
(Aravind et al., 2003).   
 
Figure 1-2: Illustration of P. falciparum merozoites.   Clare Fennell, 2008     Chapter 1, 20 
A: Ultrastructure of a merozoite showing the apical organelles (micronemes and rhoptries) used in 
invasion.  B: Shows the relative size of the merozoite and host erythrocyte during invasion.  
Clockwise, the merozoite orients, anchors and invades, until it is within the erythrocyte inside the 
parasitophorous vacuole (adapted with permission from Bannister et al. 2000 (Bannister et al., 
2000)). 
 
1.3 Life cycle of malaria parasites 
Humans are infected following injection of sporozoites into the skin, by the bite 
of an infected Anopheles mosquito (Fig. 1-3).  Sporozoites move away from the 
injection site to reach a capillary, allowing them to travel to the liver where 
they invade hepatocytes and undergo schizogony to release thousands of 
merozoites.  Merozoites enter the bloodstream where they invade erythrocytes, 
a cycle that proceeds in a synchronous manner and is responsible for malaria 
pathogenesis.  On entering erythrocytes, a proportion of malaria parasites do not 
enter schizogony but arrest their cell cycle and differentiate into male or female 
gametocytes (see 1.3.1).  Critically, gametocytes are the only form capable of 
infecting the mosquito vector, and are therefore required for transmission to the 
next human host.  Ingestion of gametocytes by a female mosquito triggers 
gametogenesis entailing the release of a single female macrogamete and eight 
male microgametes.  Release of the motile microgametes is termed 
exflagellation, because male gametes are flagellated.  Fusion of the male and 
female gametes forms the zygote, the only short-lived, diploid stage of the 
lifecycle.  Further development produces a motile ookinete, in which meiosis 
occurs and which migrates through the mosquito midgut wall to establish an 
oocyst on the hemocoel side of the midgut.  Successive rounds of division and 
differentiation within the oocysts produce mature sporozoites that spread 
throughout the mosquito.  On reaching the salivary glands the sporozoites are 
ready to commence the next cycle of infection on the mosquitoes next blood 
meal.  Clare Fennell, 2008     Chapter 1, 21 
 
Figure 1-3: Illustration of the P. falciparum life cycle.   
A: Sporozoites from the bite of an infected Anopheles mosquito are carried to the liver where they 
invade hepatocytes.  After many rounds of division merozoites are released which invade 
erythrocytes starting the indefinite asexual cycle that gives rise to disease symptoms.  Some 
asexual parasites cease division and differentiate to gametocytes.  B: Injestion of gametocytes by a 
mosquito allows the parasite to complete the life cycle; gametogenesis and fertilization form an 
ookinete which is able to infect the mosquito mid gut wall.  Sporozoites form inside the oocysts, 
and on maturation reach the salivary glands in preparation for transmission to the next human host 
(adapted from with permission from Wirth, Nature 2002 (Wirth, 2002)). 
 
1.3.1 Gametocytogenesis 
As described above sexual differentiation or gametocytogenesis is essential for 
the transmission of P. falciparum, and other Plasmodia from one vertebrate host 
to the next.  The molecular mechanisms responsible for sexual differentiation 
(gametocytogenesis) are not understood (Silvestrini et al., 2005, Alano, 2007).  
However, various studies indicate that in P. falciparum the rate of switching 
from asexual replication to gametocytogenesis varies between parasite isolates, 
between cloned lines derived from a single isolate (Graves et al., 1984), and 
importantly is not constant within a cloned line but is sensitive to environmental 
conditions (Carter and Miller, 1979).  To this end, it has been observed that 
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that have an adverse effect on asexual replication, increase the rate of 
gametocytogenesis.  These include the presence of erythrocyte lysate 
(Schneweis et al., 1991), host immune sera and lymphocytes (Schneweis et al., 
1991, Smalley and Brown, 1981), the antimalarial, chloroquine (Buckling et al., 
1997), and a high asexual parasite density (Bruce et al., 1990).  The typically 
female biased sex ratio of gametocytes in Plasmodium is also variable (Alano, 
2007).   
Commitment to gametocytogenesis occurs at an unidentified time during the 
asexual cycle, such that a schizont contains either merozoites that will continue 
the asexual cycle, or that will develop into gametocytes (Bruce et al., 1990).  
Furthermore, the sex of the gametocytes arising from the same schizont is also 
previously determined (Silvestrini et al., 2005, Smith et al., 2000).  That rates of 
gametocytogenesis are responsive to environmental change suggests that a stress 
response mechanism may be involved.  Of interest is the observation that in T. 
gondii the switch from rapidly dividing tachyzoites to differentiation to 
quiescent bradyzoites is a stress-induced response (Weiss and Kim, 2000). 
1.4 Available chemotherapies/global antimalarial strategy 
The current increase in the world malaria burden is due to a number of factors; 
particularly the emergence and spread of drug resistance in the parasite, the 
resistance to insecticides in the mosquito vector , and the breakdown of health 
infrastructure in many endemic areas (Greenwood and Mutabingwa, 2002, 
Ridley, 2002b, Ridley, 2002a, Walther and Walther, 2007).  This has been 
recognised in naming malaria as one of the WHO’s high priority diseases and in 
public-private partnership initiatives such as the Medicines for Malaria Venture.  
Development of antimalarials is particularly challenging due to the 
circumstances in which they are primarily used, which demand compounds that 
are both very safe and very cheap.  Complexity is added by the benefit of using 
drugs in combination to minimise the development of resistance (Gelb, 2007).  
Antimalarials may target parasites during the asexual cycle, thereby reducing 
the disease burden.  Compounds could also be developed aimed at interfering Clare Fennell, 2008     Chapter 1, 23 
with gametocytogenesis, which would therefore act as transmission blocking 
agents.  Transmission blocking agents would represent a useful tool to limit the 
escape of drug-resistant genotypes selected during schizogony in the human 
host.  Strategies to limit the spread of resistance to available drugs are of 
paramount importance in the context of frequent sub-curative drug treatment, 
resulting in selection of drug resistant parasites and therefore increased 
probability of their transmission (Mackinnon and Read, 2004).  Considerable 
effort continues to be put into development of a vaccine, but to date nothing 
has progressed beyond mixed results in clinical trials (Matuschewski and Mueller, 
2007).  Insecticide treated nets and indoor residual spraying are also powerful 
tools with which limit contact between humans and mosquitoes that deserve 
further investigation and investment (reviewed (Walther and Walther, 2007)). 
1.5   Protein kinases 
Since the discovery of protein kinases (Edwin G Krebs & Edmond H Fisher, Nobel 
Prize 1992) reversible phosphorylation has been established as major mechanism 
of eukaryotic cellular regulation, with central roles in proliferation, 
differentiation and metabolism (Hanks, 2003).  Protein kinases have a conserved 
catalytic domain, possession of which forms them into one of the largest 
superfamiles of homologous genes and proteins (Hanks and Hunter, 1995).  The 
protein kinase superfamily divides into two major groups; the protein-
serine/threonine kinases and the protein-tyrosine kinases (Taylor et al., 1995, 
Johnson et al., 1998).  The kinase catalytic domain comprises twelve conserved 
subdomains that result in the proteins folding into a characteristic bi-lobed 
structure, as revealed by the now numerous solved 3-D structures (Dar et al., 
2005, Taylor et al., 1992, Merckx et al., 2008).  Conservation of the catalytic 
domain maintains three key aspects of the kinase reaction: i) binding and 
orientation of the phosphate donor, ATP (or GTP); ii) binding and orientation of 
the protein (or peptide) substrate; and iii) transfer of the terminal phosphate 
from ATP (or GTP) to the acceptor (Ser, Thr, or Tyr) of the protein substrate 
(Fig. 1-4) (Hanks and Hunter, 1995).  Of particular importance for catalytic 
function are the invariant lysine in subdomain II, which is involved in the Clare Fennell, 2008     Chapter 1, 24 
anchoring and orienting ATP, and the invariant aspartate in subdomain VIB that 
mediates phosphotransfer (Hanks, 2003, Niedner et al., 2006).  
 
Figure 1-4: Schematic to show the conserved subdomains of protein kinases.  (Adapted from 
Hanks 2003 (Hanks, 2003)). 
 
1.5.1   Kinases as drug targets 
The human genome encodes 518 kinase genes that are subdivided into 20 
families on the basis of structural relatedness.  Classical protein kinases account 
for 478 of these genes, of which 388 are serine/threonine kinases, 90 are 
tyrosine kinases and the remaining 50 lack a functional catalytic site and are 
therefore termed pseudokinases (Manning et al., 2002, Boudeau et al., 2006).  
The large number of kinases and their roles in cellular processes means that 
their disregulation is associated with diverse diseases, including rheumatoid 
arthritis, cardiovascular disorders, immunodeficiency and cancer (Cohen, 2002).  
In the case of cancer, approximately half of the 100 identified oncogenes encode 
kinases, while the other half either activate kinases, or are phosphorylated by 
kinases.  In the light of this, the development of kinases as drug targets is no 
surprise (Giamas et al., 2007). 
The first kinase inhibitor tested in clinical trials (imatinab mesylate/Gleevec®) 
has proved a highly successful anticancer drug for patients with chronic 
myelogenous leukaemia (CML).  Gleevec inhibits the Abelson cytoplasmic 
tyrosine kinase that is constitutively active in most patients with CML (Giamas et Clare Fennell, 2008     Chapter 1, 25 
al., 2007).  Gleevec has also been found to inhibit additional kinases and is also 
used in the treatment of gastrointestinal stromal tumours.  This raises an 
interesting point concerning the development of compounds that inhibit more 
than a single enzyme, which may help to overcome the fact that cells may use 
more than one overlapping signalling pathway to reach the same outcome.  
There are now more than 60 kinase-targeted drugs in clinical development, and 
many more in the pre-clinical stages.  Further, kinases are second only to G-
protein coupled receptors with respect to the number of screening targets in use 
by the pharmaceutical industry to identify new molecules (Weinmann and 
Metternich, 2005). 
The conservation of the structure of the kinase domain, where ATP is bound in 
the cleft between the two lobes of the catalytic domain might suggest that 
searching for selective competitive ATP-inhibitors would be an impossible task.  
Remarkably, the minor differences between kinases result in sufficient 
differences in the 3-D structure to result in changed hydrogen bonding capacities 
and hydrophobic interactions, causing differences in affinity (Giamas et al., 
2007, Fischer, 2004).  However, other inhibition paradigms are being developed 
such as allosteric inhibition to change the conformation, preventing substrate 
binding, or direct competition with the kinase substrate.  These new strategies 
may facilitate new therapeutic opportunities and also limit off-target side 
effects, where specific inhibition is desirable (Bogoyevitch and Fairlie, 2007).   
1.6   Kinases in P. falciparum 
Plasmodium and other parasitic protists such as Toxoplasma and the 
trypanosomatids including Trypanosoma and Leishmania, belong to taxonomic 
groups that are phylogenetically hugely distant from the Opisthokonta branch, 
which includes animals and fungi (Baldauf, 2003).  Completion of the P. 
falciparum genome project (Gardner et al., 2002) allowed two independent 
analyses of the complete complement of Plasmodium kinases, or kinome (Ward 
et al., 2004, Anamika et al., 2005).  The studies were essentially in agreement, 
and identified substantial differences between the plasmodium and mammalian 
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the levels of i) the composition of the kinome, ii) the organisation of signalling 
pathways, and iii) the properties of individual enzyme orthologues, when they 
can be identified (Doerig, 2004b, Doerig et al., 2005, Doerig and Meijer, 2007).  
Concerning the composition of the kinome, members of most groups of 
eukaryotic kinases could be identified, with the exception of the tyrosine kinases 
and STEs (which are part of the mitogen activated protein (MAP) kinase 
pathway).  On the other hand, many ‘orphan’ kinases were identified that do not 
cluster with any of the identified mammalian or yeast kinase families.  
Intermediate to these extreme examples are a number of genes that clearly 
cluster with a defined kinase family, but branch off at the base of the cluster, 
such that assignment of orthology to a specific mammalian enzyme is impossible; 
these kinases are referred to as semi-orphans (Ward et al., 2004).  At the level 
of signalling cascades a notable example is the lack of a classical three-tier MAP 
kinase pathway (Dorin et al., 2005).  P. falciparum has two atypical MAPKs but 
the absence of MAPKKs indicates that their activation is through other as yet 
uncharacterised mechanisms.  Finally, with regard to divergence at the 
individual enzyme level, even clear orthologues display significant differences, 
such as the presence of large insertions/extensions, or variant regulatory sites 
(Doerig and Meijer, 2007).  Illustrations of such differences are a MAPK lacking 
the usual TxY motif (Dorin et al., 1999) and a PKG (protein kinase G) homologue 
with an atypical regulatory region (Deng et al., 2003).   
Data is accumulating that many members of the Plasmodium kinome are 
essential for schizogony, (Dorin-Semblat et al., 2007) (Doerig lab, in prep.) and 
therefore represent potential targets for curative drugs.  Kinases demonstrated 
to have an essential role in the sexual development of the parasite represent 
potential transmission-blocking targets (Reininger et al., 2005).  The emerging 
differences between parasite protein kinases and their host homologues is 
supportive of the idea of specific targeting of the former (Doerig, 2004a, Doerig, 
2004b, Doerig and Meijer, 2007, Leroy and Doerig, 2008). Clare Fennell, 2008     Chapter 1, 27 
1.7   Gene regulation in P. falciparum 
Completion of the P. falciparum genome sequence, in conjunction with that of  
the rodent malaria P. yoelli in 2002, and more recently P. berghei, and P. 
chabaudi has opened a new level of investigation into all aspects of Plasmodium 
biology, including gene regulation (Gardner et al., 2002, Carlton et al., 2002, 
Hall et al., 2005).  Initially, very few genes could be categorised as transcription 
factors, although it was acknowledged that this could have been due to 
difficulties in identification, due to their divergence from known examples, and 
exacerbated by the A-T richness of the genome (Gardner et al., 2002).  Two 
studies of the P. falciparum transcriptome followed shortly after (Le Roch et al., 
2003, Bozdech et al., 2003); the more comprehensive data set, composed of 1 
hour time points over the 48 hour intra-erythrocytic developmental cycle, 
demonstrates transcriptional regulation resulting in a continuous cascade of 
gene expression, unlike anything observed previously in eukaryotic biology 
(Bozdech et al., 2003).  Furthermore, contiguous genes on chromosomes were 
rarely found to be co-regulated (Bozdech et al., 2003).  This transcriptional 
pattern, which must underlie the complex developmental changes that occur 
during the parasite life cycle, the use of monocistronic mRNAs, and the 
conservation of basal eukaryotic transcription factors, inspired a continued 
search for a more sophisticated transcriptional network.  This has been 
rewarded with the identification of Apicomplexan AP2 (ApiAP2) DNA-binding 
proteins (Balaji et al., 2005, De Silva et al., 2008).  DNA binding specificities for 
two P. falciparum  ApiAP2 proteins have been defined and represent sequence 
motifs found in the 3’ region of sets of genes that show coregulation during the 
asexual cycle (De Silva et al., 2008).   
Despite this recent advance a body of evidence supports a significant role for 
post-transcriptional control in P. falciparum.  An analysis of the P. falciparum 
genome for transcription-associated proteins revealed only one third of the 
expected number, for the genome of a free living eukaryote; however, the 
CCCH-type zinc finger, commonly found in proteins involved in modulating mRNA 
decay and translation rates is over represented (Coulson et al., 2004).  
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initiation and mRNA decay were also identified (Coulson et al., 2004).  The 
pattern of mRNA decay rates across the P. falciparum genome contrasts with 
that observed in other organisms; the half-life of each mRNA is usually precisely 
related to its physiological role, whereas P. falciparum shows a genome-wide 
decrease in mRNA decay rate through the intra-erythrocytic developmental cycle 
(Shock et al., 2007).  Although sexual differentiation is a special case, several 
examples exist of transcripts produced in gametocytes, but translated only after 
gametogenesis has been initiated (Paton et al., 1993, Hall et al., 2005).  In P. 
berghei one mechanism of implementing this translational repression has been 
described; in female gametocytes DOZI (development of zygote inhibited), an 
RNA helicase, is found in complex with RNAs known to be translated only after 
fertilisation, including p25 and p28 (Mair et al., 2006).  PbDOZI was found to 
play a critical role in formation of ribonucleoprotein complexes, without which 
nearly 400 transcripts were degraded instead of stored (Mair et al., 2006). 
In spite of recent progress, much remains to be discovered about the regulation 
of protein levels in P. falciparum; much of this regulation may prove to be 
mediated at the level of translation. 
1.8 Stress responses 
The ability of a cell to sense and respond appropriately to stress is essential to 
maintain homeostasis.  Diverse factors may be stressful to a cell, including 
oxidative agents, chemical assault, nutrient deprivation, genetic damage and 
even the process of differentiation.  Response to stress involves induction of 
programmes of gene expression that enable damage repair, or alternatively 
induce apoptosis.  A significant element of the stress response is mediated by 
transcriptional change; however, since significant damage could result from mis-
translation or aberrant protein folding, stress responses are also mediated 
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1.8.1 Stress Activated Protein Kinases 
A large component of the stress response is mediated through a family of 
proteins termed stress-activated protein kinases (SAPKs).  The SAPKs, 
specifically JNKs and p38 kinases, are subfamilies of mitogen activated (MAP) 
kinases (see 1.6) that are expressed in essentially all tissues and respond to a 
variety of stress conditions (Engelberg, 2004).  As members of the MAPK family, 
the SAPKs are at the bottom of three-tier kinase cascades, the downstream 
targets of which are diverse, but include a range of transcription factors 
(Engelberg, 2004, Robinson and Cobb, 1997, Davis, 2000, Nebreda and Porras, 
2000).  This is of interest here for two reasons: firstly with regard to the dearth 
of P. falciparum proteins identified to play a role in transcriptional regulation, 
and of the conserved sequences on which they might act (for further discussion 
see 1.7) (Coulson et al., 2004); secondly, both bioinformatic and experimental 
approaches suggest that classical three-component MAPK signalling pathways do 
not operate in malaria parasites.  Furthermore, although the parasite kinome 
includes two MAPK homologues, none of these are members of the SAPK 
subfamily (Dorin et al., 2005). 
1.8.2   eIF2α pathway 
The SAPKs described above mediate change by regulation of transcription; gene 
function can also be regulated by modulation of protein synthesis.  Initiation, 
elongation and termination of translation can all be regulated although 
influencing the earliest stages of the pathway conserves resources most 
effectively.  Phosphorylation of eukaryotic initiation factor-2α (eIF2α) in 
response to stress is one mechanism of regulating translation initiation.  
Phosphorylation of eIF2α at residue Ser51 is a well-characterised and conserved 
mechanism of post-transcriptional control that regulates initiation of translation 
(Wek et al., 2006, Holcik and Sonenberg, 2005, Proud, 2005, Choi et al., 1992, 
Murtha-Riel et al., 1993, Colthurst et al., 1987).  This mechanism is conserved in 
the vast majority of eukaryotes.  One notable exception is the microsporidium 
Encephalitozoon cuniculi, whose kinome does not include eIF2α kinases (or other 
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(Miranda-Saavedra et al., 2007).  In mammalian cells this phosphorylation event 
is mediated by four distinct protein kinases; general control non-derepressible-2 
(GCN2), protein kinase RNA (PKR), haem-regulated inhibitor kinase (HRI), and 
PKR-like endoplasmic reticulum kinase (PERK), all four of which serve to 
integrate diverse stress signals into a common pathway (Wek et al., 2006, Holcik 
and Sonenberg, 2005, Proud, 2005, Chen and London, 1995). 
 
Figure 1-5: Integration of stress responses by phosphorylation of eIF2α.   
The eIF2α kinases (GCN2, PKR, HRI, PERK) are activated by diverse stress stimuli to 
phosphorylate eIF2α.  Phosphorylation of eIF2α inhibits the GDP-GTP exchange by reducing the 
dissociation rate of eIF2B.  This reduces the availability of the ternary complex resulting in a 
decrease in global protein synthesis, and selective translation that mediates the stress response 
(adapted with permission from Holcik & Sonenberg 2005 (Holcik and Sonenberg, 2005)). 
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Translation of eukaryotic mRNAs involves the recognition and recruitment of 
mRNAs by the translation initiation machinery, and the assembly of the 80S 
ribosome on the mRNA, which is mediated by proteins known as eukaryotic 
initiation factors (eIFs).  Formation of the 43S preinitiation complex depends on 
binding of the ternary complex that consists of the heterotrimeric G-protein 
eIF2, methionyl-initiator tRNA (met-tRNAi) and GTP (Fig. 1-5) (Holcik and 
Sonenberg, 2005, 2000).  Initiation of translation and release of the initiation 
factors involves hydrolysis of GTP to GDP, which leaves an inactive eIF2α-GDP 
complex.  Before further rounds of translation initiation can occur eIF2α must be 
reactivated by exchange of GDP for GTP by eIF2B (Holcik and Sonenberg, 2005).  
Presence of a phosphate group on the eIF2α subunit inhibits recycling of inactive 
eIF2-GDP to active eIF2-GTP by limiting the activity of the guanine nucleotide 
exchange factor activity of eIF2B (Sudhakar et al., 2000).  The consequence of 
activity of the eIF2α kinases therefore is global translation repression, since 
initiation complexes cannot form, thus preserving energy and nutrients.   
It is interesting to note however, that in spite of the mechanism described 
above, leading to translational repression, the translation of some mRNAs is 
enhanced when eIF2α is phosphorylated (Holcik and Sonenberg, 2005, Proud, 
2005).  The paradigm for such regulation is provided by the mRNA for the yeast 
protein Gcn4p that has four short upstream open reading frames (uORFs).  When 
the ternary complex (containing the initiator methionine) is plentiful these four 
uORFs are translated, but ribosomes are likely to fall off the mRNA before 
reaching the start codon of Gcn4.  When the ternary complex is in short supply 
due to eIF2α phosphorylation some ribosomes are able to move quickly along the 
mRNA reaching the Gcn4 start codon, some of which will bind a ternary 
complex, enabling translation initiation.  A similar mechanism is believed to 
operate for mammalian ATF4 (Proud, 2005).  An alternative mechanism that 
operates for other mRNAs and in some instances is regulated by eIF2α 
phosphorylation, is the use of internal ribosome entry sequences (IRESs), which 
allow translation initiation independently of the 5’cap and eIF4 complex utilised 
by most mRNAs (Fernandez et al., 2002).   Clare Fennell, 2008     Chapter 1, 32 
Signal transduction through the eIF2α pathway is very rapid; phosphorylation and 
translational repression have been shown to be complete as soon as 30 minutes 
after exposure to stress (Novoa et al., 2003), whereas in responses by activation 
of gene expression programs the latency will be measured in hours (Harding et 
al., 2002).  The immediacy of this pathway is important under stress conditions 
where rapid deployment of appropriate response and use of resources is 
essential for cell survival. 
1.8.3   eIF2α kinases, mechanisms & activation 
1.8.3.1    Domain structure 
The eIF2α kinases have a homologous catalytic domain that enables them to 
phosphorylate the same substrate, eIF2α.  However, in order to respond to 
different stimuli they have different regulatory domains (Fig. 1-6) and are 
located in different subcellular compartments.  GCN2 is one of few proteins to 
possess both a functional and an inactive kinase domain (Boudeau et al., 2006).  
The degenerate kinase domain lies N-terminal to the functional kinase domain, 
which is followed by the major motif for activation: the histidyl-tRNA synthetase 
(HisRS)-like domain (Wek et al., 1989, Wek et al., 1995, Dong et al., 2000).  The 
HisRS domain functions by binding uncharged tRNAs that accumulate during 
amino acid limitation, leading to activation of the kinase domain (Wek et al., 
1995).  PKR has an N-terminal double-stranded RNA (dsRNA) binding domain 
composed of two copies of a dsRNA-binding motif, and a C-terminal kinase 
domain (Meurs et al., 1990, Dar et al., 2005).  HRI has an N-terminal region 
containing one heme-binding domain, and a second heme-binding domain within 
an insertion in the kinase domain (Rafie-Kolpin et al., 2000, 2000, Chefalo et al., 
1998).  Finally, PERK has a single trans-membrane domain and resides in the 
endoplasmic reticulum (ER); an amino-terminal luminal domain similar to that of 
the ER-stress-sensing kinase Ire1 monitors the protein folding environment, while 
the cytoplasmic portion contains the kinase domain where it can interact with 
the translation initiation machinery (Harding et al., 1999).  PERK is involved in 
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kinase to have immediate impact on proteins destined for secretion by its 
proximity to the ribosomes on the rough ER.   
 
Figure 1-6: Schematic of the domain structures of the eIF2a kinases.   
Conserved kinase domains (KD) are depicted in green.  The two heme binding sites (H) in HRI are 
marked in red.  The double stranded RNA binding domains (dsRBD) in PKR are shown in blue.  
The N-terminal half of PERK resembles the corresponding domain of the ER stress-responsive 
IRE1 kinase.  The signal peptide (SP) and transmembrane domain (TM) of PERK are also shown.  
The regulatory histidyl-tRNA synthetase (hisRS) domain in GCN2 is shown in purple.  The 
locations of the GCN1 binding domain (blue), charged region (+/-) and pseudo-kinase domain 
(ψKD), as well as the C-terminal ribosome binding, and dimerisation domain (RB/DD) domain in 
GCN2 are also indicated (adapted from Dever 2002 (Dever, 2002)). 
 
A characteristic of the eIF2α kinases is the presence of insertions within the 
kinase domain between subdomains IV and V (Figs. 3-5 & 3-6).  The length and 
composition of these inserts is variable and no function has been ascribed to 
date, apart from HRI where one of the heme binding domains is in this region 
(Mathews, 2007).  The sequence between subdomains VII and VIII, comprising the 
activation loop may also be extended (Figs. 3-5 & 3-6) (Mathews, 2007). 
1.8.3.2    Activation mechanism 
Dimerisation and autophosphorylation appear to be an integral part of PERK, HRI 
and GCN2 kinase function (Bertolotti et al., 2000, Bauer et al., 2001, Qiu et al., 
2001, Liu et al., 2000).  For example ER stress induces ligand-independent 
lumenal-domain driven homodimerisation of PERK, following dissociation of the 
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autophosphorylates, activating the kinase domain (Liu et al., 2000).  Evidence 
suggests HRI is active as an autokinase immediately following synthesis, however 
additional multiple autophosphorylation events facilitate formation of the stable 
homodimer capable of eIF2α phosphorylation, that is positively regulated by 
heme (Bauer et al., 2001, Rafie-Kolpin et al., 2003).  In PKR, binding dsRNA 
initiates dimerization and autophosphorylation on Thr466 within the activation 
segment of its catalytic domain.  This leads to the full catalytic activation of 
PKR and the selective ability to phosphorylate eIF2α (Ung et al., 2001, Zhang et 
al., 2001, Nanduri et al., 2000).  Dar et al. have shown that in PKR the N-
terminal lobe of the catalytic domain mediates dimerization (Dar et al., 2005).  
The mechanism of dimerization in PKR is found to differ critically from the 
classical in trans activation paradigm of receptor tyrosine kinases (TRK).  Such a 
mechanism is precluded in PKR by the back-to-back arrangement of the kinase 
domain dimer, so that PKR autophosphorylation must occur in cis or through the 
action of a PKR dimer on other PKR dimers or monomers (Dar et al., 2005).   
Conservation of the activation-segment phosphoregulatory site and basic 
phosphocoordinating residues underlines the importance of activation segment 
phosphorylation for regulation of the kinase activity of three of the four eIF2α 
kinases.  GCN2 exists as a constitutive dimer, and has therefore potentially lost 
this requirement (Dar et al., 2005).  Similarities between the catalytic domains 
of the eIF2α kinase family suggest that the mechanisms of catalytic regulation 
and substrate recognition discerned from the PKR/eIF2α complex are 
functionally relevant for the eIF2α protein kinase family as a whole. 
Mutational analysis of PKR identified residues that activate PKR in the absence 
of its regulatory domains, and that map to the dimerization surface on the 
kinase catalytic domain (Dar et al., 2005, Dey et al., 2005).  Distinct sites were 
identified that block autophosphorylation and eIF2α phosphorylation, whilst 
mutation of PKR Thr466, an autophosphorylation site within the catalytic domain 
activation segment, impairs eIF2α phosphorylation (Dey et al., 2005).  An 
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dimerization triggers Thr446 autophosphorylation and specific eIF2α substrate 
recognition (Dey et al., 2005).   
1.8.3.3    Substrate recognition and phosphorylation by eIF2α 
kinases  
To understand the basis for substrate recognition by PKR and its regulation, Dar 
et al. (Dar et al., 2005) determined X-ray crystal structures of the catalytic 
domain of PKR in complex with eIF2α, and were able to show that eIF2α binds to 
the C-terminal catalytic lobe (Dar et al., 2005).  As a result of the potent 
antiviral role played by PKR, most viruses have evolved mechanisms of 
circumventing its function, and the study of these mechanisms has been 
informative in elucidating the normal workings of PKR (Kawagishi-Kobayashi et 
al., 1997, Dar and Sicheri, 2002).  The eIF2α recognition mechanism is fully 
conserved across eIF2α kinases, with the primary determinants appearing to 
consist of the unique size and orientation of helix αG, rather than a strict 
conservation of residues comprising the eIF2α contact surface (Dar et al., 2005) 
(see below, section 3.2.1, for a full discussion of the structure).  The evidence 
presented suggests that the higher-order substrate recognition mechanism 
employed by PKR is restricted to eIF2α recognition, however the possibility of 
alternate substrate targeting mechanisms are not ruled out (Dar et al., 2005). 
1.8.4 Effects of phosphorylation of eIF2α 
eIF2 has a much higher affinity for GDP than GTP so the guanine-nucleotide 
exchange factor (GEF) eIF2B is required to return eIF2 to a GTP bound state.  
Phosphorylation of eIF2α on Ser51 converts eIF2 from a substrate to a 
competitive inhibitor of eIF2B, effectively sequestering eIF2 in an inactive state.  
This results in a reduction in the availability of the ternary complex and 
therefore decreases translation of most mRNAs, by reducing initiation.  
Paradoxically, as mentioned above, phosphorylation of eIF2α increases the 
translation of certain specific mRNAs, which encode proteins involved in the 
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1.8.5 Feedback to regulate phosphorylation of eIF2α. 
Since the consequence of eIF2α phosphorylation is repression of translation, a 
cell cannot function under these conditions indefinitely; furthermore, long-term 
adaptation to stress conditions requires synthesis of new proteins.  It must 
therefore be possible to terminate the activities of the eIF2α kinases and 
remove the phosphates they add when a cell is no longer under stress, whilst 
retaining the capacity to respond appropriately for the duration of exposure to 
stressful stimuli (Rutkowski and Kaufman, 2004).  Some mRNAs may have 
features that protect them from translational repression, such as the ATF4 
mRNA, the translation of which is actually induced by global translational 
repression due to its 5’ uORF structure (Proud, 2005).  However, translation of 
most mRNAs, including important ER chaperones (such as BiP) that are 
ultimately required for the stress response, requires relief from the repressed 
state.  It is established that translational repression in response to both ER stress 
and exposure to arsenite is transient, and that expression of stress-induced 
mRNAs and their encoded proteins coincides with a phase of translational 
recovery (Brostrom et al., 1989).  Protein phosphatase 1 (PP1) has been shown 
to dephosphorylate eIF2α in vitro and in vivo (Redpath and Proud, 1990, Novoa 
et al., 2001, He et al., 1997).  Evidence suggests growth arrest and DNA damage 
gene 34 (GADD34), a stress-inducible regulatory subunit of a holophosphatase 
complex that includes PP1 as a catalytic subunit, plays a key role in the recovery 
process (Novoa et al., 2003).  GADD34 requires activation of PERK for its 
upregulation, and its expression is probably controlled by ATF4 (Rutkowski and 
Kaufman, 2004).  There is also evidence to suggest that PP1 activity may be 
negatively regulated by the redox state in vivo, such that under conditions of 
oxidative stress, PP1 activity is inhibited, increasing the levels of phosphorylated 
eIF2α (O'Loghlen et al., 2003).   
1.8.6   eIF2α kinases in protozoan parasites 
T. gondii switches from the rapidly dividing tachyzoite form to differentiate to 
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therefore hypothesised that phosphorylation of eIF2α could play a role in this 
process.  An eIF2α kinase (TgIF2K-A) and orthologue of the initiation factor 
(TgIF2α) were identified (Sullivan et al., 2004).  It was shown that TgIF2K-A 
phosphorylates the regulatory serine of yeast eIF2α in vitro and in vivo, and can 
modulate translation when expressed in the yeast model system (Sullivan et al., 
2004).  Finally, treating tachyzoites with heat shock, or alkaline stress, 
conditions which are known to induce differentiation to bradyzoites, resulted in 
increased phosphorylation of TgeIF2α (Sullivan et al., 2004).  A family of three 
potential eIF2α kinases has also been identified in Trypanosoma brucei (Moraes 
et al., 2007).  TbeIF2K2 was found to be active in vitro and able to 
phosphorylate the unusual eIF2α found in T. brucei.  TbeIF2K2 is a 
transmembrane glycoprotein that localises mostly to the flagellar pocket, 
suggesting a role in sensing protein or nutrient transport which is likely to be 
critical to an organism that relies on post-transcriptional control of gene 
expression to respond to different environmental conditions.  An eIF2α kinase 
(PfPK4) was previously identified in P. falciparum, initial characterisation 
showed PfPK4 possesses kinase activity and is expressed throughout the asexual 
cycle (Mohrle et al., 1997). 
1.9 Rationale for investigation of eIF2α kinases in P. 
falciparum and aims of this project 
As has been described above, the molecular mechanisms of a stress response in 
P. falciparum, and in particular those regulating the switch from asexual 
multiplication to differentiation into gametocytes are not understood (Dyer and 
Day, 2000).  Notably, the related apicomplexan parasite T. gondii has been 
shown to phosphosphorylate TgeIF2α in response to various stress stimuli, 
concomitant with differentiation to bradyzoites (Sullivan et al., 2004, 
Narasimhan et al., 2008).  In contrast, the microsporidium E. cuniculi, does not 
encode any eIF2α kinases (or other stress-response kinases), which may be an 
adaptation to its parasitic lifestyle (Miranda-Saavedra et al., 2007).  It is 
therefore of interest to investigate the extent to which malaria parasites may 
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The analysis of the P. falciparum kinome published by this laboratory (Ward et 
al., 2004), in conjunction with experimental approaches (Dorin et al., 2005, 
Dorin et al., 1999), shows that the parasite does not possess SAPK homologues.  
Additionally MEK1/2 and ERK/ERK2 orthologues, which mediate mating type 
differentiation in yeast are not present in the P. falciparum kinome (Barr et al., 
1996).  In contrast, the P. falciparum kinome contains three kinases that cluster 
with eIF2α kinases on phylogenetic trees (Ward et al., 2004).  This is consistent 
with the evidence supporting a significant role for post-transcriptional regulation 
of stress response in Plasmodium, compared to yeast or mammalian cells 
(Coulson et al., 2004, Wirth, 2002, Bozdech et al., 2003).  
 
The aims of this project are as follows: 
•  To express the three eIF2α kinase-related enzymes and the P. 
falciparum eIF2α orthologue in bacteria, and determine if the latter is a 
substrate for the protein kinases. 
•  To determine the function of the PfeIF2α kinase-related enzymes in 
parasite development. 
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2  Materials and Methods 
2.1 Biological and chemical reagents 
Details of biological and chemical reagents and their suppliers, including 
oligonucleotide primers and antibodies, are provided in the appendix (6.1), 
followed by details the composition of buffers, solutions and media (6.2). 
2.2   Bioinformatics 
2.2.1   PfeIF2α 
BLASTP searches of the Plasmodium genome database PlasmoDB (Bahl et al., 
2003) using metazoan eIF2α sequences were used to identify PF07_0117, which 
was then confirmed by reciprocal analysis.  Alignment of these sequences was 
performed using ClustalW (Thompson et al., 1994).  Microarray data for gene 
expression (Le Roch et al., 2003) were taken from PlasmoDB (Bahl et al., 2003). 
2.2.2   P. falciparum eIF2α kinases  
Catalytic domains of the putative PfeIF2α kinases, defined by the alignment of 
P. falciparum kinases (Ward et al., 2004) were used to identify their closest 
human and P. berghei orthologues by BLASTP analysis.  These sequences were 
aligned either against a profile generated from our previous P. falciparum 
kinome analysis (for the alignment of sequences from all families of kinases) 
(Ward et al., 2004), or against the PKinase profile from Pfam (for the multi-
species alignment of eIF2α kinase sequences) using the HMMER package (Finn et 
al., 2006).  To analyse the relationships between sequences in the alignments, 
gaps and positions with a low quality of alignment were removed.  For the 
analysis of sequences from all families of kinases alternate phylogenies 
generated with the neighbour joining method were visualised using 
NeighbourNet implemented on SplitsTree version 4 (Huson and Bryant, 2006).  To 
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package (Kumar et al., 2004) was used to generate a neighbour joining tree.  
Microarray data for gene expression (Le Roch et al., 2003) were taken from 
PlasmoDB (Bahl et al., 2003).  Information on additional domains to the protein 
kinase domains was also taken from PlasmoDB (Bahl et al., 2003). 
2.3   Methods in molecular biology 
2.3.1   Polymerase chain reaction (PCR) 
Plasmodium genes were amplified from either cDNA or gDNA using the following 
PCR systems. 
2.3.1.1    Takara 
Reactions using the Takara Ex Taq polymerase contain 0.6 units Ex Taq, 1X Ex 
Taq buffer (2mM MgCl2), dNTPs (200μM each), 10-100ng template, 1μM each 
oligonucleotide in a final volume of 25μl.  PCR conditions were as follows: 
Initial denaturation: 3 minutes, 94
oC 
30 - 32 cycles of: 
Denaturation: 30 seconds, 94
oC 
Annealing: 30-45 seconds, 45-55
oC 
Elongation: 1minute per kb to be amplified, 60 or 68
oC 
Final elongation: 60 or 68
oC, 10 minutes 
For addition of adenine overhangs for pGEM-T cloning of PCR products obtained 
with a proof-reading polymerase (which does not add adenine overhangs), Ex 
Taq buffer, dNTPs and Ex Taq polymerase (concentrations as above) were added 
to a purified PCR product, and incubated at 68
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2.3.1.2    Phusion 
Where a proof reading polymerase was required, the Phusion polymerase 
(Finnzymes) was used.  Reactions contained 1X Phusion High Fidelity buffer, 
200μM each dNTP, 0.5μM each oligonucleotide, 10-100ng template DNA, 0.5U 
Phusion polymerase in a final volume of 25μl.  PCR conditions were as follows: 
Initial denaturation: 3minutes, 98
oC 
30 cycles of: 
Denaturation: 10 seconds 98
oC 
Annealing: 30 seconds, 50 - 55
oC 
Extension: 30 seconds per kb to be amplified, 68
oC 
Final extension: 10 minutes, 68
oC 
2.3.1.3    Expand High Fidelity PCR system 
The Expand High Fidelity PCR kit (Roche) provided an alternative proof-reading 
system; it was set up in two master mixes.  The first mix contained 200μM each, 
dNTPs, 300nM each oligonucleotide, 10 - 100ng gDNA template in 12.5μl.  The 
second mix contained 1X reaction buffer, MgCl2 1.5 - 4mM, Expand High Fidelity 
enzyme mix, 1.3 units in 12.5μl.  12.5μl of each mix were then combined to 
produce a complete reaction mix in 25μl.  The MgCl2 concentration was 
increased where necessary to increase the yield, although at the expense of 
some fidelity.  The enzyme mix contained a Taq DNA polymerase and a Tgo DNA 
polymerase with proofreading activity.  PCR was carried out as follows:  
Initial denaturation: 2 mins 94
oC 
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Denaturation: 30 seconds, 94
oC 
Annealing: 30 seconds, 55
oC 
Elongation: 1minute/kb to be amplified, 68
oC 
20 cycles of  
Denaturation: 30 seconds, 94
oC 
Annealing: 30 seconds, 55
oC 
Elongation: 1 minute/kb to be amplified + additional 5 seconds for elongation at 
each subsequent cycle, 68
oC 
Final elongation: 10 minutes, 68
oC 
2.3.2   Reverse transcriptase PCR (RT-PCR) 
cDNA was prepared immediately after isolation of parasite RNA (2.5.9), using the 
SuperScript First -Strand Synthesis System (Invitrogen) as follows.  cDNA was 
prepared from total RNA and primed using random hexamers.  RNA samples were 
treated with DNase I (Invitrogen), prior to RT-PCR by incubating 1μg RNA sample, 
1μl 10X DNase I reaction buffer, 1μl DNase I, Diethylpyrocarbonate (DEPC)-
treated H2O to 10μl at room temperature (RT), 15 minutes.  DNase I was 
inactivated by addition of 1μl 25mM EDTA, 65
oC, 10 minutes.  RNA/primer mixes 
contained up to 5μg total RNA, 50 ng random hexamers, 1mM dNTP and DEPC 
treated water to 10μl and were denatured at 65
oC, 10 minutes.  Reaction mixes 
contained 2μl 10X Reverse Transcriptase buffer, 4μl, 25mM MgCl2, 0.1M DTT, 1μl 
RNaseOUT Recombinant Ribonuclease Inhibitor per reaction.  Annealing was by 
addition of 9μl reaction mix to each RNA/primer mix, incubation 25
oC, 2 
minutes, followed by 1μl (50 units) of SuperScript II Reverse Transcriptase 
(except the no Reverse Transcriptase control) and incubation 25
oC, 10 minutes.  
Reactions were incubated at 42
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at 70
oC, 15 minutes.  To improve sensitivity of subsequent PCR reactions RNA 
was removed from the cDNA:RNA hybrid molecules by addition of 1μl RNase H to 
each reaction, 37
oC, 20 minutes.  cDNA was either stored at -20
oC, or used 
immediately for PCR (2.3.1). 
2.3.3   Gene cloning techniques 
PCR products were either cloned directly into pGEM-T easy, using the adenine 
overhangs produced by the Taq (Takara) and High Fidelity (Roche) polymerases, 
or were digested using restriction sites in the oligonucleotide primers for direct 
insertion into vectors that had been digested to produce complementary sticky 
ends. 
2.3.3.1    pGEM-T easy cloning of PCR products 
PCR products carrying adenine overhangs at their 3’ ends were cloned into the 
pGEM-T easy vector (Fig. 2-1) (Promega), following manufacturer’s instructions.   Clare Fennell, 2008     Chapter 2 44 
 
Figure 2-1: Map of the cloning vector, pGEM-T Easy. 
 
2.3.3.2    Sub-cloning into destination vectors 
Inserts of verified pGEM T-easy clones were subcloned into the appropriate 
destination vector.  The inserts were removed from pGEM-T by digestion with 
the appropriate restriction endonucleases (2.3.7).  The destination plasmid was 
linearised using either the same restriction enzymes, or with enzymes to 
generate complementary sticky ends.  Both digests were separated by agarose 
gel electrophoresis, the fragments of interest excised from the gel and purified 
using the Qiagen Gel Extraction kit, according to manufacturer’s instructions.  
DNA was eluted in 30μl EB buffer. 
The insert and destination vector were ligated using T4 DNA ligase (Invitrogen).  
Molar ratios of vector to insert ranged from 3:1 - 1:3 and ligated either at RT for 
1-3 hours, or overnight at 16
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into thermocompetant E. coli XL-10 gold and plated on LB plates containing the 
appropriate antibiotics.  Single colonies were analysed by PCR screening 
followed by DNA miniprep (2.3.6) and restriction endonuclease digestion (2.3.7).  
Plasmids containing an insert of the correct size were verified by DNA 
sequencing. 
2.3.4  E. coli transformation 
5μl of a ligation reaction or 1μg of plasmid miniprep were transformed into 
thermocompetant E. coli by incubating for 5 minutes on ice, 30-42 seconds at 
42
oC, followed by 2 minutes on ice.  Cells were mixed with an equal volume of 
2YT medium and plated into LB agar plates containing the appropriate 
antibiotic. 
2.3.5   Preparation of competent cells 
Thermocompetant E. coli were prepared using the modified Rubidium Chloride 
method.  A single colony of the required strain was inoculated into 5ml LB 
medium and grown overnight at 37
oC, shaking (200rpm).  Overnight cultures 
were diluted 1:100 and grown at 37
oC, shaking, to OD600 0.4 - 0.6.  Cells were 
pelleted by centrifugation at 4500 g, 4
oC, 5 minutes, resuspended in 0.4 original 
culture volume of ice cold TFB1 and incubated on ice for 5 minutes.  Cells were 
centrifuged as before, gently resuspended in 0.04X the original culture volume 
of ice cold TFB2 and incubated on ice for 15 - 60 minutes.  Aliquots of 100μl 
were prepared, frozen on dry ice and stored at -80
oC.   
2.3.6   Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated from E. coli in two different ways, depending on the 
amount of DNA required. 
For small scale isolations the Qiaprep Spin Miniprep kit (Qiagen) was used.  A 
single colony was inoculated into 5ml LB medium containing the appropriate 
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centrifugation at 2300g, 5 minutes and plasmid DNA extracted according to 
manufacturers instructions.  DNA was eluted in 30μl EB and stored for further 
analysis. 
Relatively large amounts of plasmid DNA were required for transfection of P. 
falciparum; In this case the PlasmidMaxi kit (Qiagen) was used.  A 5ml culture 
was grown for 8 hours by inoculation of a single colony to LB medium containing 
the appropriate antibiotic.  This culture was diluted 1:100 to 250ml LB medium, 
plus antibiotic and grown overnight at 37
oC, shaking (200 rpm).  Cells were 
collected by centrifugation at 3800g, 4
oC for 20 minutes and DNA isolated 
according to manufacturers’ instructions.  DNA was eluted in 150μl H2O under 
sterile conditions and concentration assessed by spectrophotometric analysis 
(2.3.8). 
2.3.7   Restriction endonuclease digestion 
Plasmid DNA was routinely analysed by digestion with restriction endonucleases.  
Typically, reactions contained 2μl plasmid DNA, 8 units of restriction enzyme 
and 2μl of the appropriate 10X buffer in a total volume of 20μl, and were 
incubated at 37
oC for > 1 hour.  10μl of the reaction was mixed with DNA loading 
buffer and separated by agarose gel electrophoresis. 
2.3.8   Determining DNA and RNA concentration 
The concentration of nucleic acid solutions was assessed by measuring the A260 in 
a spectrophotometer.  An absorbance of 1 corresponded to 50μg/ml of DNA, or 
40 μg/ml of RNA.  The ratio of A260/A280 was used to assess the purity of the 
samples; for DNA the further the value from 1.8, the greater the level of 
impurities, likewise for RNA where a pure sample has a ratio of 2.0. 
2.3.9   DNA Sequencing 
DNA was sequenced by The Sequencing Service, University of Dundee 
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an Applied Biosystems model 3730 automated capillary DNA sequencer.  
Sequencing reactions required 200 - 300ng plasmid DNA and 3.2 pmoles 
sequencing primer per reaction. 
2.3.10    Agarose gel electrophoresis 
DNA was analysed on 0.8 - 1% agarose gels, prepared in 1X TAE at 110V for > 30 
minutes.  DNA was visualized by exposure to UV light following incorporation of 
Ethidium bromide into the gel.  When bands were to be excised for purification 
and cloning, SybrSafe was used instead of Ethidium bromide.   
2.3.11    Southern Blotting 
2μg P. falciparum gDNA were digested overnight with the appropriate restriction 
endonucleases.  Digested DNA was separated on 0.8% agarose gels, 80V 15 
minutes followed by 23 - 30V, 16 - 24 hours.  Gels were incubated in 
depurination solution for 10 minutes, rocking, room temperature (RT) and 
washed briefly in dH2O.  Next, gels were incubated in denaturation solution for 
25 minutes, rocking, RT, and washed as before.  Finally gels were incubated in 
neutralization solution for 30 minutes, rocking, RT and washed.  DNA was 
transferred to N
+ Hybond membrane by capillarity, in 10X SSC overnight.  The 
blot was constructed by layering three pieces of filter paper (whose ends are 
immersed in 10X SSC), the gel, Hybond N+ membrane (cut to fit the gel), three 
further pieces of filter paper, a thick pad of absorbent paper towels, and finally 
a weight.  The filter paper and membrane were previously soaked in 10X SSC.  
After transfer membranes were washed in 2X SSC for 5 minutes, RT and air dried 
on Whatman paper.  DNA was crosslinked to the membrane using UV light.   
To analyse the Southern blot the Gene Images AlkPhos Direct Labelling and 
Detection System were used (GE Healthcare).  The probe was labelled with a 
thermostable alkaline phosphatase enzyme according to manufacturers’ 
instructions as follows.  10μl DNA (gel purified PCR product at 5 - 10ng/μl) was 
denatured at 100
oC for 5 minutes, cooled immediately on ice and collected by a 
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crosslinker working solution were added sequentially, mixing gently after each 
addition.  The reaction was incubated at 37
oC for 30 minutes; labelled probes 
were used immediately or stored at -20
oC with 50% glycerol (v/v).   
The membrane was blocked in pre-warmed hybridization solution at 55
oC for > 2 
hours, rotating.  The probe (prepared as above) was added to the hybridization 
solution and hybridized overnight at 55
oC - 60
oC (as determined for the probe 
used), rotating.  After hybridisation, the membrane was washed twice with 
primary wash at 55
oC, >15 minutes each, and twice with secondary wash at RT, 
>5 minutes each.  Detection was with the CDP-Star chemiluminescent detection 
reagent, which uses the probe bound alkaline phosphatase to catalyze the 
decomposition of a substrate in a light-producing reaction.  Membranes were 
incubated with CDP-Star reagent RT for 5 minutes and exposed to 
autoradiography film ~1hour, RT. 
2.4   Methods in Biochemistry 
2.4.1   Sodium dodecyl sulphate polyacrylamide gel electrophesis 
(SDS-PAGE) 
Proteins were separated by polyacrylamide gel electrophoresis (PAGE) as 
described by Laemmli (1970).  Gels were prepared with between 6% and 15% 
acrylamide according to the molecular weight of the protein of interest (low 
percentage acrylamide for high molecular weight proteins and vice versa).  Gels 
were composed of a mixture of dH2O, 30% acrylamide mix (Biorad), 1.5M Tris 
(pH 8.8), 10% SDS, 10% ammonium persulphate and were polymerized by 
addition of TEMED; proportions for the appropriate percentage gel are as 
described by Sambrook & Russell (Sambrook).  Stacking gel consists of the same 
mixture, apart from the Tris, which is 1.0M (pH 6.8); proportions required for 5% 
gel are described by Sambrook & Russell (Sambrook). 
Protein samples were prepared by addition of 4X Laemmli buffer and denatured 
at 100
oC for 5 minutes.  Samples were loaded and separated in TGS at 80V for 10 
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(approximately 45 minutes).  Gels were then stained with Coomassie blue (2.4.2) 
or analysed by western blot. 
2.4.2   Coomassie blue staining of polyacrylamide gels 
Gels were removed from the casting plates and immersed in Coomassie stain for 
at least 15 minutes (rocking) at room temperature, after which the stain was 
replaced with destain solution for 2 or more hours, until the background staining 
was removed. 
2.4.3   Western blotting 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane 
using the Biorad Criterion wet transfer system.  Gels were assembled in a stack 
composed of sponge, two layers of filter paper, the gel, the membrane, two 
further layers of filter paper and lastly a sponge.  Before assembling, all 
components were immersed in the appropriate transfer buffer and care was 
taken to exclude air bubbles.  Transfer was carried out on ice, at 30V overnight 
for high molecular weight proteins, or 100V for one hour for low molecular 
weight proteins.  After transfer was complete, gels were stained with Coomassie 
(2.4.2) to assess transfer efficiency.  Membranes were blocked in 5% (w/v) non-
fat milk in PBS for at least 30 minutes, RT (or 4
oC overnight).  Primary antibodies 
were diluted in 5% milk in PBS (according to Table 5-3, appendix) and incubated 
for at least 1 hour, RT (or 4
oC overnight).  Membranes were then washed three 
times for at least 10 minutes with PBS containing 0.05% Tween20.  Secondary 
antibodies conjugated to HRP, (specific for the animal in which the primary 
antibody was raised) were diluted in 5% milk (according to Table 6-4, appendix) 
and incubated with the membrane for at least 45 minutes, RT.  Three further 
PBS/Tween20 washes were carried out (as before) before detection.  Equal 
volumes of the two detection reagents (enhanced luminol reagent and oxidizing 
reagent) were mixed and added to the membrane.  The reaction catalysed by 
the HRP produced light at 482nm, (by oxidative degradation of luminol) which 
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2.4.4   Determining protein concentration 
The concentration of protein solutions (parasite extract or recombinant protein) 
was determined by the Bradford assay.  The absorbance of a protein solution 
mixed with Bradford reagent (Biorad) was measured at 595 nm and the protein 
concentration determined by comparison to a reference curve of BSA of known 
concentration.   
2.4.5   Generation of polyclonal antibodies 
Specific peptides were selected in collaboration with Biogenes, to maximize 
immunogenicity whilst minimizing cross reactivity with other P. falciparum 
proteins.  The peptides were synthesized and used to immunise rabbits 
according to their standard protocol.  Resulting sera and immunopurified IgGs 
were tested on parasite extract and recombinant protein, (where available).   
2.4.6   Expression of recombinant proteins 
The appropriate E. coli strain was transformed with the expression vector for the 
protein in question.  A single colony was used to inoculate a 10ml overnight 
culture in LB medium containing the appropriate antibiotic.  For IPTG induction, 
the overnight culture was then diluted 1/100 into LB medium containing 
antibiotic and grown at 37
oC, shaking (200 rpm) until OD600 0.5 - 0.6 when the 
temperature was reduced to the temperature to be used for expression (15 - 
30
oC).  Expression was induced by addition of IPTG to the appropriate 
concentration once the bacteria reached an OD600 of 0.6 - 0.8.  Autoinduction 
has been reported to yield several fold more target protein than standard IPTG 
induction (Studier, 2005).  Overnight cultures were diluted 1/100 into 
autoinduction medium (Table 6-8, appendix), containing antibiotic and grown at 
15 or 30
oC for 24 or 48 hours.  After the appropriate induction time had elapsed, 
cells were collected by centrifugation at 3800g, 4
oC for 30 minutes, the 
supernatant discarded and the pellets stored at -20
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2.4.7   Purification of tagged recombinant proteins 
2.4.7.1    GST tag 
Bacterial pellets were thawed on ice in lysis buffer 1 (Table 6-7, appendix) (1ml 
per 50ml bacterial culture) containing 1mg/ml lysozyme, and DNase (2 units per 
50ml bacterial culture), and resuspended by pipetting and vortexing 
intermittently over a 30 minute period.  Cells were disrupted by sonication at 
20% amplitude (Bioblock Scientific, Vibracell 72405), 15 seconds on, 15 seconds 
off, on ice, until the viscosity was reduced.  The disrupted bacteria were 
centrifuged at 11,000g, 4
oC for 30 minutes, and the resulting supernatant used 
for purification of soluble proteins.  Prior to use, glutathione-agarose beads 
were hydrated in lysis buffer 1 for at least 1 hour, and washed 4 times in the 
same buffer, by centrifugation at 60g, 1 minute.  The cleared lysate was then 
incubated with the prepared beads (100μl of a 50% slurry, per 50 ml bacterial 
culture) and fresh PMSF to 1mM, 4
oC, rotating, 1 ½ - 2 hours.  Beads were 
recovered by centrifugation as before, and washed four times with cold lysis 
buffer 1, containing fresh PMSF (1ml buffer per 50ml bacterial culture), and 
once with elution buffer without glutathione (Tris 50mM, pH 8, NaCl 75mM).  
Bound proteins were then eluted by rotation at 4
oC, 20 minutes in elution buffer 
containing 15mM reduced glutathione (100μl per 50 ml culture)(Sigma), and the 
supernatant recovered by centrifugation as before.  Protein concentration was 
measured (2.4.4) for immediate use in kinase assays 
2.4.7.2    His tag 
Purification of His tag proteins followed the method described for GST-tagged 
proteins, section 2.4.7.1, except i) lysis buffer 2 (Table 6-7, appendix) replaced 
lysis buffer 1, ii) nickel-agarose beads replaced glutathione-agarose beads, (80μl 
of 50% bead slurry per 50ml bacterial culture), iii) after binding of proteins to 
the beads two washes were performed with lysis buffer 2, containing 10mM 
imidazole, followed by two washes containing 40mM imidazole, iv) finally, beads 
were washed once in elution buffer (50mM Tris-HCl, pH 8, 400mM NaCl) before 
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2.4.8   Immunoprecipitation 
Parasites pellets prepared by saponin lysis (2.5.7) were lysed in ice cold RIPA 
buffer (Table 6-7, appendix) (150μl buffer per ~ 100μl parasite pellet), by 
sonicating for 3 seconds at 20% amplitude (Bioblock Scientific, Vibracell 72405).  
Lysates were cleared by centrifugation at 11,000g, 4
oC for 30 minutes.  Protein 
concentration of the resulting supernatant was measured with the Bradford 
assay (2.4.4) and adjusted to 1mg/ml.  Parasite proteins were bound to the 
specific antibody by incubation with 1.5μg antibody per 100μg parasite protein, 
on ice for 2 hours.  During this time protein A -Sepharose beads (GE Healthcare) 
were washed four times in RIPA buffer.  The target protein-antibody complexes 
were then bound to the washed beads (10μl 50% bead slurry, per 100μg parasite 
protein) by rotation at 4
oC for 1 ½ hours.  Beads were washed three times in ice 
cold RIPA buffer by centrifuging at 1000g for 15 seconds at 4
oC, and then once 
with RIPA buffer containing 0.1% SDS.  At this stage, for western blot analysis the 
beads were resuspended in Laemmli buffer, or, for kinase assay, beads were 
washed once more in kinase buffer (Table 6-7, appendix), before resuspension in 
20μl kinase buffer for assay in the standard reaction mix (2.4.9).  
2.4.9   Kinase assay 
Kinase reactions (30μl) were carried out in a standard kinase buffer (Table 6-7, 
appendix) using <1μg recombinant kinase, or the immunoprecipitate from 100μg 
parasite proteins, and <10μg recombinant or artificial substrate (α-casein, β-
casein, myelin basic protein (MBP) or histone H1).  Reactions were allowed to 
proceed for 30 minutes at 30
oC and were stopped by addition of reducing 
Laemmli buffer, 3 minutes at 100
oC.  Phosphorylation of kinase substrates was 
assessed by autoradiography of dried SDS-PAGE gels. Clare Fennell, 2008     Chapter 2 53 
2.5   P. falciparum culture 
2.5.1   Asexual stage culture 
P falciparum clone 3D7 was cultured as previously described (Trager and Jensen, 
1976), (Lin et al., 1996).  In brief, asexual cultures were maintained in complete 
RPMI 1640 at a haematocrit of 5%.  Cultures were maintained at 37
oC, under an 
atmosphere of 5% CO2, 1% O2, 96% N2.  The parasitaemia (percentage of infected 
erythrocytes) was kept between 0.5% and 10%; medium was changed every other 
day at low parasitaemias (<4%) (Kim et al., 2007), or every day at higher 
parasitaemias.  Parasitaemia was determined by counting the infected 
erythrocytes in Giemsa stained blood smears.  Smears were fixed in ethanol for > 
30 seconds followed by staining with Giemsa diluted 1/10 in Giemsa buffer for 
10 -20 minutes.  Stained blood smears were analysed by light microscopy. 
2.5.2   Synchronisation of parasite culture 
Parasites were synchronized using sorbitol according to Lambros and Vanderberg 
(Lambros and Vanderberg, 1979).  Cultures containing a high proportion of ring 
stage parasites were used for synchronization.  The culture was centrifuged at 
680g for 2 minutes, RT and the supernatant discarded.  The pellet was 
resuspended in 10 pellet volumes of 5% sorbitol, incubated for 10 minutes at RT 
and centrifuged as before, and sorbitol discarded.  The pellet was washed by 
resuspending in 10 pellet volumes of warm complete medium and centrifuging.  
Finally the pellet was resuspended in the appropriate volume of warm RPMI 
complete medium and cultured as described above (2.5.1).  If necessary the 
process was repeated after 48 hours at the next ring stage of the cycle.   
2.5.3   Preparation of gametocytes 
Gametocyte cultures were set up at 0.5 - 0.7% parasitaemia in 6% haematocrit, 
in an initial volume of 15ml, to give 25ml final volume in 75cm
2 flasks.  Cultures 
were maintained as normal for 4-5 days until 8-10% parasitaemia was reached 
and parasites appeared stressed, (judged by the presence of mis-shaped ring Clare Fennell, 2008     Chapter 2 54 
stage parasites) after which the volume was increased to 25ml and medium 
changed daily until day 15 after set up, when mature gametocytes were present. 
2.5.4   Mosquito infection 
Feeding of gametocytes to mosquitoes was carried out by the Ranford-Cartwright 
lab, as described previously (Carter et al., 1993).  Briefly, a mixture of day 14 
and day 17 gametocytes was resuspended in fresh blood (and heat inactivated 
serum) to give a final packed cell volume of 40%.  The mixture was fed to 5-7 
day old mosquitoes that had not previously fed on blood, and had not been given 
glucose overnight to encourage a good blood meal to be taken.  After the feed, 
the mosquitoes were maintained at 26
oC, and supplied with ample glucose/PABA 
solution (Table 6-10, appendix).  Mosquitoes were dissected and midguts 
examined for oocysts 10 days post feeding, and salivary glands for sporozoites 16 
days post feeding.  The significance of infection prevalence variation between 
comparable clones, or between oocyst and sporozoite positive mosquitoes was 
assessed using Fisher’s exact test.  
2.5.5   Preparation of stabilates 
Frozen parasite stabilates were prepared using 3-5ml cultures containing >2% 
ring stage parasites.  Erythrocytes were pelleted by centrifugation at 850g, RT, 5 
minutes and supernatant discarded.  The pellet was resuspended in an equal 
volume of deep-freeze solution, transferred to a cryovial (0.5ml maximum per 
tube) and stored in liquid nitrogen. 
2.5.6   Thawing of stabilates 
Stabilates were removed from liquid nitrogen and thawed at room temperature 
before transferring to a 15ml tube, measuring the volume of blood.  0.2 volumes 
of solution A (Table 6-9, appendix) were added dropwise, mixing constantly, 
then allowed to stand for 3 minutes.  10 volumes of solution B (Table 6-9, 
appendix) were added, dropwise and mixed well by pipetting.  Cells were 
pelleted by centrifugation at 850g, RT for 5 minutes and the supernatant Clare Fennell, 2008     Chapter 2 55 
discarded.  Cells were resuspended by dropwise addition of the same volume of 
solution C (Table 6-9, appendix) as solution B, and mixed well.  Cells were 
centrifuged as before, supernatant discarded and resuspended in 3ml warm 
(37
oC) RPMI 1640 complete medium, adding fresh erythrocytes to obtain a 
haematocrit of 5%.  Once cultures reached >2% parasitaemia they were diluted 
to 5ml, and the appropriate drug selection applied. 
2.5.7   Isolation of parasites from infected erythrocytes 
Parasite harvest was by saponin lysis (Umlas and Fallon, 1971); erythrocytes 
were pelleted by centrifugation at 1300g, RT for 2 minutes and washed once in 
one culture volume of cold PBS, centrifugation 1300g, 4
oC for 2 minutes.  Cells 
were lysed on ice, by repeated pipetting in 1/3 culture volume cold saponin 
(0.15% (w/v) in PBS).  After lysis PBS was added to a total of 2 culture volumes 
and parasites recovered by centrifugation 5500g, 5 minutes, 4
oC.  After two 
further PBS washes, discarding the final wash, pellets were stored at –80
oC. 
2.5.8   Extraction of parasite genomic DNA 
After saponin lysis the parasite pellets were resuspended in approximately 5 
pellet volume proteinase K (150μg/ml)/SDS (2%) and incubated at 55
oC for 2 - 12 
hours.  DNA was extracted by addition of an equal volume of Phenol: 
Chloroform: Isoamyl alcohol (25:24:1) saturated with 10mM Tris, pH 8, 1mM 
EDTA (Sigma).  Tubes were inverted repeatedly to mix gently and centrifuged at 
16,000g, RT for 5 minutes.  The top aqueous layer was transferred to a new tube 
leaving protein at interface; an equal volume of Phenol: Chloroform: Isoamyl 
alcohol was added, inverted to mix and centrifuged as before.  Phenol 
extraction was repeated twice more.  After the final aqueous layer was removed 
to a new tube 0.1 volume of 3M sodium acetate (pH 5.2) was added and DNA 
precipitated in 2 - 4 volumes of ethanol, -20
oC, >30 minutes.  DNA was obtained 
by centrifugation at 16000g for 15 minutes, and discarding the supernatant.  
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2.5.9   Extraction of parasite RNA 
After saponin lysis parasite pellets were resuspended in 10 pellet volumes Trizol 
and stored at -80
oC until use.  The Trizol/parasite suspension was thawed on ice, 
2 pellet volumes of RNase free Phenol:Chloroform: Isoamylalcohol (25:24:1) 
were added, shaken for 15 seconds and incubated, RT for 3minutes.  The 
mixture was centrifuged 9000g, 4
oC, 30 minutes and the aqueous layer removed 
to a fresh tube.  Isopropanol was added at a ratio of 6:5 (supernatant: 
isopropanol) and incubated on ice for > 2 hours.  RNA was pelleted by 
centrifugation at 12000g, 4
oC for 30 minutes and the supernatant discarded.  
Pellets were washed by adding 500μl cold 75% ethanol (in DEPC treated water) 
and centrifuging 12000g, 4
oC for 5 minutes before drying with tubes inverted for 
5 minutes.  RNA was resuspended in 20μl dH20 and incubated at 60
oC, 10 minutes 
and placed on ice.  Concentration was assessed by measuring the absorbance, as 
described (2.3.8). 
2.5.10    Protein preparation from parasites 
Where a total protein mixture was required parasite pellets were lysed directly 
by addition of Laemmli buffer and boiled, 100
oC for 5 minutes.  In some 
instances, for western blot analysis, parasite pellets were resuspended in 
parasite solubilisation buffer (Table 6-7, appendix), before adding Laemmli 
buffer, and proceeding as before.  To prepare parasite protein extracts for 
immunoprecipitation, parasite pellets were resuspended in ice cold RIPA buffer 
(Table 6-7, appendix, 200μl per 25ml parasite culture at 6-10% parasitaemia) 
and sonicated at 20% amplitude (Bioblock Scientific, Vibracell 72405), for 3 
seconds.  The resulting lysate was cleared by centrifugation at 11,000g, 4
oC for 
30 minutes, and protein content quantified as described (2.4.4). 
2.5.11    Transfection 
The method of transfecting erythrocytes infected with ring stage parasites, at a 
parasitemia of 4 - 6% was used (Crabb and Cowman, 1996).  For each 
transfection, a 3ml culture was pelleted by centrifugation at 1000g, RT for 4 Clare Fennell, 2008     Chapter 2 57 
minutes, and washed by resuspending in 3ml cytomix buffer (Table 6-9, 
appendix) and centrifuged as before.  100μg of plasmid DNA was suspended in 
100μl cytomix buffer and used to resuspend the washed parasite pellet, further 
cytomix buffer was added to a total volume of 400μl.  This mixture was 
electroporated in a cold 2mm cuvette, 310V, 950μF (time constant ~10ms for 
good transfection efficiency).  The mixture was transferred to a culture flask by 
mixing with 2ml RPMI 1640 complete medium; a further 3ml fresh uninfected 
erythrocytes, RPMI mix (4% haematocrit) was added.  Medium was changed 3-4 
hours after transfection, and the following day with complete medium.  From 
the second day post transfection media containing the selection drug (Blasticidin 
2.5μg/ml) was used.  0.1ml fresh erythrocytes were added once per week, until 
parasites were detectable on Giemsa stained slides, usually ~21 days post 
transfection, after which cultures were maintained as normal for asexual 
parasites (2.5.1). 
2.5.12    Cloning of parasites by limiting dilution 
Parasites were cloned as previously described (Kirkman et al., 1996).  Briefly, 
the erythrocyte number of a culture containing 3% parasitized erythrocytes was 
determined and diluted in RPMI 1640 complete medium so that 10ml contained 
10
6 cells.  Three tubes of 15ml medium were prepared at 1% haematocrit, to 
these, 6.25, 12.5 and 25μl of the 10ml containing 10
6 cells were added.  Each 
mixture was transferred to one third of a 96 well plate, 200μl per well, to give 
36 wells with a probability of 0.25, 0.5 or 1 parasite per well, respectively.  
After 5-6 days the medium was changed.  After another 5-6 days the medium 
was changed using medium containing 1% erythrocytes and the selection drug.  
Around day 15 the plates were monitored by both the lactate dehyrogenase 
assay (2.5.12.1), and careful blood smears to ascertain which wells contained 
parasites.  Positive wells were transferred to 12 well plates, (2ml culture, 5% 
haematocrit) and monitored by blood smear until appropriate to transfer to 5ml 
cultures and cultured for further analysis. Clare Fennell, 2008     Chapter 2 58 
2.5.12.1    Plasmodium lactate dehydrogenase assay 
Plasmodium LDH (pLDH) can be distinguished from human LDH by its ability to 
use the 3-acetyl pyridine analog of NAD (APAD+) in the conversion of lactate to 
pyruvate.  pLDH activity can be measured in lysed blood samples of 0.2-10% 
parasitemia.  A mix was prepared of 100μl Malstat reagent, 10μl Diaphorase 
(1mg/ml) and 10μl NBT per well, to which 20μl culture suspension was added.  
Plates were incubated at RT for 20 minutes and monitored by eye for colour 
change; wells containing parasites change to purple (Makler and Hinrichs, 1993, 
Makler et al., 1993). 
2.5.13  Parasite growth rate analysis, by flow cytometry 
Parasite growth rate analysis was carried out in the Goldberg lab by flow 
cytometry (Liu et al., 2005), using a protocol adapted from Barkan Ginsburg et 
al. 2000 (Barkan et al., 2000).  In brief, samples of asynchronous parasite 
cultures were acquired every 30 minutes for ~4days and fixed in 0.05% 
glutaraldehyde in PBS and stored at 4°C.  The DNA content of the cells was 
measured by permeabilizing with 0.25% Triton X-100 in PBS for 5 minutes at 
room temperature followed by staining with 5μg/ml propidium iodide (Molecular 
Probes, Eugene, USA).  The cells were then diluted 10-fold in PBS and analyzed 
using an Epics XL-MCL flow cytometer (Beckman). 1x10
5 erythrocytes were 
counted in triplicate for each sample. Data were analyzed using FlowJo software 
(Treestar Inc., Ashland, USA). 
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3  Eukaryotic initiation factor 2α kinases in P. 
falciparum: bioinformatic and biochemical 
characterisation 
3.1   Identification of P. falciparum eukaryotic initiation 
factor 2α 
BLASTP searches of PlasmoDB using metazoan eIF2α sequences were used to 
identify PF07_0117 as the P. falciparum orthologue, which was confirmed by 
reciprocal analysis.  The alignment of P. falciparum eIF2α with sequences from 
T. gondii, human and rice is shown in Figure 3-1.  Overall, the P. falciparum 
sequence shares ~70%, ~ 50%, ~ 40% and ~28% identity with those of T. gondii, 
Homo sapiens  and Oryza sativa (rice) and E. cuniculi, respectively.  
Importantly, the serine residue (Ser 51 in the human orthologue) that is targeted 
for phosphorylation by eIF2a kinases is conserved in all species.  Furthermore, 
eIF2α contacts the kinase through a large number of residues that interact with 
the surface of the kinase domain.  These residues are also conserved in most 
species, as are the residues that protect the regulatory serine from the activity 
of other kinases (Dar et al., 2005); interestingly, several of these are not 
conserved in the E. cuniculi orthologue, which is consistent with the absence of 
eIF2α kinases in this organism (Miranda-Saavedra et al., 2007). 
Pf   MEGMILMSELSKRRFRSVNKLIRVGRHEVVLVLRVDSQKGYIDLSKRRVSPKDIIKCEEK   108 
Tg   MEGMILMSELSKRRFRSVNKLIRVGRHEVVMVLRVDPKKGYIDLSKRRVSPEDIVKCEEK   120 
Mm   IEGMILLSELSRRRIRSINKLIRIGRNECVVVIRVDKEKGYIDLSKRRVSPEEAIKCEDK   100 
Hs   IEGMILLSELSRRRIRSINKLIRIGRNECVVVIRVDKEKGYIDLSKRRVSPEEAIKCEDK   100 
Os   IEGMILYSELSRRRIRSIPSLIKVGRQEPAVVLRVDHDKGYIDLSKRRVSHHDRRTCEDR   102 
Ec   LEGLVLLGELSKRRVRSIQQVTKVGNIEICNVLKVDEGRGYIDLSMSKVTENEKSECRET   101 
     :**::*  ***:** **:  : ::*  *   *::**  :******  :*:  :   * :        
Figure 3-1: Alignment of eIF2α sequences. 
Sequences surrounding the conserved regulatory serine are shown (P. falciparum numbering: M49 
- K108).  The black highlighted residue marks the serine that when phosphorylated exerts the 
regulatory effect on translation.  Blue highlights indicate residues involved in contacting the kinase 
domain; pink highlights indicate conserved residues that protect the phosphorylation site from the 
activity of other kinases.  Asterisks (*) indicate the residue is identical in all sequences, colons (:) 
indicate conservation of residue properties.  Pf; P. falciparum, Tg; T. gondii; Mm; Mus musculus, 
Hs; Homo sapiens, Os; Oryza sativa, Ec; Encephalitozoon cuniculi. Clare Fennell, 2008     Chapter 3 60 
3.2   Identification of eIF2α kinases in P. falciparum 
3.2.1   In silico analysis 
The phylogenetic analysis of the full complement of P. falciparum kinases 
published by this laboratory in 2004 (Ward et al., 2004) identified a distinct 
cluster of three sequences, PF14_0423, PFA0380w and PFF1370w, the latter of 
which (called PfPK4) had previously been characterised as encoding an eIF2α 
kinase (Mohrle et al., 1997).  Reciprocal BLASTP analysis using the putative 
catalytic domains as queries confirms the relatedness of these three genes with 
the eIF2α kinase family (not shown).  In order to identify kinase families in 
phylogenetic clusters, the Ward et al. analysis contained a number of human 
kinase sequences in addition to the P. falciparum sequences; however, these did 
not include any human eIF2α kinases.  With help from Jon Wilkes, the 
bioinformatician at the Wellcome Centre for Molecular Parasitology, I therefore 
sought to extend this analysis by using a Hidden Markov Model to align the three 
putative PfeIF2α kinases with the four human eIF2α kinases; sequences from 
other kinase families were included as outgroups.  The resulting alignment was 
used to generate a phylogenetic tree (Fig. 3-2), which clearly shows that the 
three P. falciparum genes do indeed cluster with sequences of the eIF2α kinase 
family, as opposed to other families. 
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Figure 3-2: Phylogenetic tree showing the clustering of eIF2α kinases. 
Sequences were selected from across the kinase superfamily to investigate whether the proposed 
P. falciparum eIF2α kinases cluster with other members of the eIF2α kinase family.  Sequences 
were aligned using the HMMER package against a profile generated from our previous kinome 
analysis (Ward et al., 2004).  After removal of gaps and positions with a low qualify of alignment, 
alternate phylogenies generated with the neighbour joining method were visualised using 
NeighbourNet implemented on SplitsTree version 4 (Huson and Bryant, 2006). The three P. 
falciparum sequences are boxed in red, brackets indicate kinase families. 
 
To more closely investigate the relationship between the three PfeIF2α kinases 
and other members of the family, I selected sequences of eIF2α kinase catalytic 
domains from diverse species, and aligned them against the Pfam protein kinase 
domain (Pfam entry PF00069) using the HMMER package; human aurora kinase 
and CDK2 were included as outgroups (Fig. 3-3).  The crystal structures of PKR in 
complex with eIF2α and of GCN2 have been solved, revealing that helix α-G is 
longer, and in an abnormal position in eIF2α kinases, when compared to other 
kinases (Dar et al., 2005) (Padyana et al., 2005, Mathews, 2007).  By comparison 
to the structure-based alignment produced by Dar et al. 2005, Figure 3-3 
suggests that the PfeIF2α kinases, and indeed all other eIF2α kinases considered Clare Fennell, 2008     Chapter 3 62 
here, share the non-canonical α-G helix that is critical for the binding of eIF2α, 
illustrated in Figure 3-4.  The conserved Thr and Glu at the N-terminus of helix 
α-G (Fig. 3-3) were found to interact with each other to stabilise the structure 
of this helix (Dar et al., 2005).  All eIF2α kinases are required to interact with 
eIF2α; conservation of the size and position of helix α-G in the eIF2α kinases is 
consistent with such an interaction as this helix is responsible for both 
positioning the phosphoacceptor Ser51 towards the catalytic cleft of the kinase, 
and allowing the interaction to proceed without distortion of other regions of 
either the kinase or eIF2α (Dar et al., 2005). 
 
                                           I                         II 
                       ∨∨∨   *      * ** * *      ∨∨       ∨    *∨             
PfeIK1   -------keiiemnsryyrdFFEEKILGCGGFGYVMKVKNKKFNI----TYAL--KIIRLS--   463 
PfeIK2   ---------dksipyqmlanLQNEYYLSKGNNNK----MNITTTY----LYMKirKILNKY--   161 
PfPK4    -------ladflengrflrtFENISLIGQGGFGSVYKVSHRLEPGs--pTYAV--KFIYLK--  2182 
PbeIK1   -------kelinkysryyrdFSEESVLGCGGFGYVMKVKNKKFNI----AYAV--KKITLS--   448 
PbeIK2   qrskkhyftkcgilntekvkPSKKRRIG-------WDGQRQRKRK-12-MFCK--NKEKKE--   459 
PbPK4    -------ladflengrftrtFQNISLIGQGGFGSVYKVSHRLEPGs--pTYAV--KFIYLKvs   357 
TgIFKA   -------lakllengrfertFAIQKLVGQGGFGVVYQVRHLLEPGh--pIYAV--KLILLR--  4043 
TgIFKB   -------snptlssqrlckdFTSVVVAGRGGCGRVLKATHVLDGQ----TYAI--KEIKFA-a   305 
hPKR     -------etkytvdkrfgmdFKEIELIGSGGFGQVFKAKHRIDGK----TYVI--KRVKYN--   301 
hHRI     -------valeaqtsrylneFEELVILGKGGYGRVYKVRNKLDGQ----YYAI--KKILIK--   201 
hPERK    -------iknsgyisryltdFEPIQCLGRGGFGVVFEAKNKVDDC----NYAI--KRIRLP--   626 
hGCN2    -------setqrqfsryfieFEELQLLGKGAFGAVIKVQNKLDGC----CYAV--KRIPIN--   624 
ScGCN2   -------sinpatrsryasdFEEIAVLGQGAFGQVVKARNALDSR----YYAI--KKIRHT--   633 
DdIFKA   -------ydmfryhsryrtdFEEIEMIGKGGFGVVVKSRNKLDCR----YYAI--KKIKTK--   928 
DdIFKB   -------------------m------IGKGGFGVVVKSRNKLDCR----YYAI--KKIKTK--    30 
DdIFKC   -------tinphqqsryhsdFEEIQLLGRGGFGQVVKVRNKLDGR----YYAI--KKIKLD--   528 
AtGCN2   -------pnaslpssrylndFEELKPLGQGGFGHVVLCKNKLDGR----QYAV--KKIRLK--   459 
TbeIFK1  -------tfrrvsagryrseFIEQCLLGSGGFAPVYVCRKKVDGR----LYAV--KKIAIR--   309 
TbeIFK2  ---------ttpmpqlfqqhFDVLKKIGRGGEGNVFCVKHQVTGA----MYAI--KAVRIR--   660 
TbeIFK3  -------nfmsgkqsffdenFDVLMILGSGASGVVLLTRHRVTGV----LYAV--KVLIVR--   575 
Aurora   -------gamgskrqwaledFEIGRPLGKGKFGNVYLAREKQSKF----ILAL--KVLFKA--    48 
CDK2     -----------------menFQKVEKIGEGTYGVVYKARNKLTGE----VVAL--KKIRLD--    38 
 
 
 
                              III               IV                      V 
                            *∨    ∨     ∨     ∨  ∨∨                  
PfeIK1   NSKYNTQTNNKHIn-7-iMEEAIMiAKL-Q-HENIVRYYDAWVEenvdffl…//82//…-nkd   600 
PfeIK2   SKRNEEKK-----------NILKG-KYCyN-NGNFALLSYINKK-------…//16//…--nk   211 
PfPK4    VSSL-DNVSSRRY----fREIAAN-RDI-Y-SKHVVRYYTWWCEepqflp…//536//…kktp  2764 
PbeIK1   INKYNNHIKKNSKh-26-EEVIMI-AKL-Q-HENIVRYYDAWVEnnidyyl…//39//…nken   561 
PbeIK2   ENYKKIDTN--------------I-SQF-S-EKNPVSNIDNEKNkqnfi-------------k   492 
PbPK4    SLDNVNSRRYFR-------EIAAN-RDI-Y-SKHVVRYYTWWCEepqflp…//342//…kknv   743 
TgIFKA   LTLS-EDISLRRD-----REVAAN-RDL-Y-SKHVVRYYTWWCEeprflp…//599//…ppak  4688 
TgIFKB   NREHLDAHMAVFL-----REVLCL-RRL-DaHPNIVRYFNSWVEvspppl…//977//…cern  1276 
hPKR     NEKAER-------------EVKAL-AKL-D-HVNIVHYNGCW-Dgfdydpe…//15//…-skn   353 
hHRI     GATKTVCMKVLR-------EVKVL-AGL-Q-HPNIVGYHTAWIEhvhviq…//127//…lgqt   372 
hPERK    NRELAREKVMR--------EVKAL-AKL-E-HPGIVRYFNAWLEappekw…//206//…eklq   875 
hGCN2    PASRQFRRIKG--------EVTLL-SRL-H-HENIVRYYNAWIErherpa…//123//…epsv   790 
ScGCN2   EEKLST----ILS------EVMLL-ASL-N-HQYVVRYYAAWLEedsmde…//102//…kpmt   776 
DdIFKA   GYTDSNQEPLTNKl---lREVTTL-SRL-H-HQFVVRYYQAWIEkscdsf…//280//…-rkk  1255 Clare Fennell, 2008     Chapter 3 63 
DdIFKB   GYTDSNQEPLTNKl---lREVTTL-SRL-H-HQFVVRYYQAWIEkscdsf…//277//…srkk   355 
DdIFKC   SNQSLNRRILR--------EVITL-SRL-H-HQHVVRYYQAWIEsaesls…//194//…knik   765 
AtGCN2   DKEIPVNSRIVR-------EVATL-SRL-Q-HQHVVRYYQAWFEtgvvdpa…//26//…-eqd   529 
TbeIFK1  KNEAEK---ALR-------EVQSL-AAL-S-HKHIVRYYDAWIEpgcddel…//82//…mhsh   433 
TbeIFK2  EEDKQRCVR----------EAILH-SSL-D-NPNVVRYFYSWIEniarsia…//29//…vssa   731 
TbeIFK3  DKFAETAVMQ---------EVRLH-AVL-H-NEHIVRYYTCWSEmitpar…//103//…erss   720 
Aurora   QLEKAGVEHQLRR------EVEIQ-SHL-R-HPNILRLYGYFHD-------------------    83 
CDK2     TETEGVPSTAIR-------EISLL-KEL-N-HPNIVKLLDVIHT-------------------    72 
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                        V 
                   ∨ *  ∨                                                
PfeIK1   pnvnDKYLY-ILMEYCPGK-----TLREAID-----------------------CGFIcR--N   633 
PfeIK2   etkyKFNLY-IRMEYCKS------TLENYIN---------------------TRENM-----N   241 
PfPK4    vpefSIVLL-LQMELCKGY-----TLRKWLDr--------stRsdkplhfTYSDKKM-----N  2808 
PbeIK1   ikinEKYLY-ILMEYCPGK-----TLREAID-----------------------CGFIyK--N   593 
PbeIK2   nkkyKFNLY-IRMEYCKD------TIENYIN---------------------RRTRI-----N   522 
PbPK4    gpefSIVLL-LQMEFCKGF-----TLRRWLD-----------R------sSRSDKPLY-F--T   780 
TgIFKA   etlyPVVLL-IQMEMCNGV-----TLREWLDrkdrstvamgfV------pSSKNRWH-----S  4734 
TgIFKB   qckvAVSLY-IQMEYCGM------SLDEYIA---------------------QTPEV-----D  1306 
hPKR     ssrsKTKCLfIQMEFCDKG-----TLEQWIE-------------------KRRGEKL-----D   387 
hHRI     eaqyHLMLH-IQMQLCEL------SLWDWIVern-----krgRe----yvDESACPY--V--M   415 
hPERK    psspKVYLY-IQMQLCRKE-----NLKDWMN---------------------GRCTI-----E   906 
hGCN2    tteaVHYLY-IQMEYCEKS-----TLRDTID---------------------QGLYR-----D   821 
ScGCN2   avkkKSTLF-IQMEYCENR-----TLYDLIH--------------------SENLNQ-----Q   808 
DdIFKA   ppkeTHTLY-IQMEYCSKK-----TLKTLID---------------------NVGGI-----A  1286 
DdIFKB   ppkeTHTLY-IQMEYCSKK-----TLKTLID---------------------NVGGI-----A   386 
DdIFKC   kstsIPYLY-IQMEYCQK------ILR---------------N------lTETGMNL-----E   795 
AtGCN2   nnleSTYLY-IQMEYCPRTLrQVFESY---------------------------NHF-----D   559 
TbeIFK1  keeeFSTLY-IQMELCSKH-----SLRHLID-----------Q------cDKEEGSLLtAgnG   473 
TbeIFK2  tgapLNVLF-IQMEYFKSG-----TLADHFR---------------------NRNAF-----S   762 
TbeIFK3  sileGRVVF-LQLEYYRT------TLAQRLG---------------------SRGSI-----D   750 
Aurora   ----ATRVY-LILEYAPLG-----TVY------------------------RELQKLSkF--D   110 
CDK2     ----ENKLY-LVFEFLHQDLkKFMDAS-------------------------ALTGI-----P   100 
 
 
 
                                        catalytic loop 
                          VIA                  VIB                 VII 
                          ∨ *        ∨     *****  * ∨                ∨ ∨ 
PfeIK1   EKL---I-------WELIKQILKGISYIHDMKIMHRDIKPSNIFLQiTDNIL------IAKIG   680 
PfeIK2   INR---N-------YEIIQMIILGLYSIHNNNIMHRDLKPSNIFIS-DNNIV--------KIG   285 
PfPK4    HPL---E-------FDLFKQLIKGLKDIHATCFIHRDLKPENIFVD-PDTYT-------LKIG  2853 
PbeIK1   EKL---I-------WELIKQILKGIYYIHDMKMMHRDIKPSNIFLQiNDDIL------SAKIG   640 
PbeIK2   IKR---N-------IEIINMIIMGLNYIHNNNIMHRDLKPSNIFIS-NNDIV--------KIG   566 
PbPK4    YGD---KntnhpleFDLFKQLIKGLKDIHSTCFIHRDLKPENIFVD-LDTYI-------LKIG   832 
TgIFKA   MEL------------ELFKQLMKGIRDIHERGIVHRDLKPENIFVD-PDTLV-------LKIV  4777 
TgIFKB   PER---N-------EEIVAMIISGLYQCHSAGVMHRDLKPSNIFIDkETGVV--------KIG  1351 
hPKR     KVL---A-------LELFEQITKGVDYIHSKKLIHRDLKPSNIFLV-DTKQV--------KIG   431 
hHRI     ANV---A-------TKIFQELVEGVFYIHNMGIVHRDLKPRNIFLHgPDQQV--------KIG   460 
hPERK    ERErsvC-------LHIFLQIAEAVEFLHSKGLMHRDLKPSNIFFT-MDDVV--------KVG   953 
hGCN2    TVR---L-------WRLFREILDGLAYIHEKGMIHRDLKPVNIFLD-SDDHV--------KIG   865 
ScGCN2   RDE---Y-------WRLFRQILEALSYIHSQGIIHRDLKPMNIFID-ESRNV--------KIG   852 
DdIFKA   EEE---A-------FRLLRQIVEGLNHIHSQQIIHRDLKPANIFID-NEQNV--------KIG  1330 
DdIFKB   EEE---A-------FRLLRQIVEGLNHIHSQQIIHRDLKPANIFID-NEQNV--------KIG   430 
DdIFKC   DDD---I-------WKLFRQIVEGMAYVHGQGIIHRDLKPSNIFFD-SCGDI--------KIG   839 
AtGCN2   KDF---A-------WHLIRQIVEGLAHIHGQGIIHRDFTPNNIFFD-ARNDI--------KIG   603 
TbeIFK1  DKV---A-------TKIFRQLLTVVSHFHRQGIVHRDLKPDNILFE-MQSSVSSddvgTIRVA   525 
TbeIFK2  RLE---N-------VEHLLQIVRGLRYIHQQDVIHRDLKPTNIFVS-DAGIM--------KIG   806 
TbeIFK3  RFE---N-------IIIALQLFAAVRYVHRSGFLHRDVKPPNIFID--YRQV--------RLG   904 
Aurora   EQR---T-------ATYITELANALSYCHSKRVIHRDIKPENLLLG-SAGEL--------KIA   154 
CDK2     LPL---I-------KSYLFQLLQGLAFCHSHRVLHRDLKPQNLLIN-TEGAI--------KLA   144 
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                       activation loop 
         VII                                 VIII                    IX 
         ***∨                             ∨   ∨ ***                *∨    
PfeIK1   DFGLTT----------------RiGDTqINPSAGTIHYISPEQ---LN--GEPFNEKADIFSL   722 
PfeIK2   DFGLAsydytyp--…//91//…-------TLGIGTKIYAAPEQ---LI--GNKYTKAVDMFSL   417 
PfPK4    DLGLVRFIeekk--…//31//…-------GQIIGTPGYTAPE-------GGALCDEKADIYSA  2923 
PbeIK1   DFGLTT----------------KiDNTqINPSAGTVNYMSPEQ---LN--GEHFDQKADIFSL   682 
PbeIK2   DFGLA-----------------SyDYLdDTLGIGTKLYSAPEQ---LE--GNKYTKSVDIFSL   966 
PbPK4    DLGLVRFIE-----…//27//…TsQISlKGQMIGTPGYTAPE-------GGALCDEKADIYSA   902 
TgIFKA   DFGLAKFIQrenps…//50//…--EMSyKGEVIGTPAYAAPE-------GGGLCDEKADIYSS  4873 
TgIFKB   DFGLAfsrdmkq-…//751//…-------TAGVGTRAYAPPEQ---LQ--GGRYDFSVDIWAL  2095 
hPKR     DFGLVTS---------------LkNDGkRTRSKGTLRYMSPEQ---IS--SQDYGKEVDLYAL   474 
hHRI     DFGLACT-Dilqkntdwtnrn-GkRTPtHTSRVGTCLYASPEQ---LE--GSEYDAKSDMYSL   516 
hPERK    DFGLVTAMDqdeee--qtvltpMpAYArHTGQVGTKLYMSPEQ---IH--GNSYSHKVDIFSL  1009 
hGCN2    DFGLATDHL-----…//17//…SdPSGhLTGMVGTALYVSPEV---QGsTKSAYNQKVDLFSL   929 
ScGCN2   DFGLAKNVHrsldilkldsqnlPgSSDnLTSAIGTAMYVATEV---LD-GTGHYNEKIDMYSL   911 
DdIFKA   DFGLATSGA-----…//37//…NdENLsMTGGVGTPFYCCPEI---LEkNTKHYGTKVDMYSL  1414 
DdIFKB   DFGLATSGA-----…//37//…NdENLsMTGGVGTPFYCCPEI---LEkNTKHYGTKVDMYSL   514 
DdIFKC   DFGLAINNKtts--…//70//…--QQQqHTARVGTLFYTSPEQeagTN-GDSAYDDKVDMYSL   959 
AtGCN2   DFGLAKFLK-----…//14//…AgSGVdSTGQAGTYFYTAPEI---EQ-DWPKIDEKADMYSL   663 
TbeIFK1  DFGLARTLH-----…//22//…LeVGPsPTGNLGSVVYCAPEQ---ER--GESYDFSVDEYSL   590 
TbeIFK2  DFGLAKRWQ-----…//19//…AlFDDeRSFAGGTPLYWSPEQ---QC--GGSATAASDVFSL   868 
TbeIFK3  DFSISKSFLaqhv----elasnFgRTAmNTTGIGSSLYSSPEQ---LD--GEHCTSSSDAYSC   958 
Aurora   DFGWSV----------------HaPSSrRTTLCGTLDYLPPEM---IE--GRMHDEKVDLWSL   196 
CDK2     DFGLARAF--------------GvPVRtYTHEVVTLWYRAPEI---LL-GCKYYSTAVDIWSL   189 
 
 
 
                                α-G 
 
                  IX                   X 
         *∨   ∨           ∨  ∨    ∨  ∨∨                                   
PfeIK1   GVVFFEMFH----EPFSTSMERSITLSNLLKGIYPEYMKAD------------------      759 
PfeIK2   GLIIVDLFT-----ITKTnMERMKILCNARHRILPDLLIKNH-----------------      454 
PfPK4    ALILLELLC----PRFTTIMERYKrLNDFRNYYTVPDYVKIHL----------------     2962 
PbeIK1   GVVFFEMFH----EPFSTSMERSIVLSNLLKCIYPESIRSD------------------      719 
PbeIK2   GLIIIDLFIK-----TETnMERTQILCNARERILPDLLIKKH-----------------     1003 
PbPK4    ALILLELLC----PRFNTIMERyKTLNDFRNYYTVPDYVKIHL----------------      941 
TgIFKA   ALILLELLC----PRFTTVMERVKTLEDFKTSYSVPQHIRLHL----------------     4912 
TgIFKB   GLIVLDLFT-----RCNTAMEQATNFRNARDGRFPPSVTSTY-----------------     2132 
hPKR     GLILAELLH-----VCdTAFETSKFFTDLRDGIISDIFDKKE-----------------      511 
hHRI     GVVLLELFQ-----PFGTEMERAEVLTGLRTGQLPESLRKRCPVQ--------------      556 
hPERK    GLILFELLY-----PFSTQMERVRTLTDVRNLKFPPLFTQK------------------     1045 
hGCN2    GIIFFEMSYH----PMVTASERIFVLNQLRDPTSPKFPEDFDDGEH-------------      971 
ScGCN2   GIIFFEMIY-----PFSTGMERVNILKKLRSVSIEFPPDFDDNKM--------------      951 
DdIFKA   GIIFFEMCFQ-----FQTQMERSNILRDLRDNLKFPPGFESTK----------------     1452 
DdIFKB   GIIFFEMCFQ-----FQTQMERSNILRDLRDNLKFPPGFESTK----------------      552 
DdIFKC   GIVFFEMWY-----VFSTGHERVIVLRNLREKFEFPSDFERN-----------------      996 
AtGCN2   GVVFFELWH-----PFGTAMERHVILTNLKLKGELPLKWVNEF----------------      760 
TbeIFK1  GMIALEMWLA---VAGQGfRERFNIMTDISRGKPIPQWF--------------------      626 
TbeIFK2  GLIAVEFYCE-----FTTQHERLRTLGDARHGELPSALEDDFP----------------      906 
TbeIFK3  GIVLAEMYV-----QPKTVSERLHVLKAVRNGVFPESSLLKRY----------------      996 
Aurora   GVLCYEFLVGKPPFEAN---TYQETYKRISRVEFTFPDFVT------------------      234 
CDK2     GCIFAEMVTRRALFPGD---SeIDQLFRIFRTLGTPDEVVWPGVTSMPDYKpSFpkwar      245 
 
 
 
                                  XI 
                                       * 
PfeIK1    -----------NKKFQFL-SSLLAINPQERCCAYNLLHESVLftfekdftdiynlidnkrnc   809 
PfeIK2    -----------PQVAKLC-QNLLSLDYHLRWTSEELYKK---kkniyiy-------------   488 
PfPK4     -----------NPWYILM-LQMSKPNPADRPSAADVYSK--Ikvlldphltdfafsfndih-  3009 
PbeIK1    -----------NKIFQFL-LSLLEIDPQNRLSAYSLLHENFFfsyeknfneiynlvekkrnc   769 
PbeIK2    -----------PNVASLC-KKMLSLDYKSRPTSAQLYNK--Iisagdiflpdkcp-------  1044 
PbPK4     -----------NPWYILM-LQMSKPNPADRPSAADLYNK--Ikvlldphltdftfsfndinn   989 
TgIFKA    -----------HPWYLLM-KEMARPEPQHRPSAYTVLKH--Vkmlltppgdtqpqrvmllyp  4960 Clare Fennell, 2008     Chapter 3 65 
TgIFKB    -----------PWVVPFC-RWCLQNDPSKRPTIRQLYQH---ycstgsvfgpktatsrcsas  2179 
hPKR      --------------KTLL-QKLLSKKPEDRPNTSEILRT--Ltvwkkspeknerhtc-----   551 
hHRI      --------------AKYI-QHLTRRNSSQRPSAIQLLQSELFqnsgnvnltlqmkiieqeke   603 
hPERK     -----------YPCEYVMvQDMLSPSPMERP---EAINI--Ienavfedldfpgktvlrqrs  1091 
hGCN2     -----------AKQKSVI-SWLLNHDPAKRPTATELLKSELLpppqmeeselhevlhhtltn  1021 
ScGCN2    -----------KVEKKII-RLLIDHDPNKRPGARTLLNSGWLpvkhqdevikealkslsnps  1001 
DdIFKA    -----------PDQTQII-RSLLSRDPTQRPSTKQLLESGLLpskmeddilkeaiktianpt  1502 
DdIFKB    -----------PDQTQII-RSLLSRDPTQRPSTKQLLESGLLpskmeddilkeaiktianpt   602 
DdIFKC    ----------HSRQATLI-RMLIDKDPAKRPSAQQLLQSELMppkmedeyiknsirvitnpt  1047 
AtGCN2    -----------PEQASLL-RRLMSPSPSDRPSATELLKHAFPprmeselldnilrimqtsed   751 
TbeIFK1   -------YAWNPRMAEVI-ASLLERDPGKRRTSEEILNK---adlpgdpadvvealetikrh   677 
TbeIFK2   -----------EEAEVF--RQMLGEQPDGRPSVDEVVQK--Lkhivveirsggngsaklgdn   953 
TbeIFK3   -----------PELC-VV-QYLTLKDPSHRMSLMDASRA--Lrrtvyrillsffsev-----  1038 
Aurora    -----------EGARDLI-SRLLKHNPSQRPMLREVLEH---p-------------------   262 
CDK2      qdfSkVvPPLDEDGRSLL-SQMLHYDPNKRISAKAALAHPFFqdvtkpvphlrl--------   298 
 
Figure 3-3: Sequence alignment of eIF2α kinases. 
The sequences of catalytic domains of eIF2α kinases were aligned against the Pfam kinase 
domain (PF00069) using the HMMER package (J. Wilkes), Aurora kinase and CDK2 were included 
as outgroups.  Residues identical in >90% of the sequences are highlighted in black, residues 
conserved in >75% of sequences are highlighted in grey, the threonine residue within the activation 
loop, phosphorylated for activation of PKR is highlighted in red.  Positions and lengths of inserts 
within the kinase domain are indicated by breaks in the sequence marked //-//.  Conserved kinase 
domains are indicated by horizontal black lines numbered with roman numerals.  Regions of 
important function are marked with labeled blue lines.  The probable position of helix a-G is 
indicated in horizontal red bars, the longer one represents eIF2α kinases, and the shorter one 
canonical Ser/Thr kinases (see text for details).  Key residues conserved in all types of kinase are 
indicated with asterisks (*) while important residues in eIF2α kinases are marked with arrowheads 
(∨).  The alignment was adjusted by hand in domain X, with reference to Dar et al 2005.  Pf; P. 
falciparum, Pb; P. berghei, Tg; T. gondii, h; Homo sapiens, Sc; Saccharomyces cerevisiae, Dd; 
Dictyostelium discoydium, At; Arabidopsis thaliana, Tb; Trypanosoma brucei.  PlasmoDB IDs: 
PfeIK1; PF14_0434, PfeIK2; PFA0280w, PfPK4; PFF1370w, PbeIK1; PB000582.03.0, PbeIK2; 
PB001255, PbPK4; PB000480.02.0.  TgIFKA; GI44889870, TgIFKB; GI: 169656460, hPKR; 
GI4506103, hHRI; GI: 6580979, hPERK; GI: 18203329, hGCN2; GI: 65287717, ScGCN2; 
GI6320489, AtGCN2; GI: 24940154, hAurora; GI: 37926805, hCDK2; GI1942427.  Dictybase IDs: 
DdIFKA; DDB0185218, DdIFKB; DDB0185219; DdIFKC; DDB0216407; GeneDB IDs:  TbeIFK1; 
Tb11.02.5050, TbeIFK2; Tb927.4.2500, TbeIFK3; Tb927.6.2980. 
 
 
Figure 3-4: Structure of PKR-eIF2α complex. Clare Fennell, 2008     Chapter 3 66 
Ribbons representation of the PKR/eIF2α complex highlighting eIF2α recognition mediated by helix 
α-G in the C-terminal lobe of PKR and catalytic domain dimerization mediated by the N-terminal 
lobe of PKR.  The N-terminal and C-terminal lobes of PKR are coloured purple and green (left 
molecule) and red and blue (right molecule), respectively.  The activation segment is coloured 
orange and the phosphor-Thr for activation is shown as ball and stick representation.  The region 
shown with a dashed line in PKR has not been modelled due to disorder and/or deletion; this 
includes the characteristic kinase insert.  The dashed region of eIF2α has not been modeled due to 
disorder and encompasses the Ser51 acceptor site.  (Adapted with permission from Dar et al. (Dar 
et al., 2005)). 
 
3.2.1.1    PfeIK1 
The alignment in Figure 3-3 was used to generate the phylogenetic tree shown in 
Figure 3-5 which clearly shows a cluster of GCN2 related sequences, including 
PfeIK1 and its P. berghei orthologue.  Although these Plasmodium sequences 
diverge at the base of the branch, it nonetheless suggests a possible role for 
PfeIK1 in response to nutrient levels, a function fulfilled by GCN2 in yeast and 
mammalian cells.  The PF14_0423 (PfeIK1) gene model proposed in PlasmoDB 
(Bahl et al., 2003) predicts a single intron that falls close to the 5’ end of the 
sequence so that the kinase domain is encoded entirely within the second exon.  
All the residues that are required for catalytic activity (Hanks, 2003) are present 
in the PfeIK1 kinase domain (Fig. 1-4), suggesting the gene encodes an active 
enzyme.  The PfeIK1 sequence also shares the feature of insertions within the 
catalytic domain with other eIF2α kinases (Figs. 3-3 & 3-6) (Mathews, 2007).  As 
described above (1.8.3.1), GCN2 has extensions either side of the kinase domain; 
such that not only is PfeIK1 most similar to GCN2 in the sequence of its catalytic 
domain (BLASTP analysis shows 35% identity), but also in overall primary 
structure (Fig. 3-6).  Furthermore the C-terminal extension of PfeIK1 contains an 
anti-codon binding domain (Superfamily entry SSF52954) as found in amino acyl 
synthetases, that may mediate binding to uncharged tRNAs, a function that is 
performed in GCN2 by the HisRS domain present in the C-terminal extension 
(Fig. 3-6) (Wek et al., 1995).  Other functional domains present in the GCN2 
extensions (GCN1 binding domain, charged region, pseudo-kinase domain and C-
terminal ribosome binding, and dimerization domain (RB/DD), Fig. 3-6) are not 
recognizable in PfeIK1. Clare Fennell, 2008     Chapter 3 67 
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Figure 3-5: Phylogenetic tree illustrating eIF2α kinases in diverse species. 
Analysis of the sequence alignment presented in Figure 3-3; the tree was produced from the 
alignment prior to adjustments made by hand.  The three P. falciparum sequences investigated 
here are in red, apicomplexans are boxed in red, and the blue bracket indicates sequences 
clustering most closely with GCN2.  Pf; P. falciparum, Pb; P. berghei, Tg; T. gondii, Dd; 
Dictyostelium discoydium, Sc; Saccharomyces cerevisiae, Hs; Homo sapiens, At; Arabidopsis 
thaliana, Tb; Trypanosoma brucei. 
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Figure 3-6: Schematic of protein domains of human, P. falciparum, and T. gondii eIF2α 
kinases. 
Kinase domains are shown in blue, insertions within the kinase domains are shown in pink 
(characteristic for eIF2α kinases; sizes detailed in Figure3-3). Additional domains are as follows; 
GCN2: orange; GCN1 binding (G1), cream; charged region (+/-), blue marked (Ψ); pseudo kinase 
domain, pale green; histidyl tRNA synthetase domain (HisRS), dark green; ribosome binding and 
dimerization domain (RB/DD).  PERK: brown; signal sequence (SS), purple; regulatory domain 
similar to IRE1 (IRE1), yellow; transmembrane domain (TM).  HRI: brown; heme binding (H).  PKR: 
red; RNA binding domains.  PfeIK1 contains a putative amino acyl tRNA synthetase domain, green 
(aaRS), similar to the HisRS domain in GCN2.  PfPK4 has a putative transmembrane domain, 
yellow (TM), as does TgIFKA.  White is for regions of unidentified function.  The total length of the 
proteins is given by the number of amino acids, shown at right.  
 
3.2.1.2    PfeIK2 
The phylogenetic analysis of eIF2α kinases from diverse species shows PfeIK2 
(PFA0380w) clusters with its P. berghei orthologue as expected, however there is 
no clear association with any of the mammalian eIF2α kinases in particular (Fig. 
3-5).  BLASTP analysis using the kinase domain as a query shows it shares 38% 
identity with human PKR.  Interestingly PfeIK2 is also associated, albeit weakly, 
with the recently identified TgIFKB, which is suggested to respond to 
cytoplasmic stresses (Narasimhan et al., 2008).  The lack of transmembrane 
domain or other targeting sequence in PfeIK2 is consistent with a cytoplasmic 
location (Fig. 3-6).  The gene structure of pfeik2 is discussed in section 3.4.2.1; 
briefly, the kinase domain is encoded by a single exon.  Although the majority of 
residues required for catalytic activity (Hanks, 2003) are conserved in PfeIK2, Clare Fennell, 2008     Chapter 3 69 
the glycine triad in domain I, required for orientation of the ATP molecule, is 
not complete (SKGNNN); whether the tertiary structure of PfeIK2 is able to 
compensate for this to facilitate kinase activity remains unknown.  In this 
context is it interesting to note that the PfPK7 crystal structure reveals that the 
divergent glycine triad (NQGKFN in PFPK7) forms the same structure as classical 
GxGxφG kinases (where x represents any other amino acid and φ a hydrophobic 
residue), and so allows kinase activity (Merckx et al., 2008).  As discussed in 
section 1.8.3.2 phosphorylation of a conserved threonine residue in domain VIII 
is part of the activation mechanism of eIF2α kinases.  PfeIK2 is the only P. 
falciparum eIF2α kinase in which this threonine residue, and therefore 
potentially the activation mechanism, is clearly conserved (Fig. 3-3); the 
functional significance of this remains to be tested. 
Although PfeIK2 shares the features of insertions within the catalytic domain 
with other eIF2α kinases, the sequence of these insertions is not recognizably 
similar either to other eIF2α kinase inserts, or to other protein motifs.  In 
contrast to human and some other eIF2α kinases that have lengthy extensions 
containing regulatory domains (1.8.3.1) the N-terminal extension in PfeIK2 is 
short, with only 118 residues (Fig. 3-6); to date no recognizable motifs have 
been identified within this region, although this does not exclude the possibility 
of a regulatory function. 
3.2.1.3    PfPK4 
The previously published sequence of PfPK4 encodes a predicted 1123 amino 
acid sequence that encompassed a protein kinase domain (Mohrle et al., 1997).  
However, the gene prediction algorithms in PlasmoDB propose a 9219 ORF 
encoding a 3072 amino acid protein that encompasses the previously published 
sequence.  The PfPK4 sequence contains all the residues required for kinase 
activity, suggesting that the gene encodes an active kinase, consistent with 
previously published data (Mohrle et al., 1997).  PfPK4 also contains inserts 
within the kinase domain in common with eIF2α kinases; notably, these are very 
large in comparison to all other eIF2α kinases, except for the P. berghei PbPK4 Clare Fennell, 2008     Chapter 3 70 
orthologue and the two T. gondii sequences TgIFKA and TgIFKB (Fig. 3-6), the 
former of which clearly clusters with PfPK4 and PbPK4 (Fig. 3-5).  However, 
despite the similarity in size between the inserts in PfPK4, PbPK4 and T. gondii, 
the sequences of the inserts are not conserved.   
The phylogenetic analysis presented here confirms previous observations that 
PfPK4 is most closely related to TgIFKA (Sullivan et al., 2004) (Fig. 3-5), and 
cannot be assigned orthology to a specific human eIF2α kinase.  In spite of this, 
BLASTP analysis (which is a less sophisticated tool than HMM alignments) using 
the catalytic domain as the query suggests that PfPK4 is most similar to human 
PERK, with 29% identical residues.  PfPK4 also appears to be more closely 
related to its P. berghei orthologue than PfeIK1 or PfeIK2 (Fig. 3-5), which may 
be indicative of a role in a conserved function such that greater divergence has 
not occurred.  Despite the lack of sequence similarity between TgIFKA and PERK, 
evidence has recently been provided that TgIFKA localizes to the ER and shares 
some regulatory mechanisms with this human ER-stress-responsive kinase 
(Narasimhan et al., 2008).  In TgIFKA, as in PERK the transmembrane domains lie 
centrally in the protein sequence (Sullivan et al., 2004) (Harding et al., 1999), 
such that in PERK a domain extends into the lumen of the ER (discussed section 
1.8.3.1).  Although in PfPK4 the putative transmembrane domain is relatively 
close to the N-terminus (Fig. 3-6), 108 residues lie to its N-terminus that could 
enable association with other proteins; it therefore remains an interesting 
possibility that PfPK4 could perform PERK-like functions in P. falciparum. 
3.2.2   Life cycle stage specific expression of PfeIF2α kinases  
Initial hypotheses about the roles of the PfeIF2α kinases were based on data 
from the P. falciparum genome database, PlasmoDB shown in Figure 3-7.  The 
data are from the Le Roch et al. 2003 microarray study (Le Roch et al., 2003), 
and suggest PfeIK1 is expressed in merozoites and ring stage parasites.  In 
contrast, PfeIK2 mRNA appears not to be expressed in asexual stages at all, but 
is found in gametocytes and sporozoites.  PfPK4 mRNA is present in all life cycle 
stages examined, in agreement with previously published data (Mohrle et al., 
1997).   Clare Fennell, 2008     Chapter 3 71 
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Figure 3-7: Expression data for the PfeIKs taken from PlasmoDB (Le Roch et al., 2003). 
Y-axis: percentiled gene expression, relative to total gene expression.  X-axis: life cycle stage: S= 
sporozoites, ER = early rings, LR = late rings, ET = early trophozoites, LT = late trophozoites, ES = 
early schizonts, LS = late schizonts, M = merozoites and G = gametocytes.  Purple indicates 
parasites synchronised using temperature, Green represents parasites synchronised with sorbitol.  
Black is used for gametocytes and sporozoites where the synchronisation method does not apply, 
and grey represents data below the confidence level.  The red box encloses asexual stages. 
 
The PfeIK1 catalytic domain was amplified from an asexual-stage cDNA library 
(A. Craig), confirming that it is indeed expressed during asexual stages (data not 
shown).  Further, we raised an anti-peptide antibody, in order to analyse PfeIK1 
protein expression; unfortunately, the specific band identified was slightly 
smaller than expected, which would not have given undue cause for concern. 
However, critically, this band is unchanged in genotyped pfeik1
- parasites 
(4.2.1), which demonstrates that it results from cross-reactivity of the antibody 
with another protein; PfeIK1 protein expression therefore remains untested.  We Clare Fennell, 2008     Chapter 3 72 
have very recently received chicken IgYs directed against PfeIK1-derived 
peptides from our collaborator Prof. D. Goldring (Univ. of Kwazulu-Natal, South 
Africa), that will be tested in the near future.  RT-PCR and western blot analysis 
were completed for PfeIK2 and are discussed below (3.4.2.1).  We also raised an 
anti-peptide antibody to PfPK4 that specifically recognizes a band of 
approximately 80 kDa (Fig. 3-8).  Although the full length of PfPK4 is predicted 
to be a 365 kDa protein, and the kinase domain would also be a relatively large 
protein of 135 kDa, such that the precise identity of the 80 kDa band is 
unknown, the size observed here is consistent with previously published data 
that also report an 80kDa band for PfPK4 (Mohrle et al., 1997).  If this band does 
indeed represent a processed form of PfPK4 then western blot data indicates it 
is expressed throughout the life cycle but at a higher level in trophozoites and 
schizonts, than in rings or gametocytes (Fig. 3-8).   
 
 
Figure 3-8: Expression of PfPK4. 
Western blot analysis of PfPK4 expression in the parasite life cycle.  Upper panel, PfPK4; lower 
panel, PfCK2α as a loading control.  R; ring stage, T; trophozoites, S; schizonts, G; gametocyte 
enriched.  Sizes of co-migrating markers are indicated at left. 
 
 Clare Fennell, 2008     Chapter 3 73 
3.3   Cloning and expression of P. falciparum eIF2α 
3.3.1   Cloning of PfeIF2α  
The PlasmoDB accession number for the P. falciparum orthologue of eIF2α is 
PF07_0117.  Oligonucleotide primers were designed to amplify the complete 
coding sequence by PCR from a cDNA library of the P. falciparum clone 3D7, 
using the Phusion polymerase (Finnzymes).  The forward primer (No. 151, Table 
6-2, appendix) contained a BamHI restriction site the reverse primer (No.152 
Table 6-2, appendix) contained a SalI site.  Taq polymerase (Takara) was used to 
add adenine tails to enable cloning of the 990bp product into the pGEM-T Easy 
vector (Promega) for amplification and sequencing.  The correct sequence was 
removed by digestion with BamHI/SalI and inserted into the expression vector 
pGEX-4T3 (Pharmacia) (Fig. 3-9).  The pGEX-4T3 vector adds the glutathione-S-
transferase (GST) sequence to the N-terminus of PfeIF2α.  A mutant of PfeIF2α 
designed to be refractory to phosphorylation was obtained by site directed 
mutagenesis (Ser59→Ala) using the overlap extension PCR technique (primers 
no. 195 and 196) (Ho et al., 1989).   
pGEX-4T3-PfeIF2alpha
5946 bp
AMP resistance
lacIq
GST
PfeIF2alpha
bla
tac
Rep Origin 1
BamHI (931)
SalI (1927)
 Clare Fennell, 2008     Chapter 3 74 
Figure 3-9: Map of the expression vector for PfeIF2α. 
 
3.3.2 Expression of Recombinant PfeIF2α 
Different expression conditions were tested in order to optimize the yield of 
both PfeIF2α wild type and the S59A mutant.  E. coli BL21codon plus were used; 
protein expression was induced using 0.1 - 5mM IPTG, at 37
oC, or 30
oC for 2-4 
hours, or 16
oC overnight.  Samples were taken before induction of protein 
expression and after induction.  Bacteria were harvested after the appropriate 
time and lysed in lysis buffer 1 (Table 6-7, appendix.  Samples were taken of the 
soluble and insoluble fractions before purification of the soluble fraction on 
glutathione-agarose beads.  Samples were also prepared from the eluted 
proteins and the beads after elution.  Figure 3-10 shows a representative 
Coomassie-blue stained gel of this series of samples after induction with 0.25mM 
IPTG, 16
oC overnight, which was found to give the best balance of yield of full 
length protein, whilst minimizing the yield of truncated products, or degradation 
to GST only.  Figure 3-11 shows an anti-GST western blot of the purification 
stages after induction with 0.5mM IPTG for 2 hours at 30
oC; this confirms the 
expected size of 64 kDa GST-PfeIF2α and illustrates the high proportion of 
degraded proteins that arose when expression was induced at higher 
temperatures.   
Purification on affinity chromatography columns was also attempted, but batch 
purification was found to be more reliable and convenient for subsequent 
experiments. Clare Fennell, 2008     Chapter 3 75 
 
Figure 3-10: Purification of GST-PfeIF2α. 
Coomassie blue stained gel showing purification of recombinant GST-PfeIF2α wild type (WT) and 
Ser→Ala mutant (S59A) in E. coli.  1: before induction, 2: after induction (0.25mM IPTG, 16
oC over 
night), 3: soluble fraction, 4: insoluble fraction, 5: eluted proteins, 6: beads, after one elution. 
 
 
Figure 3-11: Western blot analysis of purification of wild type GST-PfeIF2α. 
Samples from successive stages of expression and purification of wild type GST-PfeIF2a were 
separated by SDS-PAGE, transferred to nitrocellulose and probed with an anti-GST antibody.  1: 
before induction, 2: after induction (0.5mM IPTG, 2 hours, 30
oC), 3: soluble fraction, 4: insoluble 
fraction, 5: eluate. 
 Clare Fennell, 2008     Chapter 3 76 
3.4   Cloning, expression and characterisation of the P. 
falciparum eIF2α kinases. 
3.4.1   PfeIK1 
3.4.1.1    Cloning of the PfeIK1 catalytic domain 
A 1278bp fragment encoding the catalytic domain of PfeIK1, was amplified from 
a P. falciparum asexual stage cDNA library (A. Craig) using the Phusion 
polymerase (Finnzymes), (forward including BamHI; no. 146, reverse including 
SalI; no. 148) followed by Taq for pGEM-T Easy cloning as described for PfeIF2α 
(3.3.1).  A catalytically inactive mutant was obtained by site directed 
mutagenesis of Lys458→Met using the overlap extension PCR method (nos. 197 & 
198, Table 6-2, appendix) (Ho et al., 1989).  The correct sequence was removed 
by digestion with BamHI/SalI and inserted into the expression vector pGEX-4T3, 
between the same sites.  The pGEX-4T3 vector was chosen to express the PfeIK1 
catalytic domain with an N-terminal GST tag following the success of this 
strategy for the expression and characterisation of several other P. falciparum 
kinase domains (for a few examples, see (Dorin et al., 2005, Reininger et al., 
2005)(Reininger et al. in prep)(Holland et al. in prep)).  Furthermore eIF2α 
kinases act as dimers (1.8.3.2); expression of the kinase domain of PKR fused to 
GST, which can form dimers, enabled purification of active kinase, where the 
kinase domain alone was inactive (Ung et al., 2001). Clare Fennell, 2008     Chapter 3 77 
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Figure 3-12: Map of the expression vector for GST-PfeIK1. 
 
3.4.1.2    Expression of recombinant PfeIK1 
The conditions required for optimal expression of GST-PfeIK1 were investigated; 
induction was with IPTG at 0.1 - 5.0 mM, or by autoinduction (2.4.6), the 
temperature was varied from 16
oC overnight to 30
oC or 37
oC for 2-4 hours, and 
E. coli BL21 codon plus cells, or Rosetta2 or RIL cells were tested.  Samples were 
taken at successive stages during induction and purification, as described for 
PfeIF2α (3.3.2), and analysed by SDS-PAGE followed by Coomassie blue staining 
or anti-GST western blot (Figs. 3-13 & 3-14).  Induction with 0.25mM IPTG at 
16
oC overnight gave the best yield of active full length GST-PfeIK1 (76 kDa); 
autoinduction gave less truncated proteins but the full length protein appeared 
to be inactive in kinase assays (not shown).   Clare Fennell, 2008     Chapter 3 78 
 
Figure 3-13: Purification of GST-PfeIK1. 
Coomassie blue stained gel of purification stages of GST-PfeIK1.  1: before induction, 2: after 
induction (0.25mM IPTG, 16
oC over night), 3: soluble fraction, 4: insoluble fraction, 5: eluate, 6: 
beads after first elution. 
 
 
Figure 3-14: Purification of GST-PfeIK1. 
Western blot analysis of purification stages of GST-PfeIK1.  Samples were collected at successive 
stages of protein expression which was induced with 0.5mM IPTG, followed by growth at 30
oC for 2 
hours.  Samples were separated by SDS-PAGE, transferred to nitrocellulose and probed with an 
anti-GST antibody.  1: before induction, 2: after induction, 3: soluble fraction, 4: insoluble fraction, 
5: eluted protein.  The arrow marks the expected size of full length GST-PfeIK1 at 76 kDa; the 
bracket marked with GST is likely to contain various truncated proteins including GST.   
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3.4.1.3    PfeIK1 is an active kinase able to phosphorylate PfeIF2α 
in vitro 
In order to test the hypothesis that the pfeik1 gene encodes a functional kinase I 
used the GST-PfeIK1 fusion protein in kinase assays.  Kinase assays were 
performed with the non-physiological substrates α- or β-casein, myelin basic 
protein (MBP) and histone H1, in the presence of wild type GST-PfeIK1, 
catalytically inactive GST-PfeIK1-K458M, or no kinase (Fig. 3-15).  The results 
demonstrate that PfeIK1 can autophosphorylate; due to the signal at the 76kDa 
band, which is also clearly observed in Figure 3-16, where the wild type kinase 
has not been provided with substrate.  Autophosphorylation has been shown to 
be part of the activation mechanism of the eIF2α kinases (reviewed (Mathews, 
2007)).  Figure 3-15 shows that GST-PfeIK1 can phosphorylate the two non-
physiological substrates, α- and β-casein, MBP and histone H1 were not 
phosphorylated (data not shown).  Weaker phosphorylation of β-casein is 
observed in the catalytically inactive mutant lane; since this activity is also 
present where there is no recombinant kinase at all, it must derive from a low 
level of contaminating kinase activity in the substrate itself, providing 
confidence that the K458M mutant is indeed inactive, and that GST-PfeIK1 is 
responsible for the kinase activity observed in the wild type lane.   Clare Fennell, 2008     Chapter 3 80 
 
Figure 3-15: PfeIK1 phosphorylates non-physiological substrates. 
Kinase assays were carried out using the recombinant catalytic domain of PfeIK1, GST-PfeIK1 
using the exogenous substrates α- and β-casein.  Assays contained 10μg α-casein (left three 
lanes), or 10μg β-casein (right three lanes), in the presence of 2μg wild type (WT), 2μg catalytically 
inactive (K458M), or no kinase (-).  Upper panel: autoradiogram, lower panel: Coomassie blue 
stained gel. 
 
In order to establish whether PfeIK1 is an eIF2α kinase as predicted, I used the 
recombinant GST-PfeIF2α as a substrate in kinase assays with GST-PfeIK1.  
Importantly, Figure 3-16 (left lane) shows that GST-PfeIK1 can phosphorylate 
wild type GST-PfeIF2α.  Furthermore, mutation of the predicted target for 
phosphorylation, Ser59, to alanine, which cannot be phosphorylated, prevents 
PfeIF2α phosphorylation.  This suggests that the mechanism of phosphorylation 
of eIF2α that, in other systems results in the regulation of translation initiation, 
may be conserved in P. falciparum.   
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Figure 3-16: GST-PfeIK1 autophosphorylates and phosphorylates wild type PfeIF2α but not 
the mutant PfeIF2α S59A. 
Kinase assays were carried out using 10μg wild type GST-PfeIF2α (left three lanes), 10μg GST-
PfeIF2α S59A (centre three lanes), or no substrate (right two lanes), in the presence of 2μg wild 
type GST-PfeIK1 (WT), 2μg catalytically inactive mutant GST-PfeIK1 (K458M), or no kinase (-).  
Upper panel: autoradiogram, lower panel: Coomassie blue stained gel. 
 
3.4.2   PfeIK2 
3.4.2.1    Verification of pfeik2 gene structure 
The four gene prediction algorithms used by PlasmoDB (Bahl et al., 2003) were 
not consistent for the exon structure of pfeik2.  The possible gene structures are 
shown in Figure 3-17A; RT-PCR was used to investigate which of these is correct.  
To generate any of these PCR products, it was necessary to use gametocyte 
cDNA as the template since there was no amplification from asexual material 
(not shown); this is consistent with the microarray data suggesting PfeIK2 is not 
expressed during asexual stages.  It was possible to amplify the 404 bp fragment 
corresponding to the 5’ end of the single exon prediction (top, Fig. 3-17A), 
confirming that mRNAs including this region are present.  However, neither 
primer pair selected to amplify across the predicted intron boundaries resulted 
in any amplification, providing evidence (albeit negative) that the single exon 
gene structure is correct.   Clare Fennell, 2008     Chapter 3 82 
 
Figure 3-17: Verification of the gene structure of pfeik2. 
A: Schematic illustrating the three possible gene structures given by the different gene prediction 
algorithms used by PlasmoDB.  Single headed arrows (top) indicate the position of primers used 
for RT-PCR analysis.  Double headed arrows indicate the expected sizes to be amplified by RT-
PCR, by each primer combination; the rounded-ended line indicates the expected sizes to be 
amplified from genomic DNA.  B: RT-PCR with different primer pairs; left panel, primers 1+2; 
centre, 1+3; right, 1+4.  
 
To confirm the RT-PCR results with regard to both the stage of expression, and 
the length of the open reading frame, a western blot was carried out comparing 
expression of PfeIK2 in asexual parasites and gametocytes.  As shown in Figure3-
18, a band of 59 kDa; the expected size of the protein encoded by the single 
exon gene is recognised exclusively in gametocytes.  This supports the RT-PCR 
data that PfeIK2 is encoded by a single exon, resulting in expression of a 59 kDa 
protein in gametocytes.  The PlasmoDB microarray data (Fig. 3-7) indicates 
PfeIK2 is also expressed in sporozoites; it would be interesting to extend the 
analysis presented here to verify this.  Clare Fennell, 2008     Chapter 3 83 
 
Figure 3-18: Western blot showing the size and stage specific expression of PfeIK2. 
Upper panel: Anti-PfeIK2 western blot, the arrow indicates PfeIK2, lower panel; anti-ERD2 loading 
control.  A; mixed asexual parasites, G; gametocyte enriched population.   
 
3.4.2.2    Cloning of the PfeIK2 catalytic domain 
Having verified the pfeik2 gene structure, the 1134 base pair fragment encoding 
the catalytic domain of PfeIK2 was amplified using the High Fidelity polymerase 
(Roche) that enables cloning to pGEM-T (Nos. 150 and 185, Table 6-2, appendix).  
The high AT content of P. falciparum genes and the presence of highly repetitive 
sequence made it difficult to obtain the entire sequence without mutations by 
PCR; an integral BstBI restriction site was used to piece together correct 
sequence to produce a construct free from mutations.  The correct contiguous 
sequence was transferred using the BamHI/ SalI restriction sites in the primers, 
to the expression vector pGEX-4T3 (Fig. 3-19). Clare Fennell, 2008     Chapter 3 84 
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Figure 3-19: Map of the expression vector for GST-PfeIK2.  
 
3.4.2.3    Expression of recombinant PfeIK2 
Expression trials for PfeIK2 were carried out using E. coli BL21 gold, Rosetta2 
and BL21 codonplus, induction of protein expression was by treatment with 
0.1mM - 5mM IPTG at 16
oC, or 25
oC, or autoinduction at 15
oC or 20
oC for 24 or 48 
hours.  As indicated in the example of expression and purification in Figure 3-20, 
induction with 0.25mM IPTG allowed the purification of a low concentration of 
the expected 73 kDa protein.  The anti-GST western blot (Fig. 3-21) confirms 
that the full length protein was expressed and found in the soluble fraction; this 
blot suggested that the protein was lost during purification. Clare Fennell, 2008     Chapter 3 85 
 
Figure 3-20: Expression of GST-PfeIK2 using E.coli BL21c+. 
Coomassie blue stained gel of purification of GST-PfeIK2 from three different conditions of 
expression; left, induced using 0.25mM IPTG; centre, by autoinduction for 24 hours; right, by 
autoinduction for 48 hours.  1: After induction, 2: soluble fraction, 3: insoluble fraction, 4: beads, 
without eluting proteins. 
 
 
Figure 3-21: Expression of GST-PfeIK2 using E. coli BL21 codon plus. 
Expression of GST-PfeIK2 was induced under three different conditions; 0.25mM IPTG 15
oC 
overnight or autoinduction at 15
oC for 24 or 48 hours.  Samples from successive stages of 
purification were separated by SDS-PAGE, transferred to nitrocellulose and probed with an anti-
GST antibody.  1: total extract after induction, 2: soluble fraction, 3: insoluble fraction, 4: beads, 
without eluting proteins. 
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3.4.2.4    Initial activity assay of recombinant GST-PfeIK2  
Kinase assays can be performed using un-eluted material still bound to the 
beads; an initial kinase assay was carried out in this way, using those GST-PfeIK2 
preparations that contained the 73kDa protein, visible on a Coomassie-blue 
stained gel.  The non-physiological substrates α- and β-casein, myelin basic 
protein and histone H1 were used, in addition to GST-PfeIF2α and a synthetic 
peptide comprising the 12 amino acids surrounding PfeIF2αSer59.  No activity 
was detected (data not shown).  However, only a small amount of full length 
recombinant protein was present in any of the preparations used.  Before 
conclusions can be drawn about whether PfeIK2 is indeed a bona fide protein 
kinase, the recombinant protein expression and purification conditions need 
further optimization.  Another approach to address this question would be to 
immunoprecipitate PfeIK2 from gametocytes, followed by kinase assay.  With 
either approach it remains possible that a lack of detectable activity is not due 
to the gene product not being a true kinase, but that it requires specific 
activation stimuli not present under the experimental conditions.   
3.4.3   PfPK4 
3.4.3.1    Cloning of PfPK4 catalytic domain 
According to the PlasmoDB gene prediction, the catalytic domain of PfPK4 is 
encoded by the 3’ 3498 nucleotides of the ORF; this was amplified using primer 
numbers 161 (forward) and 154 (reverse) (Table 6-2, appendix) and the high 
fidelity polymerase (Roche), which adds adenine tails allowing for cloning into 
pGEM-T.  The length of the sequence and characteristic high AT content of P. 
falciparum sequences prevented the obtention of a complete mutation-free 
sequence by PCR.  Restriction sites within the catalytic sites were used to piece 
together mutation free regions to obtain the complete sequence.  The BamHI 
and SalI restriction sites in the primers were used to transfer the complete 
sequence to the expression vectors pGEX-4T3 and pET-28a (Fig. 3-22).  As 
discussed above, pGEX-4T3 adds the 26 kDa GST sequence to the N-terminus of 
the protein; the pET-28a vector adds a 6-His tag to the N-terminus.   Clare Fennell, 2008     Chapter 3 87 
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Figure 3-22: Map of the His-PfPK4 expression vector. 
 
3.4.3.2     Expression of recombinant PfPK4 
The 3498 nucleotide sequence of the PfPK4 catalytic domain encodes a 136 kDa 
protein.  Initial expression trials were carried out using the pGEX-4T3 construct. 
However, due to the already large size of the protein I considered that the extra 
size of the GST tag could exacerbate expression difficulties.  Since the catalytic 
domain of PfPK4 had previously been expressed with a His tag, I switched to 
using the pET-28a construct, which encodes an N-terminal His tag.  As with other 
recombinant proteins discussed above I used a range of conditions and bacterial 
strains to attempt to induce expression of His-PfPK4.  Examples of the most 
successful conditions are shown in Figure 1-23, illustrating that the most 
abundant protein product was approximately 70 kDa.  On one occasion an anti-
His western blot (not shown) did show a faint band at >100 kDa in the soluble 
fraction sample, after induction with 5 mM IPTG at 20
oC for 1 hour.  However, 
no pure full-length His-PfPK4 was ever obtained. Clare Fennell, 2008     Chapter 3 88 
 
Figure 3-23: Expression of His-PfPK4. 
Expression of His-PfPK4 was induced using 1or 5mM IPTG at 15
oC overnight.  Samples were 
taken during expression and purification, separated by SDS-PAGE and stained with Coomassie 
blue.  The arrow marks the expected size of His-PfPK4.  1: total extract before induction, 2: after 
induction, 3: soluble fraction, 4: insoluble fraction, 5: eluate. 
 
3.4.3.3    PfPK4 activity 
In spite of poor expression and purification of recombinant PfPK4, kinase assays 
were nonetheless attempted with some of the recombinant protein preparations 
to investigate whether any of the truncated proteins had kinase activity, or if 
any small amount of full length protein had sufficiently high activity to warrant 
optimization of expression and purification.  No kinase activity was observed on 
a range of non-physiological substrates, recombinant GST-PfeIF2α or the PfeIF2α 
peptide (not shown).  This is in contrast with the activity observed by Mohrle et 
al, who reported that recombinant PfPK4 was able to phosphorylate an eIF2α-
derived peptide (Mohrle et al., 1997).  This discrepancy remains unexplained. 
Another approach to verify whether PfPK4 in indeed an active protein kinase is 
to immunoprecipitate the protein from parasite extract and subject this to 
kinase assays.  To improve the chance of specifically immunoprecipitating the 
kinase, I generated a parasite line expressing a PfPK4 with a double HA epitope 
at the C-terminus, by allelic replacement (4.1); an anti-HA antibody could then Clare Fennell, 2008     Chapter 3 89 
be used for immunoprecipitation.  Results of an initial experiment carried out 
using these parasites are shown in Figure 3-24.  PfPK4 is clearly able to 
phosphorylate the non-physiological substrates α- and β-casein (lane 1), 
compared to wild type 3D7 parasites (lane 3).  Circumstantial evidence that this 
activity is indeed derived from PfPK4 and not from some non-specific co-
purifying activity is provided by use of the CK2α-HA clone (lane 5); this kinase is 
significantly more active than PfPK4-HA (only 1/6 of the sample volume used for 
PfPK4 was loaded).  On this occasion PfPK4-HA did not phosphorylate GST-
PfeIF2α (data not shown); this may be explained by the presence of the GST tag 
inhibiting the kinase-substrate interaction, or improper folding of the 
recombinant substrate.  The low level of activity observed in lane 4 where α- 
and β-casein have been subjected to kinase assay in the absence of additional 
kinase is often seen when using these substrates (see also Fig. 3-15 and section 
3.4.1.3).   
The parasites in which wild-type PfPK4 is replace by the HA-tagged enzyme will 
provide an excellent tool to investigate whether PfPK4 is indeed an eIF2α kinase 
in P. falciparum, and if it can be activated by stress to the parasites.   This will 
be performed, for example, in the amino-acid starvation system used by our 
collaborator D. Goldberg as described in our joint manuscript (Appendix 6.3).  
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Figure 3-24: PfPK4-HA Kinase assay. 
PfPK4-HA was immunoprecipitated from parasite extract and kinase activity assayed using the 
non-physiological substrates α- and β-casein.   
 
3.5   Perspectives and Discussion 
3.5.1   Identification of PfeIF2α and its kinases 
Bioinformatic analysis presented here clearly identifies the P. falciparum 
orthologue of eIF2α; conservation of the regulatory Ser and residues involved in 
formation of the structure that enables interaction with the eIF2α kinases is also 
observed (3.1).  Similarly, in silico approaches have identified three kinases of 
the eIF2α family (3.2).  Furthermore, I have shown that GST-PfeIK1 can 
phosphorylate GST-PfeIF2α at the conserved regulatory Ser (3.4.1.3), validating 
the bioinformatic observations.  Demonstration of the ability of PfeIK1 to 
phosphorylate PfeIF2α is consistent with (but does not demonstrate) the 
hypothesis that PfeIK1 may regulate translation through phosphorylation of 
PfeIF2α in vivo.   Clare Fennell, 2008     Chapter 3 91 
The amino acid sequence of PfeIK2 suggests it will be an active eIF2α kinase, 
with the possibility of the non-canonical glycine triad allowing formation of the 
typical kinase tertiary structure (1.2.2).  From the sequence of PfPK4 (1.2.3), 
and previously published work (Mohrle et al., 1997), PfPK4 is also expected to be 
an active eIF2α kinase, supported by the preliminary IP data presented here 
(3.4.3.3).  However, to date, I have not been able to confirm that PfeIK2 or 
PfPK4 can phosphorylate PfeIF2α, largely due to technical problems in 
recombinant protein production.  There are a number of factors to address 
before further attempts at expression in E.coli: i) the location and choice of the 
tag used for affinity purification; expression of active PfPK4 (see above) was 
previously reported with a C-terminal His tag (Mohrle et al., 1997) whereas here 
the tag was at the N-terminus.  There are also examples of other kinases in our 
lab that can be expressed as active enzymes using the His tag, but either cannot 
be expressed, or are inactive when fused to GST; ii) induction of expression, 
particularly for PfPK4 where I have evidence for very limited production of the 
full length protein (3.4.3.2); significantly greater scaling up could be all that is 
required to obtain useable protein; iii) protein purification; use of the His tag 
gives greater scope for varying conditions to obtain a more pure product.   
Bacterial expression is not the only, and may not be the best route to follow; in 
addition to further IP experiments (which may also be possible with the anti-
PfeIK2 antibody (validated for immunoblotting Fig. 3-18)), another promising 
strategy for the expression of P. falciparum AT rich genes is the wheat germ 
based cell free system (Sawasaki et al., 2005).  The wheat germ system has been 
used to express a number of previously very challenging P. falciparum proteins, 
in their correctly folded form such that functional analysis was possible 
(Mudeppa et al., 2007) (Mudeppa et al. Molecular Parasitology Meeting, Woods 
Hole 2007).  Likewise, the protein kinases PfPKA (Sudo et al., 2008) and PfPK2 
(Kato et al., 2008) were successfully produced in an active form using this 
approach.  Beyond its demonstrated practicality, one argument presented for 
use of this system is particularly persuasive for the expression of kinases; since 
the ‘host cells’ are propagated in the absence of the plasmodium genes and 
their products, potential anti-proliferative activity is avoided (Mudeppa et al., 
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3.5.2   Characterisation of PfeIF2α and its kinases  
Confirmation of kinase activity and ability to phosphorylate PfeIF2α is only the 
first step in characterizing these proteins; to understand their role in the 
parasite requires elucidating their expression pattern (spatial and temporal), 
mechanisms of regulation, and the consequences thereof.  Microarray data, RT-
PCR and western blotting (3.2.2 & 3.4.2.1), show that the PfeIF2α kinases have 
distinct temporal expression patterns that suggest they have non-redundant 
functions.  As PfeIK1 is both most similar in overall structure to GCN2 and in the 
sequence of its catalytic domain (3.2.1.1), we suggest this enzyme is a good 
candidate for (or may be the orthologue of) GCN2.  Furthermore a putative aaRS 
domain is located in the C-terminal extension of PfeIK1 (3.2.1.1) that may 
mediate binding to uncharged tRNAs, a function that is performed by the HisRS 
domain in the C-terminal extension of GCN2 (Wek et al., 1995).  One approach 
to address the function of the putative aaRS domain in PfeIK1 would be to 
produce the C-terminus as a recombinant protein and analyse its RNA binding 
properties by northwestern blot, as has been done for GCN2 (Wek et al., 1995).   
Sequence analysis of PfeIK2 offers little clue to its regulation.  It can be noted 
that the absence of a transmembrane domain would be consistent with 
cytoplasmic location.  PfPK4 has a putative transmembrane domain at its N-
terminus and its catalytic domain is most similar to that of PERK (section 
3.2.1.3), suggesting it may play a role in ER stress responses.  For both PfeIK2 
and PfPK4, localization studies might inform an experimental approach to 
understanding their regulatory mechanisms, by indicating types of stress to 
which they might respond (if indeed they are stress responsive).  For example, if 
PfPK4 localises to the ER, then agents which induce ER stress in other eukaryotic 
cells could be applied, and their effects monitored on kinase activity using the 
parasite expressing the HA-tagged enzyme, as detailed above (3.4.3.3).  For 
example, tunicamycin is known to cause ER stress (Narasimhan et al., 2008).  If 
it does so in P. falciparum as well, and if and PfPK4 plays a PERK-like role, then I 
would expect to a greater kinase activity to be immunoprecipitated, and see 
increased phosphorylation of PfeIF2α in parasite extracts, in treated (versus Clare Fennell, 2008     Chapter 3 93 
untreated) parasites.  This approach is reliant on hypothesizing appropriate 
stress stimuli to investigate.   
As P. falciparum is known to survive in a challenging redox environment (Muller, 
2004), oxidative stressors would be interesting to pursue in this respect.  In 
mammalian cells HRI has been shown to be involved in mediating the response to 
oxidative stress induced by arsenite (Lu et al., 2001).  Further, in T. gondii 
arsenite treatment induces TgeIF2α phosphorylation coincident with cyst 
development (Narasimhan et al., 2008).  It remains unknown how this effect is 
mediated, but it is thought-provoking in that HRI is inhibited by hemin (Fagard 
and London, 1981), and that recombinant PfPK4 may also be (Mohrle et al., 
1997).  Hemin has also been observed to inhibit a P. falciparum in vitro 
translation system (Surolia and Padmanaban, 1991).  These observations suggest 
there may be some similarity in the regulatory mechanisms of HRI and PfPK4 (or 
some unidentified component of the translation machinery), that may extend to 
activation by oxidative stress. 
3.6   Summary 
•  Bioinformatic analysis reveals P. falciparum encodes orthologues of both 
the translation initiation factor eIF2α, and of three eIF2α kinase related 
sequences.  Furthermore, essential residues appear to be conserved such 
that the PfeIF2α kinases and PfeIF2α will fold to allow their interaction. 
•  On the basis of the similarity of the kinase domain sequence, and 
presence of a putative aaRS domain in its C-terminus, PfeIK1 is proposed 
as the P. falciparum orthologue of GCN2; it may therefore play a role in 
response to nutrient levels. 
•  Recombinant GST-PfeIK1 is an active kinase able to phosphorylate 
recombinant GST-PfeIF2α, confirming our hypothesis that P. falciparum 
has conserved the components of this mechanism for regulation of 
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•  PfeIK2 is encoded by a single exon that is expressed in gametocytes but 
not in asexual stages; sequence analysis does not provide clues to its 
regulation. 
•  The sequence of PfeIK2 contains all residues required for kinase activity 
but experimental confirmation of this awaits further study. 
•  PfPK4 protein expression is greatest in trophozoites and schizonts.  I was 
unable to confirm published observations of kinase activity by expression 
of recombinant protein.  However preliminary immunoprecipitation 
results indicate PfPK4 is indeed a bona fide active protein kinase.  
Sequence analysis suggests PfPK4 may be related to PERK, however other 
observations suggest it may be regulated in a similar manner to HRI; this 
also awaits further investigation. 
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4  Reverse genetics of eIF2α kinases in P. 
falciparum 
4.1   Construction of gene disruption and tagging 
plasmids 
To investigate the roles of the eIF2α kinases in P. falciparum we first attempted 
to disrupt the genes, in order to test whether they play an essential role in 
either asexual multiplication stages, or subsequent stages in mosquito infection.  
The strategy I used to attempt to disrupt expression of the kinases relied on 
single cross-over homologous recombination and has been used successfully for 
other P. falciparum protein kinases (Dorin-Semblat et al., 2007, Dorin-Semblat 
et al., 2008)(Fig. 4-1).  A plasmid based on the pCAM-BSD vector (Sidhu et al., 
2005) containing an insert comprising the central region of the PfeIK catalytic 
domain and a cassette conferring resistance to blasticidin was transferred by 
electroporation into asexual parasites of the 3D7 clone (Figs. 4-2, 4.3 & 4-4).  
Homologous recombination is predicted to generate a pseudo-diploid locus in 
which neither of the resulting truncated copies encodes a functional kinase.  
After recombination the 5’ copy is interrupted just prior to the glutamate 
residue in domain VIII (which provides essential structural stability to the C-
terminal lobe), and lacks all downstream coding sequence and the 3’UTR; the 3’ 
copy lacks both the promoter region and the glycine triad in domain I (which is 
responsible for orientation of the ATP) (Fig. 4-1). Clare Fennell, 2008     Chapter 4 96 
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Figure 4-1: Schematic showing the single cross-over homologous recombination strategy 
used for disruption of the PfeIK genes. 
‘ATP’ represents kinase domain I, a glycine-rich region essential for orientation of ATP by binding 
the non-transferable phosphates, ‘E’ is a glutamate residue in domain VIII required for structural 
stability of the C-terminal lobe of the enzyme; each copy in the resulting psuedo-diploid locus 
contains only one of these motifs.  Numbered arrows indicate the positions of oligonucleotide 
primers used for PCR analysis of the genotypes of parasite lines.  The use of 1 + 2 amplifies the 
wild-type locus, 3 + 4 the plasmid, 1 + 4 the 5’ integration event, 3 + 2 the 3’ integration event.  
Nested PCR was used when analysing the genotypes of infected mosquito midguts; in this case 
the wild-type locus was amplified by using primers 1 + 2 followed by 5 + 6, and the 3’ integration 
event by using primers 3 + 2 followed by 7 + 6. 
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5297 bp
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AMP resistance
cam 5'
HRP2 3'UTR
PfeIK1 knock out fragment
BamHI (2279)
HindIII (1701)
NotI (3075)
 
Figure 4-2: Map of the plasmid used for disruption of pfeik1. 
The transfection plasmid contains a 788bp PCR fragment spanning positions 1467-2255 of the 
entire 4.8kb pfeik1 coding sequence (as predicted on PlasmoDB), inserted between BamHI and 
NotI sites(PfeIK1 knock out fragment).  The HindIII site used in Southern blot analysis is also Clare Fennell, 2008     Chapter 4 97 
shown.  cam 5’; P. falciparum calmodulin promoter, BSD resistance; gene encoding blasticidin 
deaminase, HRP2 3’ UTR; 3’ untranslated region of P. falciparum histidine rich protein 2.  AMP 
indicates the ampicillin resistance gene used in preparation of the construct. 
 
pCAM-BSD - PfeIK2 KO
5279 bp
BSD resistance
AMP resistance
cam 5'
HRP2 3'UTR
PfeIK2 knock out fragment
BamHI (2279)
HindIII (1701)
NcoI (660)
NotI (3057)
 
Figure 4-3: Map of the plasmid used for disruption of pfeik2. 
The transfection plasmid contains a 771bp PCR fragment encompassing positions 430 - 1200 of 
the verified 1.5kb coding sequence of pfeik2, inserted between BamHI and NotI sites (PfeIK2 knock 
out fragment).  The HindIII and NcoI sites used in Southern blot analysis are also shown.   cam 5’; 
P. falciparum calmodulin promoter, BSD resistance; gene encoding blasticidin deaminase, HRP2 3’ 
UTR; 3’ untranslated region of P. falciparum histidine rich protein 2.  AMP indicates the ampicillin 
resistance gene used in preparation of the construct. 
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Figure 4-4: Map of the plasmid used to attempt disruption of pfpk4. 
The transfection plasmid contains an 864bp fragment encompassing positions 7861 - 8724 of the 
entire coding sequence (as predicted on PlasmoDB), inserted between BamHI and NotI sites (PK4 
knock out fragment).  The EcoRI sites used for Southern blot analysis are also shown.  cam 5’; P. 
falciparum calmodulin promoter, BSD resistance; gene encoding blasticidin deaminase, HRP2 3’ 
UTR; 3’ untranslated region of P. falciparum histidine rich protein 2.  AMP indicates the ampicillin 
resistance gene used in preparation of the construct. 
 
If gene knock-out is unsuccessful, it is important to show that the locus is 
accessible to recombination if the insertion does not cause loss-of-function of 
the gene product.  To do this I used a modification of the single cross-over 
strategy used for gene disruption (Fig. 4-5).  The pCAM-BSD vector was modified 
to contain a cloning site followed by the 3’ untranslated region (UTR) of P. 
berghei DHFR (Jean Halbert, our lab).  In addition a tag (either two 
hemagglutinin [HA] epitopes, or the Green Fluorescent Protein [GFP] (Sylvain 
Eschenalauer, our lab)) was included, so that if the genes were successfully 
targeted their tagged products would represent  useful tools for molecular 
analyses.  By cloning the 3’ end of the gene of interest without its stop codon 
into this plasmid and transfecting parasites with the resulting construct, single 
cross over results in reconstitution of a functional gene that encodes a C-
terminal double HA, or GFP tag.  This strategy was used for PfPK4, since this is 
the only one of the three PfeIK genes that I was not able to knock-out (4.4.1); 
vector maps are as shown (Figs. 4-6 & 4-7).  Clare Fennell, 2008     Chapter 4 99 
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Figure 4-5: Schematic showing the single cross-over recombination strategy used to tag 
PfPK4. 
The horizontally shaded bar represents the 3’ 664bp fragment of pfpk4, excluding the stop codon 
(STOP), cloned into the modified pCAM-BSD vector.  The vertically hatched bar represents the tag 
(either double HA or GFP) and the 3’UTR of P. berghei dhfr.  Numbered arrows indicate the 
positions of oligonucleotide primers used to analyse the genotypes of parasite lines by PCR. 
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pCAM-BSD PfPK4-double HA
6089 bp
BSD
AMP
HA tag
PK4 3'
PstI
BamHI
3'UTR (Pb DHFR)
EcoRI (666)
 
Figure 4-6: Map of the plasmid used to add a C-terminal double HA tag to PfPK4. 
A 664bp fragment encompassing positions 8553 - 9216 (PK4 3’), of the pfpk4 9219 coding 
sequence was inserted between PstI and BamHI sites.  The EcoRI site used subsequently for 
Southern blot analysis is also shown.  BSD indicates the blasticidin deaminse coding sequence, 
allowing for selection of parasites.  3’UTR (PbDHFR) acts as a 3’ UTR for the reconstituted gene to 
allow expression.  AMP indicates the ampicillin resistance gene used in preparation of the 
construct. 
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Figure 4-7: Map of the plasmid used to add a C-terminal GFP tag to PfPK4. 
A 664bp fragment encompassing positions 8553 - 9216 (PK4 3’ end), of the pfpk4 9219 coding 
sequence was inserted between PstI and BamHI sites.  The EcoRI site used subsequently for 
Southern blot analysis is also shown. 
 
4.2   PfeIK1 
4.2.1   PfeIK1 is not required for asexual growth 
PfeIK1 is expressed in asexual parasites (3.2.2 & 3.4.1.1); to investigate whether 
it plays an essential role in the parasite I attempted to generate pfeik1
- 
parasites using the pCAM-BSD-pfeik1 plasmid shown in Figure 4-2.  Blasticidin-
resistant parasite populations were obtained from two independent transfection 
experiments, and PCR analysis indicated that both resistant populations 
contained parasites whose pfeik1 locus was disrupted (data not shown).  Clonal 
lines were established by limiting dilution from both independent populations, 
and the genotypes of one representative clone derived from each transfection 
experiment (C1 & C8) analysed (Fig. 4-8).  The wild-type locus was not detected 
in clones C1 or C8 (lanes 1& 5), but is observed in the parental wild-type 3D7 Clare Fennell, 2008     Chapter 4 102 
parasites.  In contrast, fragments diagnostic of plasmid (lanes 2, 6, 10), and both 
the 5’ (lanes 3, 7, 11) and 3’ (lanes 4, 8, 12) boundaries of the integrated 
plasmid are amplified from C1 and C8, but not wild-type 3D7 parasites.   
 
Figure 4-8: PCR analysis of two pfeik1
- clones. 
Lanes 1, 5, 9 are diagnostic of the wild-type locus: primers 1 + 2 (1278bp), lanes 2, 6, 10 are 
diagnostic of the episome: primers 3 + 4 (847bp), lanes 3, 7, 11 are diagnostic of the 5’ boundary 
of the integrated plasmid: primers 1 + 4 (1050bp), lanes 4, 8, 12 are diagnostic of the 3’ boundary 
of the integrated plasmid: primers 2 + 3 (1075bp). Primers are as follows: 1= 146, 2= 148, 3= 169, 
4= 170, see Table 6-2, appendix for details.  See Figure 4-1 for primer positions. 
 
Integration of the gene disruption construct was verified by Southern blot 
analysis; using HindIII digestion a 12 kb band containing the wild-type locus is 
replaced in the mutant clones by the expected two bands resulting from 
integration; the 10.4 kb fragment contains the 5’ boundary of the integrated 
plasmid and the 6.8 kb band contains the 3’ boundary of the integrated plasmid.  
The 5.3kb band is derived from linearised plasmid or from digestion of 
concatemers of plasmid (which may or may not be integrated into the 
chromosome) (Figs. 4-9 & 4-10).   
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Figure 4-9: Schematic for pfeik1
- Southern blot. 
The fragments expected after HindIII digestion of the wild-type locus (top), disrupted peik1 locus 
(middle) and disruption plasmid (bottom), are shown.   Clare Fennell, 2008     Chapter 4 103 
 
Figure 4-10: Southern blot analysis of pfeik1
- clones. 
Several clones derived from two independent populations (left and right) were analysed.  The 
expected sizes illustrated in Figure 4-9 are shown on the right of each gel: WT: 11945bp, 5’ 
integration: 10430bp, 3’ integration: 6815bp, and the pfeik1 disruption plasmid: 5297bp.  Sizes of 
co-migrating markers are indicated on the left.   
 
The results shown in Figures 4-8 and 4-10 confirm that the pfeik1 locus was 
indeed disrupted in clones C1 and C8, and demonstrate that PfeIK1 is not 
required for completion of the asexual cycle of P. falciparum under in vitro 
culture conditions.  Furthermore, the Goldberg lab has produced growth curves 
to compare cell cycle progression in pfeik1
- and 3D7 parasites (Fig. 4-11).  
Cultured asexual parasites were synchronized and carefully monitored through 
several life cycles.  There was no significant difference in cell cycle progression 
of parental and knockout clones; cycle times of 49.0 hr +/- 0.5 and 49.2 hr +/- 
0.7, respectively, were measured (see also our joint manuscript, appendix 6.3). 
 
 
Figure 4-11: Growth of pfeik1
- parasites. Clare Fennell, 2008     Chapter 4 104 
Representative cycles of pfeik1
-, clone E6 (solid line) and wild-type 3D7 (dashed line); samples 
were taken every 30 minutes, fixed and DNA content analysed by flow cytometry.  Red; mature 
schizonts, blue; S-phase, black; G phase (G1), hpi; hours post invasion. 
 
4.2.2 PfeIK1 is not required for gametocytogenesis  
It was hypothesised that PfeIK1 plays a role in the parasite’s stress response, and 
may therefore be involved in the regulation of gametocytogenesis.  To test this 
hypothesis, I used published methods (Carter et al., 1993) to determine whether 
the pfeik1
- parasites could produce male gametocytes.  As shown in Figure 4-12, 
morphologically normal gametocytes at all stages of maturation were produced, 
suggesting that there is no defect in the ability of pfeik1
- parasites to 
differentiate from asexual stages to sexual forms.  That both male and female 
gametocytes were produced by the pfeik1
- clones was ascertained by their 
ability to productively infect mosquitoes (see next section). 
Although gametocytogenesis appeared to be qualitatively unimpaired, it is also 
possible that if PfeIK1 plays a role in regulation of differentiation, it could be 
involved at the stage of detecting the stimuli that result in the life cycle stage 
switch.  Since it remains unknown what these stimuli are in a natural infection 
of the human host, or indeed if there are one or many, gametocytogenesis could 
be quantitatively changed in pfeik1
- parasites, or qualitatively changed but 
under different conditions than were tested here.  We can nevertheless conclude 
from our experiments that PfeIK1 is not required for gametocytogenesis in vitro. 
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Figure 4-12: Giemsa stained pfeik1
- gametocytes. 
A range of gametocyte developmental stages are shown; A: stage IV, B: stage III, C: stage: II, D: 
stage V or mature gametocytes. 
 
4.2.3 PfeIK1 is not required for infection of mosquitoes or 
progression to sporozoites 
Since I had not detected a critical role of PfeIK1 in asexual stages or 
gametocytogenesis, I continued by investigating the viability of pfeik1
- parasites 
in mosquito infection experiments.  First, I obtained qualitative evidence that 
male pfeik1
- gametocytes were competent to continue development to produce 
gametes (in vitro exflagellation, data not shown).  Subsequently, pfeik1
- 
gametocytes were fed to Anopheles gambiae, and their infectivity examined by 
dissecting the parasite fed mosquitoes for oocysts and sporozoites, after the 
appropriate development periods (10 and 16 days post feeding, respectively) had 
elapsed.  As shown in Table 4-1 both the pfeik1
- clones tested were able to 
infect mosquitoes, and in the one instance I was able to investigate, the 
infection resulted in development of sporozoites that reached the salivary Clare Fennell, 2008     Chapter 4 106 
glands.  The proportion of sporozoite-positive mosquitoes was not significantly 
different from the proportion of infected mosquitoes (p= 0.74). 
 
Clone Exp. 
No. 
Infection prevalence  Median oocyst no. per 
infected mosquito (range) 
Sporozoite 
presence 
C1  1  15% (2/14)  1.5 (0-2)  ND 
C8  1  44% (7/16)  10 (0-34)  37% (7/19) 
C1  2  not fed, insufficient 
gametocytes 
ND ND 
C8  2  20% (5/25)  2 (0-5)  ND 
Table 4-1: Mosquito infection with pfeik1
- parasites. 
The two independent clonal lines C1 and C8 were stimulated to produce gametocytes on two 
separate occasions (Experiments 1 & 2).  Experience has shown that a gametocytaemia lower than 
~0.4% is extremely unlikely to be infectious, such that clone C1, experiment 2 was not continued.  
When a feed took place, the mosquitoes were dissected 10 days later when midguts were 
examined and oocysts counted.  The infection prevalence is given, followed by the number of 
mosquitoes this observation derives from.  The median number of oocysts per infected mosquito is 
shown, followed by the range in number of oocysts found on individual midguts.  If examination of 
midguts established that the parasites were infectious, and sufficient mosquitoes had fed to be able 
to continue the experiment for a further 6 days, the remaining mosquitoes were then dissected and 
examined for presence of sporozoites in the salivary glands.  Mosquitoes were scored as positive 
or negative for sporozoites.  ND= not done. 
 
It is clear this experiment has limitations: the first is the lack of wild-type 3D7 
control.  Long term in vitro culture of P. falciparum tends to result in the loss of 
the parasites’ ability to produce gametocytes at all, or loss of their infectious 
capacity.  In this instance I maintained sham-transfected 3D7 in culture along 
side the pfeik1
- parasites throughout the transfection and cloning process; 
consequently all these parasites had been in culture for ~7 months before 
mosquito experiments could commence.  It was therefore not unduly surprising 
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Without a wild-type control I cannot investigate whether the prevalence or 
intensity of infection is changed by pfeik1 disruption, however experience 
suggests that both levels observed here are within the expected range for such 
‘old’ parasites. It is possible that the fact that the pfeik1
- could still produce 
gametocytes is specifically mediated by the knock out, however I suspect it is 
most likely a chance event. 
It was important to verify that the parasites had had not reverted to a wild-type 
pfeik1 locus, which remains a possibility when using the single cross-over 
strategy.  To this end I collected midguts from infected mosquitoes 10 days post 
feeding, extracted genomic DNA and carried out nested PCR (one round of PCR is 
not sufficient when starting from the small amount of DNA present in these 
samples).  The wild-type locus could be amplified as expected from mosquitoes 
infected with wild-type 3D7 parasites, but not from those infected with pfeIK1
- 
C8 parasites (Fig. 4-13 lower panel, lanes 1, 3, 5).  Conversely, the amplicon 
diagnostic of the 3’ integration event could only be amplified from midguts of 
pfeIK1
- C8-infected mosquitoes, but not from mosquitoes infected with wild-type 
parasites (Fig. 4-13 lanes 2, 4, 8).  The wild-type infected mosquitoes used here 
came from a separate experiment and were used only to control for PCR 
amplification of the wild-type amplicon from infected midguts (and did not serve 
as controls for infection prevalence; see above). 
 
Figure 4-13: PCR analysis of pfeik1
- infected mosquito midguts. 
Nested PCR was used to analyse presence of the wild-type locus; lanes 1, 3, 5 using primers 1 + 
2, followed by 5 + 6; expected size =1012bp, and the 3’ integration event; lanes 2, 4, 6 using 
primers 3 + 2, followed by 7 + 6, expected size = 889bp.  The upper panel shows the 3’ integration 
amplicons (lanes 4 & 6); the lower panel is a longer exposure to reveal the wild-type amplicon (lane Clare Fennell, 2008     Chapter 4 108 
1).  Primers used are as follows: 1= 146, 2= 148, 3= 169, 4= 170, 5= 979, 6= 980, 7= 179, see 
Table 6-2, appendix, for details.  Primer positions are shown in Figure 4-2. 
 
4.2.4 Expression levels of remaining PfeIF2α kinases in pfeik1
- 
parasites. 
It is conceivable that the parasite can sustain disruption of one gene by 
modulating the expression of another gene that performs a related function.  To 
address this I aimed to examine protein levels of the remaining eIF2α kinases, 
after the pfeik1 gene had been disrupted.  At the time of writing these 
experiments were not completed.  However, Figure 4-14 suggests that 
expression of PfPK4 may be increased in asexual pfeik1
- clones is in comparison 
to wild-type parasites, which will be an important consideration for further 
analysis of the pfeik1
- parasites.  I am cautious in interpreting this result since I 
have shown that PfPK4 levels are higher in trophozoites and schizonts (3.2.2), so 
that the difference observed between wild type and pfeik1
- parasites in Figure 
4-14 could be due to a different mix of life cycle stages at the time of parasite 
harvest; this must now be confirmed with synchronized parasites. 
 
 
Figure 4-14: Western blot showing expression of PfPK4 in pfeik1
- parasites. 
Parasite pellets of wild-type parasites (3D7) and pfeik1
- clone C8 were resuspended in parasite 
solubilising buffer before addition of reducing Laemlli buffer.  Equal amounts of protein were 
separated by SDS-PAGE and transferred to nitrocellulose.  The membrane was cut to probe the 
upper part with anti-PfPK4, while the lower part provided a loading control with anti PfCK2α. Clare Fennell, 2008     Chapter 4 109 
 
Further experiments to complete this analysis would be to examine expression of 
PfeIK2 and PfPK4 in pfeik1
- gametocytes, which could be purified from asexual 
stages using a Percoll gradient.  Furthermore, it is also possible that in the 
absence of PfeIK1, expression of PfeIK2 could be induced in asexual stages. 
4.3 PfeIK2 
4.3.1 PfeIK2 is not required for asexual growth 
As PfeIK2 is not expressed in asexual stages (3.4.2.1) we predicted that it would 
be possible to generate PfeIK2 knock-out parasites.  I proceeded to two 
independent transfection experiments using the pCAM-BSD-pfeik2 plasmid (Fig. 
1-3), from which two independent series of clones were obtained by limiting 
dilution.  PCR analysis of five clones (Fig. 4-15) shows that PfeIK2 is indeed 
dispensable for asexual growth; C3 and F12 are independent from F4 and H1 and 
D7.  In each case the wild type amplicon is only amplified from the wild-type 
3D7 parasites, but not from any of the peik2
- clones.  Similarly, the amplicons 
diagnostic of the gene disruption plasmid, and the 5’ and 3’ boundaries of the 
integrated plasmid can only be amplified from peik2
- clones, and not from wild-
type parasites.  The peik2 locus has not been disrupted in clone D7 hence 
amplicons for the wild-type and the gene disruption plasmid are seen in lanes 21 
and 22 respectively, but not for the integrated plasmid in lanes 23 or 24.   
 
Figure 4-15: PCR analysis of pfeik2
- clones. 
Lanes 1, 5, 9, 13, 17 & 21 are diagnostic of the wild-type locus: primers 1 + 2 = 1134bp, lanes 2, 6, 
10, 14, 18 & 22 are diagnostic of the transfection plasmid: primers 3 + 4 = 829bp, lanes 3, 7, 11, 
15, 19 & 23 are diagnostic of 5’ integration:  1 + 4 = 923bp, lanes 4, 8, 12, 16, 20 & 24 are 
diagnostic of 3’ integration: 3 + 2 = 1066bp.  Primers are as follows: 1= 185, 2= 150, 3= 169, and 
for primer 4, two adjacent sequences were used; either 170 for amplification of the episome, or 168 
for amplification of the 5’ integration amplicon, see Table 6-2, appendix for details.  Primer 
positions are indicated in Figure 4-1. Clare Fennell, 2008     Chapter 4 110 
 
The genotype of peik2
- clones was verified by Southern blot; digestion with 
HindIII and NcoI yields a 6635bp fragment containing the wild-type locus, a 
5650bp fragment that contains the 5’ boundary of the integrated plasmid, and a 
5225bp fragment containing the 3’ boundary.  The 4239bp band derives from 
linearised plasmid or from digestion of concatemers of plasmid (which may or 
may not be integrated into the chromosome) (Figs. 4-16 & 4-17).  One of the 
clones shown here (D7) contains the gene disruption plasmid, but has not 
integrated it into the genomic locus so shows only the wild-type and plasmid 
bands.   
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Figure 4-16: Schematic for pfeik2
- Southern blot. 
The fragments expected following HindIII/NcoI digestion of the wild-type pfeik2
- locus (top), 
disrupted pfeik2 locus (middle) and pfeik2 gene disruption plasmid (bottom), are shown. 
 
Figure 4-17: Southern blot analysis of pfeik2
- clones. 
Several clones from two independent populations were analysed.  Fragments illustrated in Figure 
4-16 are marked here: WT: 6635bp, 5’ integration: 5650bp, 3’ integration 5225 bp and the 
transfection plasmid 4239bp.  Positions of co-migrating markers are indicated on the left of each 
gel.  
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4.3.2   PfeIK2 is not required for gametocytogenesis 
Since PfeIK2 is expressed in gametocytes but not asexual stages, I was more 
interested to investigate whether gene disruption had any effect on the 
parasites during sexual development.  I used standard methods to produce 
pfeik2
- gametocytes (Carter et al., 1993), which as shown in Figure 4-18 are 
morphologically normal and span all developmental stages.  Further, that both 
male and female gametocytes were produced by the pfeik2
- clones was 
ascertained by their ability to productively infect mosquitoes (4.3.3).  PfeIK2 
therefore has no apparent essential role in gametocytogenesis.   
 
Figure 4-18: Giemsa stained pfeik2
- gametocytes. 
A range of developmental stages is shown; A: stage III, B: stage IV, C: stage V, D: mature 
gametocyte. 
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4.3.3   PfeIK2 is not required for infection of mosquitoes or 
progression to sporozoites 
As with PfeIK1, I wanted to investigate whether disruption of PfeIK2 impaired 
the ability of the parasite to infect mosquitoes.  pfeik2
- gametocytes were fed 
to Anopheles gambiae that were dissected in order to count oocysts on midguts 
10 days post feeding, or 16 days post feeding for sporozoites in the salivary 
glands.  As shown in Table 4-2 pfeik2
- parasites are able to infect mosquitoes 
and parasite development can proceed, resulting in sporozoites invading the 
salivary glands.  In experiment 1 we compared the prevalence of infection 
between pfeik2
- H1 and wild-type; in this instance there was no reduction in the 
ability of pfeik2
- parasites to infect mosquitoes compared to wild-type parasites 
(p=0.05).  Indeed, infection with wild-type parasites yielded fewer 
oocysts/sporozoites than infection with pfeik2
- parasites.  It seems unlikely that 
the loss of PfeIK2 has rendered the parasites more infectious; this experiment 
would need to be repeated several times to be able to demonstrate such an 
effect.  In the one experiment carried through to sporozoite stage, a 
significantly smaller proportion of mosquitoes contained sporozoites, than oocyts 
(p=0.003), suggesting sporozoite development might be impaired.  Clearly this is 
a single small scale experiment and would require verification.  However, it is 
conceivable that there could be an important role for PfeIK2 in the development 
of sporozoites inside oocysts, or in their ability to reach the salivary glands. 
It took only ~3 months from the transfection procedure to generate one set of 
pfeik2
- ‘clones’ ready for mosquito infection; the results shown here are for 2 
‘clones’ (F4 & H1) derived from this population and compared with sham- 
transfected 3D7 parasites maintained in culture over the same period.  I 
recognize that F4 and H1 may not be truly independent, since they derive from 
the same transfection experiment; however, use of two parasite lines provided 
some control for experimental variation, and for the possibility that one line 
could have lost the ability to produce gametocytes (or subsequent functions) 
after dilution cloning.  It required ~ 7months of culture to generate the second, 
independent set of pfeik2
- lines, along side pfeik1
- parasites and the sham- 
transfected 3D7 parasites that had lost the ability to produce gametocytes Clare Fennell, 2008     Chapter 4 113 
(discussed in 4.2.3); these pfeik2
- parasites were also unable to produce 
gametocytes. 
Clone Exp. 
No. 
Infection 
prevalence 
Median oocyst no. per 
infected mosquito (range) 
Sporozoite 
presence 
F4 1  Insufficient 
gametocytes to 
feed 
ND ND 
H1  1  84% (21/25)  3 (1-30)  42% (10/24) 
3D7  1  57% (13/23)  2 (2-41)  ND 
F4  2  22% (6/27)  2 (1-7)  ND 
H1  2  0% (0/21)  0 (0)  ND 
3D7  2  0% (0/24)  0 (0)  ND 
Table 4-2: Mosquito infection with pfeik2
- parasites. 
Two pfeik2
- clonal lines, F4 and H1 were stimulated to produce gametocytes on two separate 
occasions (experiments 1 & 2).  Experience has shown that a gametocytaemia lower than ~0.4% is 
extremely unlikely to be infectious, such that clone F4, experiment 1 was not continued.  When a 
feed took place the mosquitoes were dissected 10 days later, midguts were examined and oocysts 
counted.  The infection prevalence is given, followed by the number of mosquitoes this observation 
derives from.  The median number of oocysts per infected mosquito is shown, followed by the 
range in number of oocysts found on individual midguts.  If examination of midguts established that 
the parasites were infectious, and sufficient mosquitoes had fed to be able to continue the 
experiment for a further 6 days, the remaining mosquitoes were dissected and examined for 
presence of sporozoites in the salivary glands.  Mosquitoes were scored as positive or negative for 
sporozoites.  Note that parasite lines F4 and H1 are not truly independent clones as they derive 
from the same population. 
Genomic DNA was extracted and nested PCR was performed to verify that pfeik2
- 
infected mosquitoes had retained their disrupted genotype.  Using a set of well 
characterized sensitive primers designed to amplify the pfmdr gene (Duraisingh 
et al., 2000) I was able to confirm that parasite DNA was present in both the 
wild-type and pfeik2
- infected midguts (data not shown).  Furthermore, in 
support of the maintainance of the disrupted locus, a single round of PCR was 
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while no amplicon was detected in pfeik2
- infected mosquitoes (data not 
shown).  Although I was unable to amplify the fragments containing either the 5’ 
or 3’ boundaries of the integrated plasmid by nested PCR (data not shown), I 
suspect this is due to differences in the sensitivity of the primers used to amplify 
the different loci.  
We consider that the probability of reversion to the wild-type locus occurring 
during development in the mosquito is sufficiently small to result in no more 
than one or two oocysts per midgut.  Therefore, since I observed greater 
numbers of oocysts than this in several midguts and as the wild-type locus was 
readily amplified from wild-type, but not from pfeik2
- infected mosquitoes this 
suggests that the parasites had indeed retained the pfeik2
- genotype. 
Taken together, these results strongly suggest that PfeIK2 does not play an 
essential role in the developmental stages required to establish mosquito 
infection, but raises the interesting possibility that it may perform a key 
function during oocyst maturation or subsequent sporozoite migration.   
 
4.4   PfPK4 
4.4.1   PfPK4 is essential for asexual growth 
PfPK4 is expressed in asexual stages (3.2.2); to address whether it performs an 
essential function in the life cycle I used the plasmid shown in Figure 4-4 to 
attempt to disrupt the gene by single cross-over.  Three separate transfections 
were performed on different occasions; in each case a blasticidin-resistant 
population was obtained.  However after at least six months in culture I never 
saw evidence of integration of the construct into the pfpk4 locus, (Figs. 4-19 & 
4-21).  PCR analysis of one representative population is shown in Figure 4-19; an 
amplicon diagnostic of the wild-type locus was amplified from both the 
transfected population and wild-type parasites (lanes 1& 5, Fig. 4-19), 
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The amplicon diagnostic of the gene disruption plasmid was amplified, as 
expected from the transfected parasites, but not from wild-type parasites (lanes 
2 & 6, Fig. 4-19).  If integration occurred it would have been detected as a 3kb 
band in lane 3, and a 1.5kb band in lane 4; this was never seen, suggesting an 
essential role for PfPK4 in the asexual life cycle. 
 
Figure 4-19: PCR analysis of attempted disruption of pfpk4. 
Lanes 1 & 5, WT primers 1+ 2, expected size = 3508bp, lanes 2 & 6 episome: = 1054bp, lanes 3 & 
7 5’ integration = 3069bp, lanes 4 & 8 3’ integration = 1474bp.  Primers used were as follows: 1= 
161, 2= 154, 3= 167, 4= 168, see Table 6-2, appendix for details.  Primer positions are indicated in 
Figure 1-1. 
 
To verify the PCR data I also analysed the blasticidin-resistant populations 
transfected with the pfpk4 gene disruption plasmid by Southern blot.  EcoRI 
digestion yields the fragments illustrated in Figure 4-20; the wild type locus at 
3347bp is detected in both transfected (‘KO’) and wild-type (3D7) parasites, 
confirming that wild type parasites are still present in the transfected 
population.  The gene disruption plasmid gives rise to the expected 2480 bp 
fragment in the transfected parasite sample.  If integration had occurred two 
intermediate sized fragments would be present, at 2832 bp for the 5’ truncated 
copy, and 3015 bp for the 3’ truncated copy; these bands were never observed, 
confirming the PCR data.  Together these data suggest that PfPK4 performs an 
essential function in the asexual replication cycle. 
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Figure 4-20: Schematic of expected fragments on Southern blot analysis of pfpk4. 
EcoRI digestion results in a 3347bp fragment from the wild-type locus (top), a 2832bp fragment if 5’ 
integration occurs and a 3015bp fragment if 3’ integration occurs, and the locus is disrupted 
(middle), the 2480bp fragment derives from the digested gene disruption plasmid. 
 
Figure 4-21: Southern blot analysis of attempted pfpk4 disruption. 
The left hand lane contains wild-type parasites (3D7); the right hand lane contains parasites 
transfected with the pfpk4 disruption construct (‘KO’), sizes of co-migrating markers are shown on 
the left.  Fragments corresponding to the wild-type locus (WT) and gene disruption plasmid (as 
shown in Figure 4-20) are indicated. 
 
As discussed in section 4.1, it is important to verify that inability to disrupt the 
function of a gene is not due to an inability to target the locus.  I elected to use 
the circumstantial evidence provided by the 3’ tagging strategy (due to the 
9.2kb size of the coding region of pfpk4, it would have been very difficult to 
implement a complementation strategy as described for other, smaller protein 
kinases such as Pfmap-2 and PfPK7 (Dorin-Semblat et al., 2007, Dorin et al., 
2005)).   
Wild-type parasites were transfected with a plasmid containing the 3’ end of 
pfpk4 without the stop codon, and either a double HA epitope, or a GFP coding 
sequence (Figs. 4-6 & 4-7).  In contrast to the lack of integration of the gene Clare Fennell, 2008     Chapter 4 117 
disruption plasmid, blasticidin-resistant populations were obtained that rapidly 
showed integration of the gene modification plasmids (Fig. 4-22).  Analysis of 
both HA and GFP-transfected populations by PCR (Fig. 4-5, for schematic) 
reveals presence of all the expected amplicons for integration (Fig. 4-22, lanes 
6-8 and 10-12).  This provides evidence that pfpk4 can be targeted for 
recombination if the locus modification does not cause loss-of-function, and 
therefore supports the conclusion that the pfpk4 gene cannot be disrupted due 
to an essential function in asexual replication. 
 
Figure 4-22: PCR analysis of integration of pfpk4 3' tags. 
Lanes 1, 5, 9: 3’ fragment of wild type gene used in plasmid, such that amplicons in lanes 5 and 9 
may derive from wild type, integrated, or free plasmid (1+ 2 = 898bp), lanes 2, 6, 10: 3’ integration 
(1+ 3, GFP = 1652bp, HA = 1000bp), lanes 3, 7, 11: 3’ integration (1 + 4, GFP = 2504, HA = 1853), 
lanes 4, 8, 12: 3’ integration (1+ 5, GFP = 2530, HA = 1879bp).  Primers used to analyse 
integration of the 3’ tags are as follows: 1= 177, 2= 154, 3=275, 4=170, 5= 168; see Table 6-2, 
appendix for details.  Primer positions are illustrated in Figure 4-5. 
 
Southern blot analysis was used to confirm the genotypes of the pfpk4 HA and 
GFP-transfected parasites.  As expected, the fragments obtained by EcoRI 
digestion of the integrated locus (Fig. 4-23) are seen in both HA and GFP 
transfected parasites, but not wild-type (Fig. 4-24).  The analysis was performed 
on uncloned populations, such that the wild-type locus is still present in the 
transfected populations (Fig. 4-24).  Provided the tags do not impair the function 
of PfPK4 it is expected that the integrated parasites will overgrow parasites that 
carry the drug resistance cassette on the episome, since unlike the genomic 
copy, this will not segregate equally to all daughter merozoites.  Figure 4-24 
shows that in the HA transfected parasites the wild-type band is dramatically 
reduced in intensity compared to the two bands diagnostic for integration in this Clare Fennell, 2008     Chapter 4 118 
lane, or the wild-type band in the other two samples, suggesting that integrated 
parasites are indeed able to overgrow the wild-type parasites.   
Wild type PfPK4 locus
3347 EcoRI EcoRI
pCAM-BSDtag-PfPK4 
EcoRI
GFP: 6740, HA: 6089
BSD
Recombined tagged PfPK4 locus
BSD
EcoRI EcoRI EcoRI
2314 GFP: 7776, HA: 7124
Wild type PfPK4 locus
3347 EcoRI EcoRI
Wild type PfPK4 locus
3347 EcoRI EcoRI 3347 3347 EcoRI EcoRI EcoRI EcoRI
pCAM-BSDtag-PfPK4 
EcoRI
GFP: 6740, HA: 6089
BSD pCAM-BSDtag-PfPK4 
EcoRI
GFP: 6740, HA: 6089
BSD
EcoRI EcoRI
GFP: 6740, HA: 6089 GFP: 6740, HA: 6089
BSD BSD BSD
Recombined tagged PfPK4 locus
BSD
EcoRI EcoRI EcoRI
2314 GFP: 7776, HA: 7124
Recombined tagged PfPK4 locus
BSD
EcoRI EcoRI EcoRI
2314 GFP: 7776, HA: 7124
BSD BSD BSD
EcoRI EcoRI EcoRI EcoRI EcoRI EcoRI
2314 GFP: 7776, HA: 7124 2314 GFP: 7776, HA: 7124
 
Figure 4-23: Schematic of expected sizes for Southern blot analysis of pfpk4 3' tags. 
EcoRI digestion will yield the following fragments: wild-type: 3347bp; 5’ integration: 7776bp for GFP 
transfected parasites, 7124bp for HA transfected parasites; 3’ integration: 2314bp for both HA and 
GFP transfectants; transfection plasmid: 6740bp for GFP and 6089bp for the HA construct.   
 
Figure 4-24: Southern blot analysis of pfpk4 3' tag populations. 
Left lane: wild-type 3D7 parasites, centre: pCAM-BSD-pfpk4GFP transfected parasites, right: 
pCAM-BSD-pfpk4HA transfected parasites.  The expected fragments diagnostic of the parasite 
genotypes illustrated in Figure 4-23 are indicated on the right.  Sizes of co-migrating markers are 
shown on the left. 
 
In addition to analysis of the locus by PCR and Southern blot, I was also 
interested to know whether functional PfPK4 is expressed with the double HA 
tag.  To date I have not been able to show this by western blot.  However as 
discussed in section 3.4.3.3, preliminary IP results suggest that the tagged 
protein is expressed and active.   Clare Fennell, 2008     Chapter 4 119 
 
4.5   Discussion and Perspectives 
4.5.1   PfeIK1 
It would be informative to compare the prevalence and intensity of pfeik1
- 
mosquito infections with those of wild-type parasites, as it remains possible that 
their infectious capacity is reduced; this would require new transfections in the 
hope of integration occurring more rapidly in order to limit the effects of 
prolonged in vitro parasite culture on the experiment. 
As discussed in section 3.2.1, PfeIK1 is a putative GCN2 orthologue and may 
therefore play a role in the parasites’ response to nutrient deprivation.  This is 
particularly interesting in the context of a recent report that amino acid 
starvation of P. falciparum does result in increased phosphorylation of PfeIF2α 
(Dan Goldberg, Molecular Approaches to Malaria, Lorne 2008; see our joint 
manuscript in Appendix 6.3).  We are collaborating with the Goldberg lab to 
investigate this in pfeik1
- clones.  Whether or not increased phosphorylation of 
PfeIF2α is observed in pfeik1
- parasites (in which, as discussed in section 4.2.4, 
increased expression of PfPK4 could compensate for loss of PfeIK1) it would be 
ideal to be able to immunoprecipitate PfeIK1 from starved parasites for in vitro 
kinase assay in order to assess whether it is activated by starvation.  Chicken 
anti-PfeIK1 IgYs  have recently been produced by our collaborator Dean Goldring 
(Pietermaritzbutg),  which if specific will provide a useful tool; otherwise the C-
terminal tagging strategy deployed for PfPK4 should be used. 
4.5.2   PfeIK2 
As for PfeIK1, the mosquito infection experiments should be repeated before it 
can be concluded that PfeIK2 does not play an essential role during sexual 
development; in particular, PCR analysis of the disrupted pfeik2 locus from the 
minute amounts of DNA present in infected midguts must be optimized to enable 
comprehensive analysis of the genotypes of the oocysts.  Furthermore, since 
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fascinating to see if pfeik2
- sporozoites are competent to invade and proliferate 
in hepatocytes; this clearly poses considerable technical challenges, but we are 
setting up collaborations to try to address this question.   
4.5.3   PfPK4  
I have presented evidence that PfPK4 is essential for asexual multiplication of P. 
falciparum.  However, since I have been unable to generate pfpk4
- parasites, I 
do not have a tool to investigate whether PfPK4 plays a specific role in 
gametocytogenesis, which we hypothesized as a possible role for the PfeIF2α 
kinases (1.3.1).  It would be interesting to investigate whether the essential 
functions of PfPK4 occur at particular life cycle stages; several possible 
strategies could be used to address this.  The first is to generate a ‘chemical 
genetics’ mutant (Bishop et al., 2001).  Briefly, mutation of a large-side chain 
residue known as the gate-keeper residue (Met2776 in PfPK4) to an amino acid 
with a small side chain such as glycine sensitizes the enzyme to a specific 
inhibitor that is too bulky to inhibit wild-type kinases.  The Met→Gly mutant 
enzyme is predicted to retain activity in the absence of compound.  It would be 
theoretically possible to produce such mutants using the single cross-over 
strategy employed for gene disruption and tagging; parasite populations could 
then be synchronized and the inhibitor added at different stages of the life cycle 
and effects on parasite survival observed.  Secondly, a tetracycline inducible 
system has also been described for P. falciparum that could be deployed to 
express proteins with dominant negative function, or to generate conditional 
knockouts as has been shown in T. gondii (Meissner et al., 2005) (Meissner et al., 
2002).  Thirdly, use of FKBP destabilization domain-fusion proteins has been 
described in P. falciparum (Armstrong and Goldberg, 2007).  Briefly, the FKBP 
domain promotes degradation of the protein to which it is fused, unless the 
ligand of the destabilization domain, Shld1, is present.  It is therefore possible 
that the FKBP domain could be integrated at the 3’ end of the gene of interest 
(as described here for HA or GFP, section 4.1) to produce a C-terminal fusion, 
transgenic parasites would have to be established in the presence of the Shld1, 
but its removal would activate the destabilisation domain thus creating a 
conditional knock out.  Clare Fennell, 2008     Chapter 4 121 
4.5.4 Expression levels of remaining PfeIF2α kinases, following 
disruption of one of the three genes. 
Section 1.2.4 described initial western blot experiments to investigate the 
expression of PfPK4 in pfeik1
- parasites, PfeIK2 could also be investigated in this 
way.  It would also be possible to analyse asexual pfeik2
- parasites for a change 
in PfPK4 or PfeIK1 expression.  However, since PfeIK2 is not expressed in asexual 
stages I consider it unlikely that there would be any change in expression of the 
other eIF2α kinases in these parasites during the asexual cycle.  As PfeIK2 is 
expressed in gametocytes it would be more important to investigate expression 
of PfPK4 in pfeik2
- gametocytes.  Clearly the same principles apply to the 
investigation of PfeIK1 expression levels in the absence of PfeIK2; this may now 
be possible with the very recently acquired chicken IgYs.   
Alternative strategies exist to address the possible compensation of knock-out of 
one kinase by the function of another; one would be to tag the remaining 
kinase(s) in a knock-out clone, and use the tags to monitor protein expression by 
western blot as described, and their activity by immunoprecipitation followed by 
kinase assay.  Another, would be to look at localisation of the remaining 
kinase(s), either with the antibodies to the native proteins, or to tags.  Thirdly, 
attempts to generate double knock-outs of pfeik1 and pfeik2 would in principle 
answer the question of whether one compensates for another, although this 
would clearly be complicated in mosquito stage experiments due to the problem 
of lengthy in vitro culture that would be required.   
4.6   Summary 
•  Using the single cross over strategy I have shown PfeIK1 and PfeIK2 are 
dispensable for asexual replication. 
•  Further, disruption of neither PfeIK1 nor PfeIK2 affects the ability of the 
parasite to infect mosquitoes and produce sporozoites. 
•  I provide evidence that PfPK4 is essential for asexual replication. Clare Fennell, 2008     Chapter 4 122 
•  Without pfpk4
- parasites I was unable to determine if PfPK4 plays a 
specific role in gametocytogenesis. 
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5  Discussion and conclusions 
5.1   Identification of PfeIF2α and its kinases 
As discussed above (3.5.1), I have identified the P. falciparum orthologue of 
eIF2α and a phylogenetic cluster of PfeIF2α kinases.  Furthermore I have 
confirmed that PfeIK1 is able to phosphorylate PfeIF2α on Ser 59, providing 
support for the hypothesis that regulation of translation initiation may occur in 
P. falciparum by this mechanism.  However, crucially, I have not verified 
whether the other two putative PfeIF2α kinases, PfeIK2 and PfPK4, are able to 
phosphorylate PfeIF2α, because I was unable to produce these two enzymes in 
the form of active recombinant enzymes.  With regard to PfPK4, this is at odds 
with Mohrle et al. who published activity of PfPK4-His on an eIF2α-derived 
peptide (Mohrle et al., 1997); the most obvious way to reconcile our different 
findings is the location of the tag used in recombinant protein production (see 
below, 5.2.1 for further comment).  I have described factors which should be 
considered prior to any further attempts to express these two proteins in E. coli 
(3.5.1).  In addition, as the mammalian and yeast eIF2α kinases dimerize for 
activity through their accessory domains (reviewed (Mathews, 2007)), it is 
possible that production of recombinant proteins incorporating more than the 
kinase domain alone may allow expression of active enzymes.  I also described 
the possibility of using the wheat germ cell free system to produce recombinant 
PfeIF2α kinases (Sawasaki et al., 2005, Mudeppa et al., 2007).  Although the 
wheat germ system appears attractive, it may also not be practical; if (as seems 
likely), the wheat eIF2α sequence is as well conserved as rice (Fig. 3-1), it is 
probable that if the proposed PfeIF2α kinases are indeed active, they will 
phosphorylate the eIF2α in the cell free system and thus inhibit translation, and 
therefore their own synthesis.   
An alternative approach to identifying the kinase that is responsible for 
phosphorylation of a given residue has been described by Maly et al. (Maly et al., 
2004).  In this approach, the residue that is the target for phosphorylation is 
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to proceed containing the Ser-Cys mutant substrate, potential upstream kinases 
(e.g. a whole cell extract) and a specific crosslinking compound.  The crosslinker 
utilizes on one hand the reactive cysteine that has been introduced into the 
substrate, and on the other hand a conserved lysine in the catalytic cleft of the 
kinase, which results in a covalent bond between the substrate and the kinase.  
The complex can then be purified via a tag in the substrate, and the trapped 
kinase identified by immunoblotting where there are known candidates, or mass 
spectrometry if there are not.   
5.2   Investigation of the role of PfeIF2α kinases 
5.2.1   Activation stimuli 
I have presented preliminary data showing that PfPK4-HA can be 
immunoprecipitated from parasite extracts and used in in vitro kinase assays 
(3.4.3.3), an approach that has been successfully used to show activity of two 
divergent eIF2α kinases in T. gondii (Narasimhan et al., 2008).  This approach 
may be effective to verify whether PfPK4-HA can phosphorylate PfeIF2α by 
using GST-PfeIF2α as the substrate in in vitro kinase assays, including the 
Ser59→Ala mutant as a control to confirm the target of phosphorylation.  These 
experiments are required to confirm and extend previously published results; 
Mohrle et al. (1997) described activity of PfPK4-His against an eleven-residue 
peptide representing the human eIF2α sequence containing the target serine 
(Ser51 in human) (Mohrle et al., 1997).  The data they presented suggests that 
the recombinant protein was quite active, since other eIF2α kinases have been 
found to have 1000-fold less activity on a short peptide, than on the whole 
eIF2α molecule (Mellor and Proud, 1991) (subsequently explained by the crystal 
structure of PKR and eIF2α, which shows the large surface area involved in the 
kinase-substrate interaction (3.1) (Dar et al., 2005)).  However, the Mohrle et 
al. study did not include a kinase-dead mutant, and was carried out by 
scintillation counting, as against SDS-PAGE followed by autoradiography, so that 
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Similarly, immunoprecipitation from gametocyte extracts can be tried with our 
anti-PfeIK2 antibody, but the possibility remains that the kinases may be 
maintained in an inhibited condition, so that no activity would be detected. 
5.2.1.1    Starvation 
I suggest that such immunoprecipitation experiments should be carried out in 
conjunction with investigation of activation stimuli.  It is possible to detect 
phosphorylation of PfeIF2α by immunoblotting after amino acid deprivation of 
the parasites (Babbitt & Goldberg, MAM 2008; our joint manuscript, Appendix 
6.3).  We hypothesize that since PfeIK1 appears to be the orthologue of GCN2, 
then it will be the kinase responsible for mediating this starvation response.  The 
pfeik1
- parasites are one useful tool with which to investigate this (in progress).  
It would clearly be advantageous to be able imunoprecipitate PfeIK1 from 
starved parasites for in vitro kinase assay; either a very recently available anti-
sera will facilitate this, or PfeIK1-HA parasites should be generated.  Both PfeIK2 
and PfPK4 could be investigated in this way. 
5.2.1.2    Oxidative stress 
Consideration of other candidate stress stimuli should take into account the 
conditions in which the parasite must survive.  For example, as discussed 
previously (3.5.2), P. falciparum is vulnerable to oxidative stress, and has 
limited capacity to neutralize damaging oxidative agents (Muller, 2004); it would 
not be surprising therefore, to find additional mechanisms that function to 
protect the parasite in the event of redox mechanisms being overwhelmed.  It 
has been shown in other eukaryotic systems that arsenite mediates oxidative 
stress (Patel et al., 2002, Novoa et al., 2003), and that HRI is activated under 
these conditions as part of the cellular stress response (Lu et al., 2001).  In view 
of speculated HRI-like activity in P. falciparum (3.5.2), (and unknown 
mechanism of HRI activation by arsenite (Lu et al., 2001)), but also the 
interesting finding that arsenite induces differentiation from tachyzoites to 
bradyzoites in conjunction with eIF2α phosphorylation in T. gondii (Narasimhan 
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5.2.1.3    Heat shock 
I am intrigued by the possibility that P. falciparum must regulate its functions in 
response to the greater than 10
oC difference between its mosquito vector and 
human host, in addition to the repeated exposure to heat shock on account of 
the febrile episodes that are part of malaria pathology.  In view of this 
substantial exposure to heat shock, inherent in the parasite life cycle it is not 
surprising that the major classes of heat shock proteins are well represented in 
P. falciparum (reviewed (Acharya et al., 2007)).  In addition to the 
characterized activation stimuli of eIF2α kinases (1.8.3.2), other stress stimuli 
including heat shock are also known to induce phosphorylation of eIF2α 
(Brostrom and Brostrom, 1998).  It has been demonstrated that in erythroid cells 
HRI is the principle eIF2α kinase activated by heat shock.  Furthermore, 
evidence suggests that hsp90 and hsc70 are required for this effect (Uma et al., 
1997, Uma et al., 1999, Lu et al., 2001).  Heat shock is therefore also a 
candidate activator for the PfeIF2α kinases. 
5.2.2   Complementation of yeast mutants 
I have provided evidence that components of the mechanism for 
phosphorylation of eIF2α are conserved in P. falciparum, and that therefore 
translation may be regulated in response to stress; this remains to be shown 
experimentally.  Since S. cerevisiae has only a single eIF2α kinase (GCN2) that is 
not essential for growth under normal conditions, mutant strains have been 
established that enable analysis of other eIF2α kinases (Vattem et al., 2001), 
including the divergent eIF2α kinases of T. gondii (Sullivan et al., 2004) and T. 
brucei (Moraes et al., 2007).  There are two key isogenic strains in which GCN2 
has been deleted, one expresses wild type eIF2α (such as strain H1894), the 
other expresses the Ser51→Ala mutant of eIF2α that cannot be phosphorylated 
(strain J82, SUI2-S51A); a galactose-inducible promoter is used to express a GST 
fusion of the heterologous eIF2α kinase.  If the exogenous kinase is active, the 
resulting hyperphosphorylation of eIF2α results in a significant reduction in 
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confirm that any growth defect observed in the GCN2Δ strain is mediated by 
phosphorylation at this position; growth of the Ser51→Ala strain is expected to 
be unaffected by the heterologous kinase.  We initiated a collaboration to carry 
out these experiments with the PfeIF2α kinases; initial trials were unsuccessful 
(R. Wek lab), likely due to poor expression of the P. falciparum proteins in 
yeast.  Just as it may be necessary to improve prokaryotic expression of AT-rich 
plasmodium genes, by use of cells with additional tRNA genes, so codon 
optimisation could be required for expression of the same genes in yeast.  
PfeIK1 and PfeIK2 have more modest sized catalytic domains (than PfPK4); gene 
synthesis could be a practical approach.  If expression in yeast is achieved then 
the Ser51→Ala strain can also provide a useful means of producing GST-tagged 
proteins for in vitro kinase assay. 
5.2.3   Effect of phosphorylation of PfeIF2α on translation? 
Three strategies are under consideration to address whether certain stress 
conditions influence translation rates in P. falciparum, and whether this is via 
phosphorylation of PfeIF2α.   
The first strategy is to use published methods to set up an in vitro translation 
system using P. falciparum components (Surolia and Padmanaban, 1991) 
(Ferreras et al., 2000).  Theoretically, the system described by Ferreras et al. 
2000 could be generated from parasites cultured under normal or stress 
conditions, or from wild type or pfeik
- parasites.  Use of an in vitro system has 
the advantage of being more readily manipulated, for example by 
supplementing with a recombinant PfeIK, or potential inhibitor (Ferreras et al., 
2002).  In the second strategy, protein production can be examined by replacing 
the methionine and cysteine in the culture medium with [
35S]Met/Cys and 
monitoring [
35S] incorporation; it is expected that if a stress stimulus leads to 
phosphorylation of eIF2α and translation arrest, then in the same amount of 
total protein the stressed sample will only have incorporated a fraction of the 
[
35S], compared to an unstressed sample (Narasimhan et al., 2008).  Finally, a 
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is accompanied by a reduction in translation initiation by examining 
polyribosome profiles.  It is expected that in stressed parasites if the eIF2α 
mechanism is operative a reduction in polysomes will be seen, and free 
ribosomes and monosomes correspondingly increased (Han et al., 2001, 
Narasimhan et al., 2008).  If this can be shown to be the case, then purifying 
the polysomes that are maintained in these conditions might allow the 
identification of the mRNAs that are translated under stress, which would yield 
interesting information with respect to the mediation of the stress response. 
5.3 Perspectives 
5.3.1   Phosphoregulation is a two way process. 
Phosphorylation is such a widely used post translational signaling mechanism 
largely because it can be readily reversed by the action of protein phosphatases, 
resulting in systems that can be tightly regulated.  In general, organisms have 
fewer Ser/Thr phosphatases than their corresponding complement of Ser/Thr 
kinases (Gallego and Virshup, 2005), and P. falciparum is no exception to this 
(Wilkes, 2008).  It is increasingly clear that phosphatases operate as hetero-
oligomeric complexes, where the diverse regulatory subunits with which a 
catalytic subunit associates, provide specificity of action by targeting specific 
substrates (Barford et al., 1998, Bollen, 2001).  Regulation of translation by the 
dephosphorylation of eIF2α is less well understood than the action of the eIF2α 
kinases, however it is clear that since the downstream consequences of eIF2α 
phosphorylation include changes in gene expression, translation must be allowed 
to continue, if a new complement of proteins is to be produced (Novoa et al., 
2003).  Interestingly, many viruses can block the activity of PKR and hence 
phosphorylation of eIF2α, (Mohr, 2007), others prevent translational arrest by 
modulating dephosphorylation of eIF2α (Mulvey et al., 2003); this contributed to 
the identification of protein phosphatase 1 (PP1) as the catalytic subunit 
responsible for eIF2α-P dephosphorylation (He et al., 1997, He et al., 1998).  In 
mammalian cells, growth arrest and DNA damage gene (GADD)34 has been 
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PP1 and specifically promotes the dephosphorylation of eIF2α in vitro (Novoa et 
al., 2001).  Furthermore GADD34 expression is induced by stress downstream of 
eIF2α kinase activity (the precise mechanism is not know, but it does depend on 
phosphorylation of eIF2α), thereby orchestrating a programmed shift from 
translational repression to stress-induced gene expression (Novoa et al., 2003).   
P. falciparum has been shown to encode a functional PP1 enzyme 
(Bhattacharyya et al., 2002), and one interaction and regulatory effect has been 
identified (Daher et al., 2006).  It is expected from the mechanisms of 
regulation of other eukaryotic phosphatases, and particularly in view of the 
small size of the P. falciparum Ser/Thr phosphatome (Wilkes, 2008), that many 
more regulatory interactions (that may include a GADD34-like protein) will be 
found.  Recently, the ubiquitously expressed adaptor protein Nck that is 
composed of Src homology domains, has been shown to reduce eIF2α 
phosphorylation in mammalian cells, in a stress specific manner (Cardin et al., 
2007).  Queries of PlasmoDB for Src-homology domains, does not return any 
matches (Interpro IDs: Src homology-3 domain; IPR001452, SH2 motif; 
IPR000980, SH3, type-5 bacterial; IPR013667, SH3, type 3; IPR013247, Variant 
SH3; IPR011511 and Bacterial SH3-like region; IPR003646).  As P. falciparum does 
not encode classical tyrosine kinases (Ward et al., 2004) it is not surprising that 
there are no apparent Src homology domains making it unlikely that this 
mechanism operates in P. falciparum. 
5.3.2   Gametocytogenesis; a stress induced response? 
As discussed in section 1.3.1, commitment to gametocytogenesis remains an 
enigmatic process; in particular, although environmental conditions modulate its 
induction, no single molecule or signalling pathway has been shown to act as an 
inducing factor (reviewed (Alano, 2007)).  T. gondii differentiates from rapidly 
dividing tachyzoites to quiescent bradyzoites on exposure to a number of 
cellular stresses that also induce phosphorylation of TgeIF2α (Sullivan et al., 
2004, Narasimhan et al., 2008).  These observations led us to hypothesise that 
the withdrawal from proliferation and switch to differentiation into gametocytes 
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phosphorylation of PfeIF2α a candidate mediator of this process.  Although I 
have shown that neither PfeIK1or PfeIK2are required for production of 
gametocytes or subsequent completion of the sexual cycle, our reverse genetics 
data do not allow us to formally exclude that one of the eIF2α kinases is indeed 
a mediator of the switch to sexual development.  First, the PfPK4 gene cannot 
be inactivated; it is conceivable that superimposed to its essential function in 
asexual growth (which we demonstrated), PfPK4 also plays a role in 
gametocytogenesis (which we cannot demonstrate due to the lack of a pfpk4
- 
clone).  Second, our preliminary data suggest that pfeik1
- parasites appear to 
overexpress PfPK4.  This may complement for a function of the former gene in 
asexual growth or in sexual development.   
It remains an open question as to how the observed inducers of 
gametocytogenesis function.  Conditions shown to increase gametocytogenesis, 
such as sub-lethal concentrations of chloroquine (Buckling et al., 1997) are 
therefore candidates for inclusion in experiments seeking to identify conditions 
inducing PfeIF2α phosphorylation and activation of PfeIF2α kinases. 
5.3.3   Relative importance of translation control in P. falciparum 
When I began this project, the prevailing view was that translation might play a 
highly significant role in the regulation of P. falciparum gene expression 
(discussed in section 1.7).  This was largely based on the small number of 
identified transcription-associated proteins, and dearth of well conserved 
promoter elements (reviewed (Coleman and Duraisingh, 2008)).  However, these 
observations did not detract from the unusual, and clearly tightly regulated 
cascade of gene expression observed through the P. falciparum life cycle (Le 
Roch et al., 2003), or the interesting finding that distinct transcriptional states 
were observed in clinical isolates that did not correlate with anything previously 
observed in vitro (Daily et al., 2007).  Recent discoveries of cis-regulatory 
elements and the ApiAP2 plant-like transcription factors (Balaji et al., 2005) 
(Young et al., 2008) are calling into question the view that transcriptional 
control in P. falciparum is relatively uncomplicated (reviewed (Coleman and 
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a key role in P. falciparum gene expression still stands, it is unlikely to be as 
significant as was previously thought. 
5.3.4   Search for new therapeutic targets 
As outlined in section 1.5.1, regulation of reversible phosphorylation, 
specifically by targeting kinases is a promising therapeutic approach; the eIF2α 
are no exception.  It has been proposed that inhibition of PERK may synergise 
with other cancer therapies (Blais and Bell, 2006), however a cautionary note 
was added recently in view of the heterogeneous nature of tumour cells.  PERK 
activity can promote cell survival, which provides the basis of rationale for its 
inhibition, however it may also be responsible for maintaining the slow dividing 
or dormant state of some regions of primary tumours or disseminated cells, such 
that inhibition would have a harmful effect  (Ranganathan et al., 2008).  In 
addition, proof of concept for selectively targeting dephosphorylation has been 
provided with the identification of salubrinal, a compound that inhibits 
dephosphorylation of eIF2α; this approach may be beneficial in diseases 
involving ER stress or viral infection (Boyce et al., 2005).  
The underlying aim of our laboratory is to identify new therapeutic targets for 
the treatment of malaria, via the absorbing route of seeking to decipher events 
that control proliferation and differentiation in P. falciparum; kinases are strong 
candidates.  In the context of this overall aim, I can conclude that PfeIK1 and 
PfeIK2 are not therapeutic targets, as I have shown they are not required for 
asexual multiplication, and notwithstanding as yet unidentified essential roles in 
sporozoites stages, do not have potential as transmission blocking targets either.  
A possible essential role in exo-erythrocytic (liver) stages would provide 
rationale for prophylaxis.  We are currently establishing a collaboration with a 
laboratory that has access to infection of hepatocytes with P. falciparum 
sporozoites, in order to assess the ability of the pfeik1
- or pfeik2
- sporozoites to 
establish a productive infection of hepatocytes.  On the contrary, due to its 
apparent essential role in the asexual cycle, PfPK4 is promising, but cannot be 
pursued until active recombinant protein, the basis of a high throughput screen, 
can be produced. Clare Fennell, 2008     Chapter 5 132 
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6  Appendix 
6.1   Biological and chemical reagents 
General chemicals were purchased from Sigma. 
Biogenes  Custom antibody production 
Biorad  Bradford reagent, 30% Acrylamide/Bis mix 
Blood transfusion service  Human full blood 
Calbiochem  Gentamycin, Blasticidin S hydrochloride 
Eurogentec  Smartladder, DNA ladder 
Fermentas  PageRuler™ prestained protein ladder 
Finnzymes   Phusion DNA polymerase 
GE Healthcare  γ-
32[P]ATP, Gene Images AlkPhos Direct Labelling and 
Detection system, Gene-Images CDP-Star detection 
kit, Amersham Hyperfilm, Hybond-N
+  
Genscript  PfeIF2α S59 peptide (ILMSELSKRRFR) 
GIBCO RPMI  1640 
Invitrogen  DNase I, SuperScript II, T4 DNA ligase 
Kodak  Medical X-Ray film 
Qiagen  DNA miniprep kit, maxiprep kit, gel extraction kit 
New England Biolabs  Restriction enzymes, BSA, Broad Range protein 
marker 134 
Novagen pET-28a 
Perkin-Elmer  Western Lightning Chemiluminescence reagent Plus 
Pharmacia pGEX-4T3 
Promega pGEM-T  easy 
Roche  High fidelity polymerase, complete protease inhibitor 
tablets +/- EDTA 
Takara  Ex Taq DNA polymerase 
Table 6-1: Supppliers of biological and chemical reagents. 
 
6.1.1   Oligonucleotide primers 
Oligonucleotide primers were designed to amplify genes for recombinant protein 
expression, gene disruption, 3’ tagging and sequencing.  Where PCR products 
were to be subcloned into appropriate destination plasmids, the oligonucleotide 
primers included a 5’ extension containing the relevant restriction site.   
081  pGEX, GST forward  GGG CTG GCA AGC CAG GTT TGG TGG 
082  pGEX, GST reverse  GGG GGA GCT GCA TGT GTC AGC GC 
95  SP6  ATT TAG GTG ACA CTA TAG 
123  T7  TAA TAC GAC TCA CTA TAG GG 
145  PfeIK1 (PF14_0423) full 
length, forward (BamHI) 
GGG ATC CAT GAC AAG TGA GGA CAA 
GAC AGC 
146  PfeIK1 (PF14_0423) catalytic 
domain, forward (BamHI) 
GGG GGG ATC CAT GGG GAA AAA AAA 
ACA TGG 135 
147  PfeIK1 (PF14_0423) full 
length, reverse (SalI) 
GGG GGT CGA CTT AAA AAT ATT TAA 
TTA GGT AG 
148  PfeIK1 (PF14_0423) catalytic 
domain, reverse (SalI) 
GGG GGT CGA CCG TAA AAA GTA CAC 
TTT CGT G 
149  PfeIK2 (PFA0380w) 5’ end of 
longest predictions (BamHI) 
GGG GGG ATC CAT GCT AAT AAA TAA 
AAG AAA AAG 
150  PfeIK2 (PFA0380w) catalytic 
domain, reverse (SalI) 
GGG GGT CGA CTC AAT ATA TAT ATA 
TAT TTT TTT TTT TC 
151  PfeIF2α (PF11_0117) forward 
(BamHI) 
GGG GGG ATC CAT GAC TGA AAT GCG 
AGT AAA AGC 
152  PfeIF2α  (PF11_0117) reverse 
(SalI) 
GGG GGT CGA CTT AAT CTT CCT CCT 
CCT CGT C 
153  PfPK4 entire gene, forward 
(BamHI) 
GGG GGG GAT CCA TGT GTA ATT TTA 
TAA AAA AAG GT 
154  PfPK4 catalytic domain, 
reverse (SalI) 
GGG GGT CGA CCT ATT TGT CTG CAC 
CAT TAT TCT C 
161  PfPK4 catalytic domain 
forward (BamHI) 
GGG GGG ATC CAT GAA AAA ACG GAT 
ACG TAG TAG T 
167  pCAM-BSD forward  TAT TCC TAA TCA TGT AAA TCT TAA A 
168  pCAM-BSD reverse  CAA TTA ACC CTC ACT AAA G 
169  pCAM-BSD forward, 2  ATT TAT TAA ACT GCA GCC C 
170  pCAM-BSD reverse, 2  AAG CTG GAG CTC CAC CGC 
171  PfeIF2α S59C, forward  GTC CGA ACT ATG CAA AAG AAG 136 
172  PfeIF2α S59C, reverse  CTT CTT TTG CAT AGT TCG GAC 
173  PfPK4 F3, sequencing  GTT CGA GTG CTA GGA ATT TGT C 
174  PfPK4 F4, sequencing  GTA GTT GTT ATA GTG CTA GTA G 
175  PfPK4 F5, sequencing  GTT TTC GCC GAT AAT GAA GAA TC 
176  PfPK4 F6, sequencing  CCA AAT TCT CGA ACC GAA ACG 
177  PfPK4 F7, sequencing  GCA GAT GGA ATT GTG TAA AGG 
178  PfPK4 F8, sequencing  GGA CAA ATT ATA GGA ACC CCT GG 
179  PfeIK1 gene disruption F 
(BamHI) 
GGG GGG ATC CGT AAT GAA AGT AAA 
AAA TAA G 
180  PfeIK1 gene disruption R 
(NotI) 
GGG GCG CCG GCG AGG TGA AAT ATA 
ATG AAT TGT TCC 
183  PfeIK2 gene disruption, 
forward (BamHI) 
GGG GGG ATC CAT GAA TAT AAC AAC 
CAC TTA TTT A 
184  PfeIK2 gene disruption, 
reverse (NotI) 
GGG GCG CCG GCG TGG AGC TGC ATA 
TAT TTT TGT TCC 
185  PfeIK2 catalytic domain, 
forward (BamHI) 
GGG GGG ATC CAT GTT CAT AAA ATC 
ATG TAA TGA TAA AAG C 
186  PfPK4 gene disruption 
reverse (BamHI) 
GGG GGG ATC CCC AAA TTC TCG AAC 
CGA AAC G 
187  PfPK4 gene disruption 
reverse 
GGG GCG CCG GCG  TGG TGC TGT 
ATA ACC AGG GG 
195  PfeIF2α S59A forward  GTC CGA ACT AGC CAA AAG AAG 137 
196  PfeIF2α S59A reverse  GTC CGA ACT AGC CAA AAG AAG 
197  PfeIK1 K458M forward  CTT ATG CAT TAA TGA TTA TAA G 
198  PfeIK1 K458M reverse  CTT ATA ATC ATT AAT GCA TAA G 
199  PfeIK2 K157M forward  ATG AAA ATA AGG ATG ATA TTA AAT 
200  PfeIK2 K157M reverse  ATT TAA TAT CAT CCT TAT TTT CAT 
201  PfPK4 K2177M forward  CCA ACA TAT GCT GTG ATG TTT ATT 
202  PfPK4 K2177M reverse  CCA ACA TAT GCT GTG ATG TTT ATT 
224  PfeIK2 gene structure long 
forward (BamHI) 
GGG GGG ATC CCC AAC AAA TAT ATT 
ATC ACC ACA AG 
225  PfeIK2 gene structure short, 
forward (BamHI) 
GGG GGG ATC CAT GTA TTA TTT CAC 
AAA AGT TGT ATC C 
226  PfeIK2 gene structure reverse 
(SalI) 
GGG GGT CGA CCG CAA GCA TTT GGT 
AGG GAA TGC 
275  pHGB reverse  CGA ACA TTA AGC TGC CAT ATC C 
470  PfPK4 reverse, integral 
BstAPI 
GGA TTT CTT TTG GCA TCA GAT GCA 
TAG G 
486  PfeIK1 Kdead D660N reverse  GAT ATT TGA AGG TTT AAT ATT TCT 
ATG C 
487  PfeIK1 K dead D660N forward  GCA TAG AAA TAT TAA ACC TTC AAA 
TAT C 
589  PfeIK2 intron forward  CTC GAA CCA TCC TAA ATA GCA GAG 
GAC 138 
635  GFP reverse  CAG GTA GTT TTC CAG TAG TGC 
616  PfPK4 3’ end forward (PstI) GGG  GCT GCA GGA TTG GAG ATT TAG 
GAT TAG TAC G 
617  PfPK4 3’ end reverse (BamHI) GGG  GGG ATC CTT TGT CTG CAC CAT 
TAT TCT C 
979  PfeIK1 nested forward  CCT TTA ACT GTT CAG TTA GC 
980  PfeIK1 nested, reverse  CCA TAG AAG TCG AAA ATG GTT C 
Table 6-2: Oligonucleotide primers. 
Sequences are given 5’ to 3’, restriction sites are in bold. 
 
6.1.2   Bacterial strains 
XL10-gold  Tet
r Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F′ proAB lacI 
qZΔM15 Tn10 (Tet
r) Amy Cam
r] 
BL21-codon plus   
Rosetta 2 (DE3)pLysS (Novagen)  F
- ompT hsdSB(rB
- mB
-) gal dcm (DE3) 
pLysSRARE2 (Cam
R) 
BL21-CodonPlus-RIL 
(Stratagene) 
E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal 
endA Hte [argU ileY leuW Camr] 
 
6.1.3   P. falciparum strain 
3D7 139 
6.1.4   Mosquitoes 
Anopheles gambiae 
6.1.5   Antibodies 
Target Animal  Dilution  Source 
PfeIK2 Rabbit  Serum,  1/1500  Biogenes 
PfPK4   Rabbit  Immunopurified, 
1/600 
Biogenes 
ERD2  Rat  Serum, 1/500  Gift from Dr Helen 
Taylor 
GST Rabbit  Immunopurified 
1/5000 
Sigma 
His Rabbit  Immunopurified 
1/1000 
Santa Cruz 
HA (either HRP 
coupled, or not) 
Mouse 
monoclonal 
1/1000 Roche 
Table 6-3: Primary antibodies. 
 
Target Dilution  Source 
Rabbit IgG   1/10,000  Sigma 
Rat IgG  1/15,000  Gift from Dr Helen 
Taylor 
Mouse IgG  1/10,000  Sigma 
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6.2   Buffers, solutions and media 
6.2.1   General Buffers 
1X PBS  137mM NaCl, 2,7mM KCl, 10mM Na2HPO4, 2mM KH2PO4 
Table 6-5: General buffer composition. 
 
6.2.2   DNA analysis 
1X TAE  40mM Tris-Acetate, 1mM EDTA 
6X DNA loading dye  0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF, 30% (w/v) glycerol 
10X Ex Taq buffer  Contains 20mM Mg2
+ 
20X SSC   0.3M Na3Citrate, 3M NaCl 
Denaturation solution  1.5M NaCl, 0.5MNaOH 
Depurination solution  0.25mM HCl 
Southern hybridization 
buffer 
Gene Images Alk Phos Hybridization buffer, 
containing 0.5M NaCl and 4% (w/v) blocking 
reagent (from kit). 
Southern primary wash  1M Urea, 0.1% (w/v) SDS, 50mM Na phosphate (pH 
7.0), 150mM NaCl, 1mM MgCl2, 0.2% (w/v) 
blocking reagent. 
Southern secondary wash  50mM Tris base, 100mM NaCl, 2mM MgCl2. 
Table 6-6: Composition of buffers used for DNA analysis. 
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6.2.3   Protein analysis 
Coomassie Stain  0.25g Coomassie brilliant blue/ 100ml 
destain solution 
Destain solution  5% acetic acid, 22% methanol 
Kinase buffer  20mM Tris-HCl, pH 7.5, 20mM MgCl2, 2mM 
MnCl2, phosphatase inhibitors (10mM NaF, 
10mM β glycerophosphate), 10μM ATP and 
0.1MBq [γ-
32P] ATP 
4X Laemmli loading buffer  40% Glycerol, 20% β-mercaptoethanol (14M 
stock), 2% SDS, 0.25M Tris, pH 6.9, plus 
bromophenol blue to a dense colour. 
Lysis Buffer 1, for GST-fusion 
protein preparation 
2mM EDTA, 1mM DTT, 1mM BHH, 0.5% (w/v) 
Triton X100, 1X complete protease inhibitor 
(Roche), 1mM PMSF 
Lysis buffer 2, for His-fusion 
protein preparation 
100mM Tris-HCl pH 7.5, 300mM NaCl, 1X 
EDTA-free protease inhibitor (Roche), 1mM 
PMSF. 
Parasite solubilisation buffer  0.1% SDS, 0.05% Sodium deoxycholate, 
complete protease inhibitor (1tablet per 
10ml), in PBS 
RIPA buffer  150mM NaCl, 20mM MgCl2, 1% NP-40, 0.5% 
Triton, 30mM Tris (pH 8.0), 10mM NaF, 1mM 
PMSF, 1X complete protease inhibitor 
cocktail (Roche). 
1X TGS, running buffer  25mM Tris, 192mM glycine, 0.1% (w/v) SDS, 
pH 8.3 142 
Towbin buffer - standard  25mM Tris pH 8.3, 192mM glycine, 20% 
methanol,  
Towbin buffer - high molecular 
weight 
50mM Tris pH 8.3, 384mM glycine, 20% 
methanol, 0.1% SDS,  
Table 6-7: Composition of buffers used for protein analyses, including recombinant protein 
preparation. 
 
6.2.4   Bacterial culture 
Ampicillin  1000X stock: 50mg/ml in dH2O 
Autoinduction medium  400ml LB, 8 ml 50X ‘M’ (see below), 8 ml 50X 5052, 0.8 
ml 1M MgSO4  
Chloramphenicol  1000X stock, 34mg/ml in ethanol 
Kanamycin  1000X stock: 10mg/ml in dH2O 
Luria-Bertani medium  10g/L tryptone, 5g/L yeast extract, 10g/L NaCl, pH 7.5 
Luria-Bertani agar  Luria-Bertani medium plus 15g/L Tayo Agar 
50X ‘M’  1.25 M Na2HPO4, 1.25 M KH2PO4, 2.5 M NH4Cl, 0.25 M 
Na2SO4 
Tetracycline  100X stock: 5mg/ml in ethanol 
TFB1  30mM potassium acetate, 10mM CaCl2, 50mM MnCl2, 
100mM RbCl, 15% glycerol.  pH 5.8 (using 1M acetic 
acid), filter sterilized 
TFB2  100mM MOPS (pH6.5), 75mM CaCl2, 10mM RbCl, 15% 
glycerol.  pH 6.5 (using 1M KOH), filter sterilized 143 
2YT  16g/L tryptone, 10g/L NaCl, 10g/L yeast extract, pH 
7.6 
50X 5052  25 % glycerol, 2.5 % glucose, 10 % lactose  
Table 6-8: Buffers, medium and antibiotics used for bacterial preparation and culture. 
 
6.2.5   P. falciparum culture 
Blasticidin  2.5μg/ml in complete RPMI 
Complete RPMI 1640 
medium 
For 5L: 79.45g RPMI 1640 powder (GIBCO), 0.25g 
hypoxanthine (Sigma), 10g NaHCO3, 0.25mg 
gentamycine sulphate (VWR International), 0.5% w/v 
of Albumax II-lipid rich bovine serum albumin 
(Invitrogen), pH 7.2. 
Note: for gametocyte cultures for mosquito infection 
Albumax was replaced with heat inactivated (1 hour, 
56
oC) human AB serum, 10% v/v. 
Cytomix  120 mM KCl, 0.15 mM CaCl2, 2mM EGTA, 5 mM MgCl2, 
10 mM K2HPO4/KH2PO4, 25 mM HEPES 
Deep freeze solution  4.2 % (w/v) sorbitol, 0.9 % (w/v) NaCl, 28% (v/v) 
glycerol 
Giemsa buffer  21.1mM Na2HPO4, 4.4mM KH2PO4, pH 7.4 
Incomplete medium  For 5L: 79.45g RPMI 1640 powder (GIBCO), 0.25g 
hypoxanthine (Sigma), pH 7.2. 
Malstat reagent  13mg/ml Tris/HCl pH 9.0, 20mg/ml Lithium-L-lactate, 
0.66mg/ml APAD, 0.2% Triton X100. 144 
Solution A  12% (w/v) NaCl 
Solution B  1.6% (w/v) NaCl 
Solution C  0.9% (w/v) NaCl, 0.2% dextrose 
Sorbitol 50g/L 
Table 6-9: Composition of solutions used for P. falciparum culture. 
 
6.2.6   Mosquito breeding 
Glucose solution for adult 
mosquitoes 
5.0% (w/v) D-glucose, 0.05% (w/v) PABA 
Table 6-10: Solution for mosquitoes. 
 
6.3   Submitted manuscript 
PfeIK1, a eukaryotic initiation factor 2α kinase of the human malaria parasite 
Plasmodium falciparum. 
Prepared for submission to Malaria Journal, December 2008 (see over). 145 
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